

- A**
- Aamdal S, *see* Avril MF
see Cheng JD
see Sundström S
- Aarseth JH, *see* Monstad SE
- Aasebø U, *see* Sundström S
- Abbasiano V, *see* Sartori S
- Abbou CC, *see* Patard J-J
- Abbruzzese JL, *see* Hoff PM
see Shirao K
see Xiong HQ
- Abdelaziz N, *see* Hébert-Croteau N
- Abla O, *see* Gassas A
- Abonour R, *see* Houck W
- Abraham EH, *see* Okunieff P
- Abraira V, *see* Montalbán C
- Abram P, *see* Howell A
- Abrams J, *see* Citron ML
- Abseher R, *see* Haslinger C
- Acharya MR, *see* Sparreboom A
- Achille E, *see* Tournigand C
- Acholonu SA, *see* Escalón MP
- Ackerman A, *see* Auerbach M
- Adams-Campbell LL, Ahaghotu C, Gaskins M, Dawkins FW, Smoot D, Polk OD, Gooding R, DeWitty RL. Enrollment of African Americans Onto Clinical Treatment Trials: Study Design Barriers, 730
- Adams H, *see* Waber DP
- Adams J, *see* Papandreou CN
- Adams MJ, Lipsitz SR, Colan SD, Tarbell NJ, Treves ST, Diller L, Greenbaum N, Mauch P, Lipshultz SE. Cardiovascular Status in Long-Term Survivors of Hodgkin's Disease Treated With Chest Radiotherapy, 3139
- Adams S, O'Neill D, Bhardwaj N. Maturation Matters: Importance of Maturation for Antitumor Immunity of Dendritic Cell Vaccines (correspondence), 3834
- Adamson PC, *see* Anderson BD
see Blaney SM
- Adeleine P, *see* Gerard J-P
- Adem C, Jenkins RB, Capron F, Stoppa-Lyonnet D. High-Risk Lesions in High-Risk Women: A High-Risk Formalin-Based Biology! (correspondence), 1159
- Aderka D, *see* Pfeffer MR
- Adjei AA, *see* Dy GK
see Rinehart J
- Adkins DR, *see* Hoerr AL
- Adrover E, *see* Alba E
- Advani R, *see* Greenberg PL
- Advani R, Rosenberg SA, Horning SJ. Stage I and II Follicular Non-Hodgkin's Lymphoma: Long-Term Follow-Up of No Initial Therapy, 1454
- Aelony Y. Need for Further Information on Pemetrexed Study (correspondence), 4234
- Agarwala SS, *see* Soulieres D
- Agarwala SS, Kirkwood JM, Gore M, Dreno B, Thatcher N, Czarnetski B, Atkins M, Buzaid A, Skarlos D, Rankin EM. Temozolomide for the Treatment of Brain Metastases Associated With Metastatic Melanoma: A Phase II Study, 2101
- Agarwal R, *see* Lieskovsky YE
- Agelidou A, *see* Georgoulas V
- Agelidou M, *see* Georgoulas V
- Aghajanian C, *see* Dupont J
see Sabbatini P
- Agliano AM, *see* Gradilone A
- Agugliaro DJ, *see* Diener-West M
- Agus D, *see* Scher HI
- Ahaghotu C, *see* Adams-Campbell LL
- A'Hern R, *see* Hess V
- Ahlbom A, *see* Lens MB
- Ahles TA, *see* Tannock IF
- Ahmadi R, *see* Steiner HH
- Ahrar K, *see* Goetz MP
- Aish LS, *see* Gaur S
- Ajani JA, *see* Benson AB III
see Gunderson LL
see Kouvaraki MA
- Ajani JA, Mansfield PF, Janjan N, Morris J, Pisters PW, Lynch PM, Feig B, Myerson R, Nivers R, Cohen DS, Gunderson LL. Multi-Institutional Trial of Preoperative Chemoradiotherapy in Patients With Potentially Resectable Gastric Carcinoma, 2774
- Ajani JA. Operate on My Stomach Cancer? Oh, No—Not You, or Not Yet! (correspondence), 1763
- Akechi T, Okuyama T, Sugawara Y, Nakano T, Shima Y, Uchitomi Y. Major Depression, Adjustment Disorders, and Post-Traumatic Stress Disorder in Terminally Ill Cancer Patients: Associated and Predictive Factors, 1957
- Akhurst T, *see* Downey RJ
- Akins J, *see* Raut CP
- Akslen LA, *see* Stefansson IM
- Alakech B, *see* Hanna H
- Alatrash G, Hutson TE, Molto L, Richmond A, Nemecek C, Mekhail T, Elson P, Tannenbaum C, Olencki T, Finke J, Bukowski RM. Clinical and Immunologic Effects of Subcutaneously Administered Interleukin-12 and Interferon Alfa-2b: Phase I Trial of Patients With Metastatic Renal Cell Carcinoma or Malignant Melanoma, 2891
- Alba E, *see* Colomer R
- Alba E, Martín M, Ramos M, Adrover E, Balil A, Jara C, Barnadas A, Fernández-Aramburo A, Sánchez-Rovira P, Amenedo M, Casado A. Multicenter Randomized Trial Comparing Sequential With Concomitant Administration of Doxorubicin and Docetaxel As First-Line Treatment of Metastatic Breast Cancer: A Spanish Breast Cancer Research Group (GEICAM-9903) Phase III Study, 2587
- Al-Batran S-E, Atmaca A, Hegewisch-Becker S, Jaeger D, Hahnfeld S, Rummel MJ, Seipelt G, Rost A, Orth J, Knuth A, Jaeger E. Phase II Trial of Biweekly Infusional Fluorouracil, Folinic Acid, and Oxaliplatin in Patients With Advanced Gastric Cancer, 658
- Albelda SM, Serman DH. TNFerade to the Rescue? Guidelines for Evaluating Phase I Cancer Gene Transfer Trials (editorial), 577
- Albert ED, *see* Glas J
- Albert PS, *see* Chan LW
- Albertini MR, *see* King, DM
- Alberts SR, *see* Gill S
see Goldberg RM
- Alberts SR, Schroeder M, Erlichman C, Steen PD, Foster NR, Moore DF Jr, Rowland KM Jr, Nair Suresh, Tschetter LK, Fitch TR. Gemcitabine and ISIS-2503 for Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma: A North Central Cancer Treatment Group Phase II Trial, 4944
- Albertsen PC, *see* Johnson TK

AUTHOR INDEX

- Albitar M, *see* Kurzrock R
- Albrecht W, *see* Collette L
- Aldige CR, *see* Lippman SM
- Aldred MA, Huang Y, Liyanarachchi S, Pellegata NS, Gimm O, Jhiang S, Davuluri RV, de La Chapelle A, Eng C. Papillary and Follicular Thyroid Carcinomas Show Distinctly Different Microarray Expression Profiles and Can Be Distinguished by a Minimum of Five Genes, 3531
- Alegakis A, *see* Georgoulas V
- Aleksic A, *see* Chintagumpala M
- Alexandre J, *see* Raymond E
see Yovine A
- Alfonsi M, *see* Denis F
- Aliani S, *see* Reinhard H
- Alimena G, *see* Breccia M
- Alimonti A, *see* Ferretti G
- Alinari L, *see* Zinzani PL
- Aljada IS, Ramnath N, Donohue K, Harvey S, Brooks JJ, Wiseman SM, Khoury T, Loewen G, Slocum HK, Anderson TM, Bepler G, Tan D. Upregulation of the Tissue Inhibitor of Metalloproteinase-1 Protein Is Associated With Progression of Human Non-Small-Cell Lung Cancer, 3218
- Aljurf M, *see* Zaidi SZA
- Alkuzweny B, *see* Czuczman MS
- Allal A, *see* Huguenin P
- Alland L, *see* Keller AM
- Allan SJ, *see* Olivotto IA
- Allen MJ, *see* Chau I
- Allen SL, *see* Kolitz JE
- Allen U, *see* Gassas A
- Alley JG, *see* Turner JE
- Alliot C. Fluoxetine Versus Placebo in Advanced Cancer Outpatients (correspondence), 204
- Allmer C, *see* Gunderson LL
- Almenar D, *see* Fernández-Martos C
- Alonzo TA, *see* Lange JB
- Alpaugh RK, *see* Cheng JD
- Alpen B, Kuse R, Parwaresch R, Müller-Hermelink HK, Stolte M, Neubauer A. Ongoing Monoclonal B-Cell Proliferation Is Not Common in Gastric B-Cell Lymphoma After Combined Radiochemotherapy, 3039
- Alperin JB, *see* Raja V
- Al-Saleem TI, *see* Pollack A
- Altemus RM, *see* Okunieff P
- Al-Thenayan E, Maghfoor I. Complications of Malignancy: Case 1. Systemic Tumor Embolism From Lung Cancer at Presentation, 372
- Altundag K, *see* Altundag M
see Altundag O
- Altundag M, *see* Altundag O
- Altundag M, Altundag K, Cengiz M, Altundag O. The Field of Radiation Therapy May Effect Health-Related Quality of Life in Patients With Operable Breast Cancer (correspondence), 1765
- Altundag O, *see* Altundag M
- Altundag O, Altundag K, Altundag M. Free Circulating DNA: Good As a Diagnostic Marker in Lung Cancer? (correspondence), 3201
- Altundag O, Altundag K. Pamidronate, Hypocalcemia, and Calcium and Vitamin D Supplementation (correspondence), 2035
- Altundag O, Yavas O, Altundag K, Gonen C, Turker A, Uner A. Unusual Abdominal Tumors: Primary Omental T-Cell Lymphoblastic Lymphoma, 1522
- Alvarez AM, *see* Santolaya ME
- Alvarez D, *see* Crombet T
- Alvarnas J, *see* Somlo G
- Amato RJ, *see* Fizazi K
- Ambinder RF, *see* Chan ATC
see Sparano JA
- Amenedo M, *see* Alba E
- Ames F, *see* Thomas E
- Ames FC, *see* Chen AM
see Raut CP
- Ames MM, *see* Reid JM
- Amess J, *see* Davies AJ
- Amin B, *see* Gradishar WJ
- Amistá P, *see* Brandes AA
- Amling CL, *see* Freedland SJ
- Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, Kusuda L, Sexton WJ, Soderdahl DW, Donahue TF, Foley JP, Chung AK, McLeod DG. Pathologic Variables and Recurrence Rates As Related to Obesity and Race in Men With Prostate Cancer Undergoing Radical Prostatectomy, 439
- Amylon MD, *see* Lieskovsky YE
- Anagnostopoulos A, *see* Bamias A
- Anaissie E, *see* Miceli M
- Ananthaswamy HN, *see* Lev DC
- Anastasi J, *see* Marcucci G
- Andersen BL, Farrar WB, Golden-Kreutz DM, Glaser R, Emery CF, Crepsin TR, Shapiro CL, Carson WE III. Psychological, Behavioral, and Immune Changes After a Psychological Intervention: A Clinical Trial, 3570
- Andersen J, *see* Ejlertsen B
- Anderson BD, *see* Smith MA
- Anderson BD, Adamson PC, Weiner SL, McCabe MS, Smith MA. Tissue Collection for Correlative Studies in Childhood Cancer Clinical Trials: Ethical Considerations and Special Imperatives, 4846
- Anderson J, *see* Wharam MD
- Anderson JR, *see* Arndt C
- Anderson K, *see* Richardson P
- Anderson KO, Mendoza TR, Payne R, Valero V, Palos GR, Nazairo A, Richman SP, Hurley J, Gning I, Lynch GR, Kalish D, Cleeland CS. Pain Education for Underserved Minority Cancer Patients: A Randomized Controlled Trial, 4918
- Anderson N, *see* Linden HM
- Anderson S, *see* Dupont J
see Sabbatini P
see Taghian A
- Anderson TM, *see* Aljada IS
- Anderson WF, *see* Jatoi I
- Anderson WF, Chu KC, Chang S. In Reply (correspondence), 383
- Ando K, *see* Nakajima H
- Andre F, Slimane K, Bachelot T, Dunant A, Namer M, Barrelier A, Kabbaj O, Spano JP, Marsiglia H, Rouzier R, Delaloge S, Spielmann M. Breast Cancer With Synchronous Metastases: Trends in Survival During a 14-Year Period, 3302
- Andre T, *see* Rao S
- André T, *see* Tournigand C
- Andrulis IL, *see* Bull SB
- Anfossi M, Numico G. Empathy in the Doctor-Patient Relationship (correspondence), 2258
- Ang KK. Concurrent Radiation Chemotherapy for Locally Advanced Head and Neck Carcinoma: Are We Addressing Burning Subjects? (editorial), 4657
- Annane D, Depondt J, Aubert P, Villart M, Géhanho P, Gajdos P, Chevret S. Hyperbaric Oxygen Therapy for Radionecrosis of the Jaw: A Randomized, Placebo-Controlled, Double-Blind Trial From the ORN96 Study Group, 4893
- Ansari RH, *see* Davis NB
- Anscher M, *see* Marks LB
- Antal D, *see* Hequet O
- Anthes M, *see* Roa W
- Antoch G, Saoudi N, Kuehl H, Dahmen G, Mueller SP, Beyer T, Bockisch A, Debatin JF, Freudenberg LS. Accuracy of Whole-Body Dual-Modality

AUTHOR INDEX

- Fluorine-18–2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography and Computed Tomography (FDG-PET/CT) for Tumor Staging in Solid Tumors: Comparison With CT and PET, 4357
- Antonescu CR, *see* Cormier JN
see French CA
- Anwuri VA, *see* Shariat SF
- Aparicio J, *see* Fernández-Martos C
- Aplenc R, *see* Lange BJ
- Appelbaum FR. Use of Granulocyte Colony-Stimulating Factor Following Hematopoietic Cell Transplantation: Does Haste Make Waste? (editorial), 390
- Aquino VM, Weitman SD, Winick NJ, Blaney S, Furman WL, Kepner JL, Bonate P, Krailo M, Qu W, Bernstein M. Phase I Trial of Tirapazamine and Cyclophosphamide in Children With Refractory Solid Tumors: A Pediatric Oncology Group Study, 1413
- Arafat W, *see* Casado E
- Arai K, *see* Sano T
- Aravantinos G, *see* Bamias A
- Arcese W, *see* Ringdén O
- Archer KJ, *see* Marcucci G
- Archer V, *see* Casson AG
- Arcuri E, *see* Caraceni A
- Ardavanis A, *see* Georgoulas V
- Arends R, *see* Rowinsky EK
- Argiris A, Li Y, Murphy BA, Langer CJ, Forastiere AA. Outcome of Elderly Patients With Recurrent or Metastatic Head and Neck Cancer Treated With Cisplatin-Based Chemotherapy, 262
- Arlandis F, *see* Fernández-Martos C
- Arlen PM, *see* Dahut WL
- Armand J-P, *see* Raymond E
- Armanios M, Xu R, Forastiere AA, Haller DG, Kugler JW, Benson AB III. Adjuvant Chemotherapy for Resected Adenocarcinoma of the Esophagus, Gastro-Esophageal Junction, and Cardia: Phase II Trial (E8296) of the Eastern Cooperative Oncology Group, 4495
- Armstrong FD, *see* Landier W
- Armstrong J. Fellow Suffering, 4425
- Armstrong K, Schwartz JS, Randall T, Rubin SC, Weber B. Hormone Replacement Therapy and Life Expectancy After Prophylactic Oophorectomy in Women With *BRCA1/2* Mutations: A Decision Analysis, 1045
- Arnaud P, *see* Hequet O
- Arndt C, *see* Lange BJ
- Arndt C, Hawkins D, Anderson JR, Breitfeld P, Womer R, Meyer W. Age Is a Risk Factor for Chemotherapy-Induced Hepatopathy With Vincristine, Dactinomycin, and Cyclophosphamide, 1894
- Arndt V, Merx H, Stegmaier C, Ziegler H, Brenner H. Quality of Life in Patients With Colorectal Cancer 1 Year After Diagnosis Compared With the General Population: A Population-Based Study, 4829
- Arnold A, *see* Tripathy D
- Aronson N, *see* Samson DJ
- Aronson WJ, *see* Freedland SJ
- Arredondo Y, *see* Dang NH
- Arsène, *see* Bouché O
- Arthur DC, *see* Byrd JC
- Artibani W, *see* Patard J-J
- Arun B, *see* Ayers M
- Asanger M, *see* Lukaschek J
- Asbury P, *see* Rinehart J
- Ascani S, Went P, Liberati AM, Piccaluga PP, Zinzani PL, Pileri SA. Difficult Diagnostic and Therapeutic Cases: True Thymic Hyperplasia in a Patient Treated for T-Cell Lymphoma, 953
- Aschele C, Debernardis D, Lonardi S, Bandelloni R, Casazza S, Monfardini S, Gallo L. Deleted in Colon Cancer Protein Expression in Colorectal Cancer Metastases: A Major Predictor of Survival in Patients With Unresectable Metastatic Disease Receiving Palliative Fluorouracil-Based Chemotherapy, 3758
- Ascierto PA, *see* Casula M
- ASCO Aromatase Inhibitors Technology Assessment Working Group. In Reply (correspondence), 1526
- Ashan G, *see* Schey SA
- Ashley D, *see* Fouladi M
see Stewart CF
- Ashley DM, *see* Gajjar A
- Asmar L, *see* Neubauer M
- Asselain B, *see* Louis-Sylvestre C
- Aster JC, *see* French CA
- Astolfi M, *see* Corradini P
- Astruc E, *see* Blot E
- Atallah D, *see* Gholam D
- Atkins CD. Dose-Dense Chemotherapy As Adjuvant Treatment for Breast Cancer (correspondence), 749
- Atkins D, *see* Wang Y
- Atkins M, *see* Agarwala SS
- Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou S-H, Marshall B, Boni JP, Dukart G, Sherman ML. Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma, 909
- Atkinson S, *see* Mandel K
- Atmaca A, *see* Al-Batran S-E
- Atoui R, *see* Miceli M
- Atzpodien J, Kirchner H, Jonas U, Bergmann L, Schott H, Heynemann H, Fornara P, Loening SA, Roigas J, Müller SC, Bodenstein H, Pomer S, Metzner B, Rebmann U, Oberneder R, Siebels M, Wandert T, Puchberger T, Reitz M. Interleukin-2- and Interferon Alfa-2a-Based Immunotherapy in Advanced Renal Cell Carcinoma: A Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemotherapy Group (DGCIN), 1188
- Au GKH, *see* Kwong DLW
- Au WY, *see* Hon C
- Aubert P, *see* Annane D
- Auerbach M, Ballard H, McIlwain M. In Reply (correspondence), 4428
- Auerbach M, Ballard H, Trout JR, McIlwain M, Ackerman A, Bahrain H, Balan S, Barker L, Rana J. Intravenous Iron Optimizes the Response to Recombinant Human Erythropoietin in Cancer Patients With Chemotherapy-Related Anemia: A Multicenter, Open-Label, Randomized Trial, 1301
- Augustine E, *see* Okunieff P
- Auriti A, *see* Longo R
- Averbuch SD, *see* Giaccone G
see Herbst RS
- Aversa Z, *see* Breccia M
- Avilés CL, *see* Santolaya ME
- Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M, Neuber K, Bieber T, Gilde K, Porta VG, Fra J, Bonnetterre J, Saïiag P, Kamanabrou D, Pehamberger H, Sufliarsky J, Gonzalez Larriba JL, Scherrer A, Menu Y. Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study, 1118
- Ayala GE, *see* Shariat SF
- Ayanian JZ, *see* Earle CC
see Meyerhardt JA
- Ayanian JZ, Chrischilles EA, Wallace RB, Fletcher RH, Fouad MN, Kiefe CI, Harrington DP, Weeks JC, Kahn KL, Malin JL, Lipscomb J, Potosky AL, Provenzale DT, Sandler RS, van Ryn M, West DW. Understanding Cancer Treatment and Outcomes: The Cancer Care Outcomes Research and Surveillance Consortium, 2992
- Aydeniz B, *see* Krauss K
- Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, Lecoche M, Metivier J, Booser D, Ibrahim N, Valero V, Royce M, Arun B, Whitman

- G, Ross J, Sneige N, Hortobagyi GN, Puzstai L. Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast Cancer, 2284
 Azzoli C, *see* Miller VA
 Azzoli CG, *see* Pfister DG
 Azzoli CG, Pfister DG, Johnson DH, Somerfield MR. In Reply (correspondence), 5020
- B**
- Babb JS, *see* Cheng JD
 Babiak A, *see* Schirrmeyer H
 Babiera G, *see* Raut CP
 Baccarani M, *see* Zinzani PL
 Bacci G, Longhi A, Forni C, Ruggieri P, Briccoli A, De Paolis M, Setola E. In Reply (correspondence), 2511
 Bacharach SL, *see* Tan AR
 Bachelot T, *see* Andre F
 Bacik J, *see* Kondagunta GV
 see Motzer RJ
 Bacon M, *see* Bezjak A
 see Butler L
 Badel K, *see* Devine SM
 Bader P, Kreyenberg H, Hoelle W, Dueckers G, Handgretinger R, Lang P, Kremens B, Dilloo D, Sykora K-W, Schrappe M, Niemeyer C, von Stackelberg A, Gruhn B, Henze G, Greil J, Niethammer D, Dietz K, Beck JF, Klingebiel T. Increasing Mixed Chimerism Is an Important Prognostic Factor for Unfavorable Outcome in Children With Acute Lymphoblastic Leukemia After Allogeneic Stem-Cell Transplantation: Possible Role For Pre-Emptive Immunotherapy?, 1696
 Bafaloukos D, *see* Bamias A
 Bagnall-Reeb HA, *see* Dillon PW
 Bahrain H, *see* Auerbach M
 Bains MS, *see* Brenner B
 see Downey RJ
 Bajetta E, *see* Del Vecchio M
 see Howell A
 Bajorin D, *see* Kondagunta GV
 Bajorin D. The Phase III Candidate: Can We Improve the Science of Selection? (editorial), 211
 Bajorin DF, *see* Hansen HH
 Bakale G, *see* Sodee DB
 Baker LH, *see* Leu KM
 Baker S Jr, *see* Pfister DG
 Balan S, *see* Auerbach M
 Baldie PA, *see* Raez LE
 Bale AE, *see* Choi DH
 Balestri F, *see* Marchetti M
 Balil A, *see* Alba E
 Ballard H, *see* Auerbach M
 Ballen KK, Becker PS, Yeap BY, Matthews B, Henry DH, Ford PA. Autologous Stem-Cell Transplantation Can Be Performed Safely Without the Use of Blood-Product Support, 4087
 Ballman K, *see* Ellis M
 Ballo MT, *see* Pisters PWT
 see Zagars GK
 Balmaceda C, *see* Modak S
 Balzarini L, *see* Parra HS
 Bamias A, Aravantinos G, Deliveliotis C, Bafaloukos D, Kalofonos C, Xiros N, Zervas A, Mitropoulos D, Samantas E, Pectasides D, Papakostas P, Gika D, Kourousis C, Koutras A, Papadimitriou C, Bamias C, Kosmidis P, Dimopoulos MA. Docetaxel and Cisplatin With Granulocyte Colony-Stimulating Factor (G-CSF) Versus MVAC With G-CSF in Advanced Urothelial Carcinoma: A Multicenter, Randomized, Phase III Study From the Hellenic Cooperative Oncology Group, 220
 Bamias A, Deliveliotis C, Fountzilas G, Gika D, Anagnostopoulos A, Zorzou MP, Kastritis E, Constantinides C, Kosmidis P, Dimopoulos MA. Adjuvant Chemotherapy With Paclitaxel and Carboplatin in Patients With Advanced Carcinoma of the Upper Urinary Tract: A Study by the Hellenic Cooperative Oncology Group, 2150
 Bamias C, *see* Bamias A
 Bandelloni R, *see* Aschele C
 Bander NH, *see* Milowsky MI
 Banerjee M, George J, Song EY, Roy A, Hryniuk W. Tree-Based Model for Breast Cancer Prognostication, 2567
 Banghar PK, *see* Khalid I
 Bapsy PP, *see* Devi VL
 Barats J-C, *see* Bonnetterre J
 see Fargeot P
 Barbera L, *see* MacKillop WJ
 Barber G, *see* Ginsberg JP
 see Silber JH
 Barbet N, *see* Gerard J-P
 Barbieri M, *see* Caraceni A
 Bardet E, *see* Denis F
 Bardi G, Fenger C, Johansson B, Mitelman F, Heim S. Tumor Karyotype Predicts Clinical Outcome in Colorectal Cancer Patients, 2623
 Bardo DME, *see* Katzenstein HM
 Bar-Eli M, *see* Lev DC
 Barker L, *see* Auerbach M
 Barlogie B, *see* Durie BGM
 see Miceli M
 Barnadas A, *see* Alba E
 Barnard D, *see* Lange BJ
 Barnd DL, *see* Slingluff CL Jr
 Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneaun FD, Lai P, Sawaya RE. Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System, 2865
 Baron AE, *see* Hirsch FR
 Barone R, *see* Glehen O
 Barosi G, *see* Marchetti M
 Barrelier A, *see* Andre F
 Barrera M, *see* Sung L
 Barron N, *see* Palmieri C
 Barr RD, *see* Mandel K
 Bartlett JB, *see* Schey SA
 Barton DPJ, *see* Hess V
 Baruchel A, *see* de Botton S
 Barulli S, *see* Marchetti M
 Baselga J, *see* Vanhoefler U
 Baselga J. Combining the Anti-EGFR Agent Gefitinib With Chemotherapy in Non-Small-Cell Lung Cancer: How Do We Go From INTACT to Impact? (editorial), 759
 Basen-Engquist K, *see* Navo MA
 see Taylor CLC
 Basso U, *see* Brandes AA
 Bast RC Jr, *see* Skates SJ
 Bastit L, *see* Blot E
 Battershell A, *see* Demmy TL
 Bauduer F, *see* Marchetti M
 Bauer A, *see* Ströbel P
 Bauer H, *see* Steiner HH
 Baulieux J, *see* Gerard J-P
 Bauman G, *see* Roa W
 Baum M, *see* Cuzick J
 Bayol N, *see* Senzer N
 Beà S, Colomo L, López-Guillermo A, Salaverria I, Puig X, Pinyol M, Rives S, Monserrat E, Campo E. Clinicopathologic Significance and

AUTHOR INDEX

- Prognostic Value of Chromosomal Imbalances in Diffuse Large B-Cell Lymphomas, 3498
- Bear HD. In Reply (correspondence), 1766
- Beard C, *see* D'Amico AV
- Bearzi I, *see* Scartozzi M
- Beatty PA. On the Death of a Spouse: Reflections of a Medical Oncologist, 959
- Becherer A, *see* De Santis M
- Becich M, *see* Yu YP
- Beck JF, *see* Bader P
- Becker A, *see* Santolaya ME
- Becker K, *see* Wieder HA
- Becker PS, *see* Ballen KK
- Beckhove P, *see* Steiner HH
- Beckwith JB, *see* Seibel NL
- Bedenne L, *see* Bouché O
- Beer A, *see* Wieder HA
- Beer KT, *see* Huguenin P
- Beer TM, *see* Fromme EK
- Beerman H, *see* Creutzberg CL
- Beex LVAM, *see* Span PN
- Begovic M, *see* Gunderson LL
- Beguin Y, Weber G. Serum Selenium in Lymphoma (correspondence), 3429
- Beiderbeck AB, *see* Graaf MR
- Bekele BN, *see* Lu C
- Bekele L, *see* Dy GK
- Belda-Iniesta C, *see* Casado E
- Belfiglio M, *see* Nicolucci A
- Belinson J, *see* Markman M
- Belldegrun AS, *see* Patard J-J
- Beller M, *see* Gulec SA
- Bello JL, *see* Montalbán C
- Bellon JR, *see* Lin NU
- Belly R, *see* Rao S
- Beltran M, *see* Colomer R
- Benda J, *see* Moore DH
- Bendotti C, *see* Marchetti M
- Benedetti F, *see* Corradini P
- Benedetti G, Rastelli F, Damiani S, Calandri C, Crinò L. Challenging Problems in Malignancy: Presentation of Small-Cell Lung Cancer With Marked Hyperamylasemia, 3826
- Benedetti J, *see* Gill S
- Benedict WF, *see* Shariat SF
- Beneduce G, *see* Izzo F
- Benhattar J, *see* Guillou L
- Benítez J, *see* Valle L
- Benito A, *see* Sangro B
- Benjamin R, *see* Hanna H
- Benjamin RS, *see* Cormier JN
see Pisters PWT
- Ben-Josef E, *see* Loblaw DA
- Benk J, *see* Laack E
- Benner A, *see* Fröhling S
see Schlenk RF
- Bennett CL, *see* Chang S
see Dolan NC
see Golub RM
see Loblaw DA
- Bennett JM, *see* Greenberg PL
see Tallman MS
- Ben-Porat L, *see* Miller VA
- Benson A, *see* Kemeny N
- Benson AB III, *see* Armanios M
see Martenson JA Jr
see Meyerhardt JA
- Benson AB III, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA Jr, McCallum R, Mitchell EP, O'Dorisio TM, Vokes EE, Wadler S. Recommended Guidelines for the Treatment of Cancer Treatment-Induced Diarrhea, 2918
- Benson AB III, Catalano PJ. A Rose, Is a Rose, Is a Rose... or Not (editorial), 1773
- Benson AB III, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, Krzyzanowska MK, Maroun J, McAllister P, Van Cutsem E, Brouwers M, Charette M, Haller DG. American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer, 3408
- Bentzen SM, *see* Trotti A
- Bepler G, *see* Aljada IS
- Bepler G, Sharma S, Cantor A, Gautam A, Haura E, Simon G, Sharma A, Sommers E, Robinson L. *RRM1* and *PTEN* As Prognostic Parameters for Overall and Disease-Free Survival in Patients With Non-Small-Cell Lung Cancer, 1878
- Berardi R, *see* Scartozzi M
- Berchuck A, *see* Skates SJ
- Berd D, Sato T, Maguire HC Jr, Kairys J, Mastrangelo MJ. Immunopharmacologic Analysis of an Autologous, Hapten-Modified Human Melanoma Vaccine, 403
- Berdel WE, *see* Koch P
see Zander AR
- Bereder JM, *see* Glehen O
- Berek JS, Taylor PT, Gordon A, Cunningham MJ, Finkler N, Orr J Jr, Rivkin S, Schultes BC, Whiteside TL, Nicodemus CF. Randomized, Placebo-Controlled Study of Oregovomab for Consolidation of Clinical Remission in Patients With Advanced Ovarian Cancer, 3507
- Beres RA, *see* Goetz MP
- Berg SL, *see* Blaney SM
see Bomgaars L
see Chintagumpala M
- Berg W, *see* Scher HI
- Bergerot P, *see* Denis F
- Bergh J, *see* Brandberg Y
- Berglund Å, *see* Sørbye H
- Bergman C, *see* Norton TR
- Bergmann E, *see* Weber A
- Bergmann L, *see* Atzpodien J
- Berk S, *see* Zimmerman TM
- Berkhof J, *see* Langendijk JA
- Berlfein J, *see* Czuczman MS
- Berman A, *see* Tan AR
- Berman AW, *see* Low JA
- Bermejo JL, *see* Hemminki K
- Bernard JL, *see* Glehen O
- Bernard M, *see* Nimubona S
- Bernardo P, *see* Sparano JA
- Bernier J, *see* Huguenin P
- Bernstein M, *see* Aquino VM
see Blaney SM
- Bernstein V, *see* Olivetto IA
- Berry DA, *see* Citron ML
see Winer EP
- Berthold F, *see* Simon T
- Berthou C, *see* Rossi J-F
- Bertolino M, *see* Bruera E
- Berwick M, Matullo G, Song YS, Guarrera S, Dominguez G, Orlov I, Walker M, Vineis P. Association Between Aryl Hydrocarbon Receptor Genotype and Survival in Soft Tissue Sarcoma, 3997
- Besser M, *see* Fife KM
- Bessman DJ, *see* Raja V
- Betensky RA, *see* Fernandez-Teijeiro A

AUTHOR INDEX

- Betticher DC, *see* Gautschi O
 Beyene J, *see* Sung L
 Beyer J, *see* Kollmannsberger C
 see Rick O
 Beyer T, *see* Antoch G
 Bezjak A, *see* Butler L
 see Meyers CA
 Bezjak A, Tu D, Bacon M, Osoba D, Zee B, Stuart G, Roy J-A, Piccart M, Eisenhauer E. Quality of Life in Ovarian Cancer Patients: Comparison of Paclitaxel Plus Cisplatin, With Cyclophosphamide Plus Cisplatin in a Randomized Study, 4595
 Bhatia S, *see* Landier W
 Bhattacharya S, *see* Kammula S
 Biamonte R, *see* De Placido S
 Bianchi-Scarrà G, *see* Casula M
 Bianco R, *see* Cuzick J
 Biasco G, Pantaleo MA, Di Febo G, Calabrese C, Brandi G. Risk of Duodenal Adenomas in Familial Adenomatous Polyposis to Progress Toward Advanced Neoplastic Disease (correspondence), 3835
 Bieber T, *see* Avril MF
 Biegel JA, *see* Hilden JM
 Bielack S, *see* Kager L
 Bielack SS, Jürgens H. Surgical Expertise and Outcome in Osteosarcoma Trials (correspondence), 2511
 Bienvenu B, *see* Dupont J
 Bieri S, *see* Huguenin P
 Biermann JS, *see* Leu KM
 Biessy C, *see* Stattin P
 Biganzoli L, *see* Bottomley A
 Bigner DD, *see* Rich JN
 Bigosch C, *see* Gautschi O
 Bihlmayr J, *see* Fröhling S
 Billet AL, *see* Hudson MM
 Billmire DF, *see* Cushing B
 see Rogers PC
 Billups C, *see* Hudson MM
 Billups CA, *see* Sanders RP
 see Wagner LM
 Bird BR, *see* Myers DA
 Birkmeyer JD. Understanding Surgeon Performance and Improving Patient Outcomes, 2765
 Bishop JAN, *see* Lens MB
 Bishop MR, Fowler DH, Marchigiani D, Castro K, Kasten-Sportes C, Steinberg SM, Gea-Banacloche JC, Dean R, Chow CK, Carter C, Read EJ, Leitman S, Gress R. Allogeneic Lymphocytes Induce Tumor Regression of Advanced Metastatic Breast Cancer, 3886
 Bisogno G, *see* Carli M
 Bissonette EA, *see* Slingluff CL Jr
 Bitter K, *see* Kovács AF
 Bjarnason G, *see* Hrushesky W
 Bjorkstrand B, *see* Morris C
 Black PM, *see* Chakravarti A
 Blackstein ME, *see* Bull SB
 Blackstock AW, *see* Marks LB
 Blake PR, *see* Hess V
 Blanchard RA, *see* Schlechter BL
 Blaney S, *see* Aquino VM
 Blaney SM, *see* Bomgaars L
 see Chintagumpala M
 Blaney SM, Bernstein M, Neville K, Ginsberg J, Kitchen B, Horton T, Berg SL, Krailo M, Adamson PC. Phase I Study of the Proteasome Inhibitor Bortezomib in Pediatric patients With Refractory Solid Tumors: A Children's Oncology Group Study (ADVL0015), 4804
 Blatt J, *see* Landier W
 Blay JY, *see* Yovine A
 Blay J-Y, *see* Negrier S
 Blessing JA, *see* Moore DH
 see Morris M
 Bloch S, *see* Kissane DW
 Block SD, *see* Earle CC
 Bloemena E, *see* van Beek J
 Bloomfield CD, *see* Byrd JC
 see Kolitz JE
 see Marcucci G
 Bloomfield K, *see* Haque B
 Blot E, Astruc E, Bastit L. Delay of Postoperative Radiotherapy in Head and Neck Cancer Patients (correspondence), 1342
 Blum KA, *see* Hoerr AL
 see Tedesco KL
 Blum P, *see* Schirrmeyer H
 Blum W, *see* Hoerr AL
 Bober SL, Hoke LA, Duda RB, Regan MM, Tung NM. Decision-Making About Tamoxifen in Women at High-Risk for Breast Cancer: Clinical and Psychological Factors, 4951
 Boccadoro M, *see* Corradini P
 Bockisch A, *see* Antoch G
 Bodenstein H, *see* Atzpodien J
 Bodis S, *see* Weder W
 Bodurka DC, *see* Navo MA
 see Taylor CLC
 Body J-J, *see* Mancini I
 Bogart JA. Hypofractionated Radiotherapy for Advanced Non-Small-Cell Lung Cancer: Is the LINAC Half Full? (editorial), 765
 Boggess JF, *see* Moore DH
 Boiron J-M, *see* Thomas X
 Bokemeyer C, *see* De Santis M
 see Kollmannsberger C
 see Rick O
 Bok R, *see* Oh WK
 Boku N, *see* Shirao K
 Bolis G, Scarfone G, Polverino G, Raspagliesi F, Tateo S, Richiardi G, Melpignano M, Franchi M, Mangili G, Presti M, Villa A, Conta E, Guarnerio P, Cipriani S, Parazzini F. Paclitaxel 175 or 225 mg per Meters Squared With Carboplatin in Advanced Ovarian Cancer: A Randomized Trial, 686
 Bolla S, *see* Haque B
 Bomalaski JS, *see* Izzo F
 Bomgaars L, *see* Chintagumpala M
 Bomgaars L, Geyer JR, Franklin J, Dahl G, Park J, Winick NJ, Klenke R, Berg SL, Blaney SM. Phase I Trial of Intrathecal Liposomal Cytarabine in Children With Neoplastic Meningitis, 3916
 Bommer M, *see* Schirrmeyer H
 Bonadonna G, *see* Demicheli R
 Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD Plus Subtotal Nodal Versus Involved-Field Radiotherapy in Early-Stage Hodgkin's Disease: Long-Term Results, 2835
 Bonadonna G, Zambetti M, Moliterni A, Gianni L, Valagussa P. Clinical Relevance of Different Sequencing of Doxorubicin and Cyclophosphamide, Methotrexate, and Fluorouracil in Operable Breast Cancer, 1614
 Bonate P, *see* Aquino VM
 Bonciarelli G, *see* Montella L
 Bonenkamp JJ, *see* Hartgrink HH
 Bonerandi JJ, *see* Avril MF
 Bonezzi C, *see* Caraceni A
 Bonfante V, *see* Bonadonna G
 Boni J, *see* Raymond E
 Boni JP, *see* Atkins MB
 Bonichon F, *see* Guillou L
 Bonnema J, *see* de Bock GH
 Bonner M, *see* Mulhern RK

- Bonnetain F, *see* Bouché O
 Bonneterre J, *see* Avril MF
see Fargeot P
 Bonnetere J, Roché H, Kerbrat P, Fumoleau P, Goudier M-J, Fargeot P, Montcuquet P, Clavère P, Barats J-C, Monnier A, Veyret C, Datchary J, Van Praagh I, Chapelle-Marcillac I. Long-Term Cardiac Follow-Up in Relapse-Free Patients After Six Courses of Fluorouracil, Epirubicin, and Cyclophosphamide, With Either 50 or 100 mg of Epirubicin, As Adjuvant Therapy for Node-Positive Breast Cancer: French Adjuvant Study Group, 3070
 Bonney S, *see* Palmer DH
 Bonomi P, *see* Pérez-Soler R
 Bonsanto MM, *see* Steiner HH
 Boom RPA, *see* van der Hoeven JJM
 Boop FA, *see* Merchant TE
 Booser D, *see* Ayers M
 Booth L, *see* Velikova G
 Bordeleau LJ, *see* Goodwin PJ
 Bordessoule D, *see* de Botton S
see Marchetti M
 Borgoño CA, *see* Scorilas A
 Bornhaeuser M, *see* Kiehl MG
 Borwhat MJ, *see* Demmy TL
 Bosch C, *see* Fernández-Martos C
 Bosl GJ, *see* Kondagunta GV
 Bosnjak S, *see* Bruera E
 Bossi P, *see* Licitra L
 Bossi PF, *see* Licitra L
 Bossuyt PMM, *see* van Westreenen HL
 Boswell WD, *see* Levine AM
 Botti G, *see* Casula M
 Bottomley A, *see* Collette L
see Efficace F
 Bottomley A, Biganzoli L, Cufer T, Coleman RE, Coens C, Efficace F, Calvert HA, Gamucci T, Twelves C, Fargeot P, Piccart M. Randomized, Controlled Trial Investigating Short-Term Health-Related Quality of Life With Doxorubicin and Paclitaxel Versus Doxorubicin and Cyclophosphamide As First-Line Chemotherapy in Patients With Metastatic Breast Cancer: EORTC Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study, 2576
 Bottoni U, *see* Gradilone A
 Bouafia F, *see* Hequet O
 Boucheix C, *see* Thomas X
 Bouché O, Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, Arsène D, Paitel JF, Guérin-Meyer V, Mitry E, Buecher B, Kaminsky MC, Seitz JF, Rougier P, Bedenne L, Milan C. Randomized Multicenter Phase II Trial of a Biweekly Regimen of Fluorouracil and Leucovorin (LV5FU2), LVFU2 plus Cisplatin, or LV5FU2 Plus Irinotecan in Patients With Previously Untreated Metastatic Gastric Cancer: A Fédération Francophone de Cancérologie Digestive Group Study—FFDC 9803, 4319
 Bouffet E, *see* Spiegler BJ
 Bouzy J, *see* Fizazi K
 Bower M, *see* Powles T
see Stebbing J
 Bowie E, *see* Given C
 Bowman L, *see* Chang S
 Boyce H, *see* Kellie SJ
 Boyd J, *see* Spentzos D
 Boyer M, *see* Butow P
 Boyer MJ, *see* Viney RC
 Bradley JD, Dehdashti F, Mintun MA, Govindan R, Trinkaus K, Siegel BA. Positron Emission Tomography in Limited-Stage Small-Cell Lung Cancer: A Prospective Study, 3248
 Bradshaw PT, *see* Thomas CH
 Bradstock K, *see* Thomas X
 Brady A, *see* Given C
 Brady D, *see* Meyerhardt JA
 Brady MF, *see* Thigpen JT
 Brahim JS, *see* Tan AR
 Brain E, *see* Yovine A
 Brand R, *see* Morris C
 Brandberg Y, *see* Liljegren A
 Brandberg Y, Lidbrink E, Michelson H, Wilking N, Bergh J, Wiklund T, Erikstein B. In Reply (correspondence), 1765
 Brændengen M, *see* Sørbye H
 Brandes AA, Basso U, Reni M, Vastola F, Tosoni A, Cavallo G, Scopece L, Ferreri AJ, Panucci MG, Monfardini S, Ermani M. First-Line Chemotherapy With Cisplatin Plus Fractionated Temozolomide in Recurrent Glioblastoma Multiforme: A Phase II Study of the Gruppo Italiano Cooperativo di Neuro-Ocologia, 1598
 Brandes AA, Tosoni A, Basso U, Reni M, Valduga F, Monfardini S, Amistà P, Nicolardi L, Sotti G, Ermani M. Second-Line Chemotherapy With Irinotecan Plus Carmustine in Glioblastoma Recurrent or Progressive After First-Line Temozolomide Chemotherapy: A Phase II Study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO), 4779
 Brandi G, *see* Biasco G
 Brandt DS, *see* Kemeny N
 Brasher PMA, *see* Roa W
 Braun AH, *see* Vanhoefer U
 Braun T, *see* Rick O
 Brawley OW. The Study of Accrual to Clinical Trials: Can We Learn From Studying Who Enters Our Studies? (editorial), 2039
 Breathnach OS, *see* Myers DA
 Breccia M, Muscaritoli M, Aversa Z, Mandelli F, Alimena G. Imatinib Mesylate May Improve Fasting Blood Glucose in Diabetic Ph+ Chronic Myelogenous Leukemia Patients Responsive to Treatment (correspondence), 4653
 Bredenfeld H, Franklin J, Nogova L, Josting A, Fries S, Mailänder V, Oertel J, Diehl V, Engert A. Severe Pulmonary Toxicity in Patients With Advanced-Stage Hodgkin's Disease Treated With a Modified Bleomycin, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone, and Gemcitabine (BEACOPP) Regimen Is Probably Related to the Combination of Gemcitabine and Bleomycin: A Report of the German Hodgkin's Lymphoma Study Group, 2424
 Breen TL, Shane E. Prolonged Hypocalcemia After Treatment With Zoledronic Acid in a Patient With Prostate Cancer and Vitamin D Deficiency (correspondence), 1531
 Bregni M, *see* Corradini P
 Breimer L, *see* Dupont J
 Breitfeld P, *see* Arndt C
 Breitfeld PP, *see* Walterhouse DO
 Bremnes R, *see* Sundström S
 Bremnes RM, *see* Hirsch FR
 Breneman JC, *see* Wharam MD
 Brennan MF, *see* Cormier JN
 Brennan MF. In Reply (correspondence), 1764
 Brenner B, Ison DH, Minsky BD, Bains MS, Tong W, Gonen M, Kelsen DP. Phase I Trial of Combined-Modality Therapy for Localized Esophageal Cancer: Escalating Doses of Continuous-Infusion Paclitaxel With Cisplatin and Concurrent Radiation Therapy, 45
 Brenner B, Tang LH, Klimstra DS, Kelsen DP. Small-Cell Carcinomas of the Gastrointestinal Tract: A Review, 2730
 Brenner DE, *see* Lippman SM
 Brenner H, *see* Arndt V
 Brenner H, Hakulinen T. Are Patients Diagnosed With Breast Cancer Before Age 50 Years Ever Cured?, 432
 Breslow NE, *see* Seibel NL
 Bressac-de Paillerets B, *see* Spatz A

AUTHOR INDEX

- Breysch M, *see* Steiner HH
 Brezden-Masley C, *see* Krzyzanowska MK
 Briccoli A, *see* Bacci G
 Bridges J, *see* Hess V
 Brière J, *see* Mounier N
 Brisson J, *see* Hébert-Croteau N
 Brittain MA, *see* Michael M
 Britton KE, *see* Davies AJ
 Broaddus RR, *see* Slomovitz BM
 Broccia G, *see* Marchetti M
 Brockstein BE. Metastatic Osteosarcoma: A Curable Advanced Malignancy (correspondence), 5017
 Broët P, *see* Hoang-Xuan K
 Brogan B, *see* Schwartz MD
 Bron D, *see* Rossi J-F
 Brooks JA, *see* Schneider PB
 Brooks JJ, *see* Aljada IS
 Broome C, *see* Burris H III
 Brouwers M, *see* Benson AB III
 see Burgers JS
 see MacKillop WJ
 Brouwers MC, *see* Figueredo A
 Browman G, *see* Burgers JS
 see MacKillop WJ
 Brown D, *see* Muler JH
 Brown DR, *see* Simon MS
 Brown G, *see* Chau I
 Brown J, Shvartsman HS, Deavers MT, Burke TW, Munsell MF, Gershenson DM. The Activity of Taxanes in the Treatment of Sex Cord-Stromal Ovarian Tumors, 3517
 Brown JM, *see* Velikova G
 Brown JR, *see* Figueroa BE
 Brown JV, *see* Sabbatini P
 Brown P, Buckner J. In Reply (correspondence), 967
 Brown PM, *see* Velikova G
 Brown R, *see* Mulhern RK
 Brualdi L, *see* Kellie SJ
 Brücher BLD, *see* Wieder HA
 Bruemmer B, *see* Robien K
 Bruera E, *see* Elsayem A
 see Roa W
 Bruera E, Palmer JL, Bosnjak S, Rico MA, Moyano J, Sweeney C, Strasser F, Willey J, Bertolino M, Mathias C, Spruyt O, Fisch MJ. Methadone Versus Morphine As a First-Line Strong Opioid for Cancer Pain: A Randomized, Double-Blind Study, 185
 Bruera ED. In Reply (correspondence), 4029
 Brun EA, *see* Levitz JS
 Brunet R, *see* Cassidy J
 Brunetto VL, *see* Fleming GF
 see Gallion HH
 Brunner H, *see* Hoogerbrugge N
 Brännler G, *see* Glas J
 Brunsvig P, *see* Sundstrøm S
 Bryant B, *see* Raja V
 Bryant J, *see* Taghian A
 Bryce CJ, *see* Chia SK
 Bubendorf L, *see* Nevalainen MT
 Bublely GJ, *see* Oh WK
 Bucana C, *see* Mathew P
 Buccisano F, *see* Marchetti M
 Buchanan GR, *see* Sung L
 Buchholtz TA, *see* Chen AM
 Buchholz TA, *see* Huang EH
 Büchner T, *see* Schlenk RF
 Buckley JD, *see* Dillon PW
 Buckner J, *see* Brown P
 Budroni M, *see* Casula M
 Buecher B, *see* Bouché O
 Buettner PG, *see* Eigentler TK
 see Leiter U
 Buijs C, Willemse PHB, Tinga DJ, Hollema H, de Vries EG, Mourits MJE. Side Effects of Therapy: Tamoxifen and Uterine Abnormalities, 2505
 Bukowski R, *see* Rowinsky EK
 see Alatrash G
 Bull SB, Ozcelik H, Pinnaduwege D, Blackstein ME, Sutherland DAJ, Pritchard KI, Tzontcheva AT, Sidlofsky S, Hanna WM, Qizilbash AH, Tweeddale ME, Fine S, McCready DR, Andrulis IL. The Combination of p53 Mutation and *neu/erbB-2* Amplification Is Associated With Poor Survival in Node-Negative Breast Cancer, 86
 Bult P, *see* Hoogerbrugge N
 Bundi M, *see* Went PT
 Bunn PA Jr, *see* Hanna N
 see Hirsch FR
 Burant C, *see* Simon CM
 Burgart LJ, *see* Garrity MM
 Burger B, *see* Kemeny N
 Burger P, *see* Hilden JM
 Burger PC, *see* Fisher PG
 Burger RA, *see* Fleming GF
 see Thigpen JT
 Burgers JS, Fervers B, Haugh M, Brouwers M, Browman G, Philip T, Cluzeau FA. International Assessment of the Quality of Clinical Practice Guidelines in Oncology Using the Appraisal of Guidelines and Research and Evaluation Instrument, 2000
 Burgess MA, *see* Pisters PWT
 Burhansstipanov L, *see* Peterit DG
 Burk M, *see* Laack E
 Burke TW, *see* Brown J
 see Slomovitz BM
 Burkholder I, *see* Laack E
 Burks RT, *see* Fleming GF
 Burris H III, Yardley D, Jones S, Houston G, Broome C, Thompson D, Greco FA, White M, Hainsworth J. Phase II Trial of Trastuzumab Followed by Weekly Paclitaxel/Carboplatin As First-Line Treatment for Patients With Metastatic Breast Cancer, 1621
 Burritt MF, *see* Dispenzieri A
 Burrows L, *see* Hancock BW
 Burstein HJ, *see* Schrag D
 Burtneff BA, *see* Psyrri A
 Busch TM, *see* Friedberg JS
 Bushey TIL, *see* Jatoi A
 Buter J, *see* Langendijk JA
 see van der Hoeven JJM
 Butler L, Bacon M, Carey M, Zee B, Tu D, Bezjak A. Determining the Relationship Between Toxicity and Quality of Life in an Ovarian Cancer Chemotherapy Clinical Trial, 2461
 Butow P, Devine R, Boyer M, Pendlebury S, Jackson M, Tattersall MHN. Cancer Consultation Preparation Package: Changing Patients but Not Physicians Is Not Enough, 4401
 Butow PN, *see* Hagerty RG
 see Leighl NB
 Butts C, *see* Cassidy J
 Buyse M, *see* Diéras V
 see Piebdois P
 see Tournigand C
 Buzaid A, *see* Agarwala SS
 Buzdar A, *see* Cuzick J
 Buzdar AU, *see* Huang EH
 see Thomas E

AUTHOR INDEX

- Buzdar AU. Phase III Study of Letrozole Versus Tamoxifen As First-Line Therapy of Advanced Breast Cancer in Postmenopausal Women: Analysis of Survival and Update of Efficacy From the International Letrozole Breast Cancer Group (correspondence), 3199
- Buzyn A, *see* Thomas X
- Byrd JC, Ruppert AS, Mrózek K, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Stamberg J, Koduru PRK, Moore JO, Mayer RJ, Davey FR, Larson RA, Bloomfield CD. Repetitive Cycles of High-Dose Cytarabine Benefit Patients With Acute Myeloid Leukemia and inv(16)(p13; q22) or t(16;16)(p13; q22): Results From CAL6B 8461, 1087
- Byrne MJ, *see* Nowak AK
- C**
- Cadranel J, *see* Mary-Krause M
- Caenazzo A, *see* Marchetti M
- Cairncross JG, *see* Roa W
- Calabrese C, *see* Biasco G
- Calais G, *see* Denis F
- Calaminus G, *see* Schneider DT
- Calandra G, *see* Devine SM
- Calandri C, *see* Benedetti G
- Caldes T, *see* Pasche B
- Caldwell R, *see* Diener-West M
- Caligiuri MA, *see* Kolitz JE
see Perrotti D
- Callstrom MR, *see* Goetz MP
- Calvert HA, *see* Bottomley A
- Calvieri S, *see* Gradilone A
- Camitta BM, *see* Godder K
- Campana F, *see* Louis-Sylvestre C
- Campbell AD, Cohn SL, Reynolds M, Seshadri R, Morgan E, Geissler G, Rademaker A, Marymount M, Kalapurakal J, Haut PR, Duerst R, Kletz M. Treatment of Relapsed Wilms' Tumor With High-dose Therapy and Autologous Hematopoietic Stem-Cell Rescue: The Experience at Children's Memorial Hospital, 2885
- Camphausen K, *see* Chan LW
- Campiglio M, *see* Normanno N
- Campo E, *see* Beà S
- Campane M, *see* Fargeot P
- Campos J, *see* Fernández-Martos C
- Campos JM, *see* Fernández-Martos C
- Candas B, *see* Labrie F
- Canellos GP, Duggan D, Johnson J, Niedzwieki D. How Important Is Bleomycin in the Adriamycin + Bleomycin + Vinblastine + Dacarbazine Regimen? (correspondence), 1532
- Canniff J, *see* Garcia-Carbonero R
- Cannistra SA, *see* Spentzos D
- Cannistra SA. The Ethics of Early Stopping Rules: Who Is Protecting Whom?, 1542
- Cantor A, *see* Bepler G
- Cantù G, *see* Licitra L
- Cao MG, Puig S, Mellado B. Survivin Expression in Sentinel Lymph Nodes From Melanoma Patients (correspondence), 2751
- Capanna R, *see* Goetz MP
- Capdeville R, *see* Peng B
- Capelle L, *see* Hoang-Xuan K
- Cappuzzo F. In Reply (correspondence), 2036
- Caprino D, Wiley TJ, Massimo L. Childhood Cancer Survivors in the Dark, 2748
- Capron F, *see* Adem C
- Caracandas J, *see* Neubauer M
- Caracciolo D, *see* Corradini P
- Caraceni A, Zecca E, Bonezzi C, Arcuri E, Tur RY, Maltoni M, Visentin M, Gorni G, Martini C, Tirelli W, Barbieri M, De Conno F. Gabapentin for Neuropathic Cancer Pain: A Randomized Controlled Trial From the Gabapentin Cancer Pain Study Group, 2909
- Caran E, *see* Michalkiewicz E
- Carboni A, *see* Casula M
- Carducci MA, *see* Scher HI
- Carey M, *see* Butler L
- Carillio G, *see* Longo R
- Carli M, Colombatti R, Oberlin O, Bisogno G, Treuner J, Koscielniak E, Tridello G, Garaventa A, Pinkerton R, Stevens M. European Intergroup Studies (MMT4-89 and MMT4-91) on Childhood Metastatic Rhabdomyosarcoma: Final Results and Analysis of Prognostic Factors, 4787
- Carlini P, *see* Ferretti G
- Carlson J, *see* Norton TR
- Carpenter J, *see* Citron ML
- Carpentier AF, *see* Hoang-Xuan K
- Carrasquillo JA, *see* Tan AR
- Carr D, *see* McNicol E
- Carrie C, *see* Meyers CA
see Pommier P
- Carrington BM, *see* Davies AJ
- Carroll AJ, *see* Byrd JC
see Marcucci G
- Carroll PR, *see* Cooperberg MR
- Carsin B, *see* Nimubona S
- Carson WE III, *see* Andersen BL
- Carstensen M, *see* Zander AR
- Carteni G, *see* De Placido S
- Carter C, *see* Bishop MR
- Carter D, *see* Choi DH
- Carter S, *see* Hoff PM
- Casado A, *see* Alba E
- Casado E, De Castro J, Belda-Iniesta C, Feliu J, González-Barón M, Arafat W. Doomed Trials for Promising Adenoviruses: A Rationale for Success (correspondence), 1162
- Casazza S, *see* Aschele C
- Cascinu S, *see* Scartozzi M
- Casini M, *see* Corradini P
- Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, Debraud F, Figuer A, Grossmann J, Sawada N, Schöffski P, Sobrero A, Van Cutsem E, Diaz-Rubio E. XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal Cancer, 2084
- Cassileth BR, *see* Vickers AJ
- Cassileth PA, *see* Raez LE
see Tallman MS
- Casson AG, Darnton SJ, Archer V, Ferry D, Stocken D, Mulholland P. In Reply (correspondence), 2513
- Castel LD, *see* Meropol NJ
- Castello G, *see* Izzo F
- Castiglia D, *see* Casula M
- Castleberry R, *see* Kretschmar CS
see Zebrack BJ
- Castleberry RP, *see* Cushing B
- Castro K, *see* Bishop MR
- Casula M, Colombino M, Satta MP, Cossu A, Ascierto PA, Bianchi-Scarrà G, Castiglia D, Budroni M, Rozzo C, Manca A, Lissia A, Carboni A, Petretto E, Satriano SMR, Botti G, Mantelli M, Ghiorzo P, Stratton MR, Tanda F, Palmieri G. BRAF Gene Is Somatic Mutated but Does Not Make a Major Contribution to Malignant Melanoma Susceptibility: The Italian Melanoma Intergroup Study, 286
- Catalano G, *see* De Pas T
- Catalano PJ, *see* Benson AB III
- Catalano RB, *see* Benson AB III
- Catania L, *see* Waber DP
- Caudrelier J-M, *see* Meyers CA

- Caulet-Maugendre S, *see* Nimubona S
- Cavaliere F, *see* Glehen O
- Cavallo G, *see* Brandes AA
- Ceccotti P, *see* Sartori S
- Cella D, *see* Fallowfield L
see Fleming GF
see Moore DH
- Cengiz M, *see* Altundag M
- Cengiz M. Internal Mammary Lymphatic Irradiation: To Be or Not to Be? (correspondence), 2257
- Cerea G, *see* Pedrazzoli P
- Cha SS, *see* Gill S
- Chachoua A, *see* Pérez-Soler R
- Chakravarti A, Zhai G, Suzuki Y, Sarkesh S, Black PM, Muzikansky A, Loeffler JS. The Prognostic Significance of Phosphatidylinositol 3-Kinase Pathway Activation in Human Gliomas, 1926
- Champagne P, *see* Labrie F
- Champlin RE, *see* Eapen M
see Escalón MP
see Ueno NT
- Chan A, *see* Roa W
- Chan ATC, *see* Yeo W
- Chan ATC, Ma BBY, Lo YMD, Leung SF, Kwan WH, Hui EP, Mok TSK, Kam M, Chan LS, Chiu SKW, Yu CKH, Cheung KY, Lai K, Lai M, Mo F, Yeo W, King A, Johnson PJ, Teo PML, Zee B. Phase II Study of Neoadjuvant Carboplatin and Paclitaxel Followed by Radiotherapy and Concurrent Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: Therapeutic Monitoring With Plasma Epstein-Barr Virus DNA, 3053
- Chan ATC, Tao Q, Robertson KD, Flinn IW, Mann RB, Klencke B, Kwan WH, Leung TW-T, Johnson PJ, Ambinder RF. Azacitidine Induces Demethylation of the Epstein-Barr Virus Genome in Tumors, 1373
- Chan LS, *see* Chan ATC
- Chan LW, Moses MA, Goley E, Sproull M, Muanza T, Coleman CN, Figg WD, Albert PS, Ménard C, Camphausen K. Urinary VEGF and MMP Levels As Predictive Markers of 1-Year Progression-Free Survival in Cancer Patients Treated With Radiation Therapy: A Longitudinal Study of Protein Kinetics Throughout Tumor Progression and Therapy, 499
- Chan PKS, *see* Yeo W
- Chan RTT, *see* Kwong DLW
- Chan W-M, *see* Liu DTL
- Chan W-M, Liu DTL, Lai CKC, Tse MWY, Ng JSK, Lam DSC. Soft Tissue Sarcomas: Orbital Alveolar Soft Part Sarcoma in a Child, 2027
- Chandrinovs V, *see* Georgoulis V
- Chang C, *see* Dupont J
see Shuch B
- Chang DZ, Zhang JX, Filippa DA, Portlock CS. Unusual Abdominal Tumors: Localized Amyloid Associated With Gastric Adenocarcinoma, 1520
- Chang G-C, Yang T-Y, Chen K-C, Yin M-C, Wang R-C, Lin Y-C. Complications of Therapy in Cancer Patients. Case 1. Paronychia and Skin Hyperpigmentation Induced by Gefitinib in Advanced Non-Small-Cell Lung Cancer, 4646
- Chang RJ, *see* Rock CL
- Chang S, *see* Anderson WF
- Chang S, Long SR, Kutikova L, Bowman L, Finley D, Crown WH, Bennett CL. Estimating the Cost of Cancer: Results on the Basis of Claims Data Analyses for Cancer Patients Diagnosed With Seven Types of Cancer During 1999 to 2000, 3524
- Chang SM, *see* Puduvali VK
- Chang T, *see* Hanna N
- Chang Y-L, *see* Tsai M-S
- Chansky K, *see* Edelman MJ
- Chapelle-Marcillac I, *see* Bonnetterre J
see Fargeot P
- Chapet O, *see* Gerard J-P
- Chapman PB, *see* Su YB
- Chapman PB. T-Cell Chauvinists Versus Antibody Advocates—Can't We All Just Get Along? (editorial), 4446
- Chappell R, *see* Petereit DG
- Charboneau JW, *see* Goetz MP
- Chareonthaitawee P, *see* Thompson MA
- Charette M, *see* Benson AB III
- Charette ML, *see* Figueredo A
- Charrin C, *see* Thomas X
- Charron M, *see* DuBois SG
- Chassé E, *see* Gautschi O
- Chatterjee R, Palla K, Kottaridis PD. Cavernosal Arterial Insufficiency and Metabolic Syndrome Probably Represent a Common Pathology of Endothelial Dysfunction in Recipients of High-Dose Therapy and Stem-Cell Transplantation (correspondence), 2253
- Chatterjee SJ, Datar R, Youssefzadeh D, George B, Goebell PJ, Stein JP, Young L, Shi S-R, Gee C, Groshen S, Skinner DG, Cote RJ. Combined Effects of p53, p21, and pRb Expression in the Progression of Bladder Transitional Cell Carcinoma, 1007
- Chatzinikolaou I, *see* Hanna H
- Chaudri-Ross HA, *see* Mouridsen H
- Chau I, *see* Lal R
- Chau I, Allen MJ, Cunningham D, Norman AR, Brown G, Ford HER, Tebbutt N, Tait D, Hill M, Ross PJ, Oates J. The Value of Routine Serum Carcino-Embryonic Antigen Measurement and Computed Tomography in the Surveillance of Patients After Adjuvant Chemotherapy for Colorectal Cancer, 1420
- Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate Prognostic Factor Analysis in Locally Advanced and Metastatic Esophago-Gastric Cancer—Pooled Analysis From Three Multicenter, Randomized, Controlled Trials Using Individual Patient Data, 2395
- Chaumette-Plankaert M-T, *see* Toumi N
- Chavaillon A, *see* Saurin J-C
- Chavez Y, *see* Mandelblatt JS
- Chayvialle J-A, *see* Saurin J-C
- Cheever MA, *see* Disis ML
- Chen AC, *see* Neugut AI
- Chen AM, Meric-Bernstam F, Hunt KK, Thames HD, Oswald MJ, Outlaw ED, Strom EA, McNeese MD, Kuerer HM, Ross MI, Singletary SE, Ames FC, Feig BW, Sahin AA, Perkins GH, Schechter NR, Hortobagyi GN, Buchholz TA. Breast Conservation After Neoadjuvant Chemotherapy: The M. D. Anderson Cancer Center Experience, 2303
- Chen AR, *see* Godder K
- Chen CC, *see* Dahut WL
- Chen C-L, *see* Kuo S-H
- Chen G, *see* Talarico L
- Chen I, *see* Fizazi K
- Chen K-C, *see* Chang G-C
- Chen L-T, *see* Kuo S-H
- Chen MG, *see* Sparano JA
- Chen M-H, *see* D'Amico AV
- Chen PX, *see* Innocenti F
- Chen S-C, *see* Tsai M-S
- Chen W, *see* Gill S
- Chen W-J, *see* Tsai M-S
- Chen WY, *see* Kroenke CH
- Chen Y, *see* Ghia KK
- Chen Y-M, *see* Gradishar WJ
- Cheng ACK, *see* Kwong DLW
- Cheng A-L, *see* Kuo S-H
- Cheng JD, Babb JS, Langer C, Aamdal S, Robert F, Engelhardt LR, Fernberg O, Schiller J, Forsberg G, Alpaugh RK, Weiner LM, Rogatko A. Individualized Patient Dosing in Phase I Clinical Trials: The Role of Escalation With Overdose Control in PNU-214936, 602

AUTHOR INDEX

- Chernenko S, *see de Perrot M*
- Cherqui D, *see Toumi N*
- Cheung KY, *see Chan ATC*
- Cheung N-KV, *see Kushner BH*
- Chevreau C, *see Negrier S*
- Chevret S, *see Annane D*
see de Botton S
- Chi SN, Gardner SL, Levy AS, Knopp EA, Miller DC, Wisoff JH, Weiner HL, Finlay JL. Feasibility and Response to Induction Chemotherapy Intensified With High-Dose Methotrexate for Young Children With Newly Diagnosed High-Risk Disseminated Medulloblastoma, 4881
- Chianese-Bullock KA, *see Slingluff CL Jr*
- Chiang W-C, *see Tsai M-S*
- Chia SK, Speers CH, Bryce CJ, Hayes MM, Olivotto IA. Ten-Year Outcomes in a Population-Based Cohort of Node-Negative, Lymphatic and Vascular Invasion–Negative Early Breast Cancers Without Adjuvant Systemic Therapies, 1630
- Chibbar R, *see Khandwala HM*
- Chien CY, *see Lin TY*
- Chim CS, Ooi GC, Loong F, Liang R. Unusual Presentations of Hematologic Malignancies: Solitary Bone Plasmacytoma: Role of Magnetic Resonance Imaging and Positron Emission Tomography, 1328
- Chin AJ, *see Ginsberg JP*
see Silber JH
- Chin DL, *see Greenberg PL*
- Chintagumpala M, *see Fouladi M*
see Gajjar A
see Stewart CF
- Chintagumpala M, Blaney SM, Bomgaars LR, Aleksic A, Kuttesch JF, Klenke RA, Berg SL. Phase I and Pharmacokinetic Study of Thalidomide With Carboplatin in Children With Cancer, 4394
- Chisti N, *see Tisman G*
- Chiu KM, *see Lin TY*
- Chiu SKW, *see Chan ATC*
- Chlebowsky RT, Pettinger M, Stefanick ML, Howard BV, Mossavar-Rahmani Y, McTiernan A. Insulin, Physical Activity, and Caloric Intake in Postmenopausal Women: Breast Cancer Implications, 4507
- Chochinov HM. Dignity and the Eye of the Beholder, 1336
- Choi DH, Lee MH, Bale AE, Carter D, Haffty BG. Incidence of *BRCA1* and *BRCA2* Mutations in Young Korean Breast Cancer Patients, 1638
- Choi PCL, *see Liu DTL*
- Chollet D, *see Studer UE*
- Chomienne C, *see de Botton S*
- Chopin DK, *see Patard J-J*
- Choti MA, *see Goetz MP*
- Chow C, *see Tan AR*
- Chow CK, *see Bishop MR*
- Chow E, *see Lutz S*
- Chow V, *see Khandwala HM*
- Chow W, *see Somlo G*
- Choy DDK, *see Kwong DLW*
- Chrischilles EA, *see Ayanian JZ*
- Christensen B, *see Jatoi A*
- Christensen R, *see Mulhern RK*
- Christiani DC, *see Gurubhagavatula S*
- Christiansen H, *see Weber A*
- Christofilakis C, *see Georgoulis V*
- Chu K, *see Senzer N*
- Chu KC, *see Anderson WF*
- Chu P, *see Somlo G*
- Chu PG, *see Yen Y*
- Chu SH, *see Lin TY*
- Chua B, *see Olivotto IA*
- Chua DTT, *see Kwong DLW*
- Chung AK, *see Amling CL*
- Chung GG, *see Psyrrri A*
- Ciancia G, *see Picardi M*
- Ciancia R, *see Picardi M*
- Cicccone F, *see Zinzani PL*
- Cigna E, *see Gradilone A*
- Cimprich B, *see Given C*
- Cindolo L, *see Patard J-J*
- Cipriani S, *see Bolis G*
- Cirrincione C, *see Citron ML*
- Cisar LA, *see Lima CMR*
- Citron ML, Berry DA, Cirrincione C, Hudis C, Norton L, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Carpenter J, Hurd D, Holland JF, Smith B, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB. In Reply (correspondence), 751
- Clairmont C, *see Wadler S*
- Clark BJ, *see Ginsberg JP*
see Silber JH
- Clark E, *see Ayers M*
- Clark GM, *see Pérez-Soler R*
- Clark MA, *see Izzo F*
- Clarke DM, *see Kissane DW*
- Clarke IA, *see Schey SA*
- Clavère P, *see Bonnetterre J*
- Clayton J, *see Davies AJ*
- Cleeland CS, *see Anderson KO*
- Climent MA, *see Fernández-Martos C*
- Cloughesey TF, *see Puduvali VK*
- Clough K, *see Louis-Sylvestre C*
- Clough R, *see Marks LB*
- Cluzeau FA, *see Burgers JS*
- Cnaan A, *see Ginsberg JP*
see Silber JH
- Coates A, *see Crivellari D*
- Cobleigh M, *see Tripathy D*
- Cochrane A, *see Sung L*
- Coens C, *see Bottomley A*
see Efficace F
- Cofré J, *see Santolaya ME*
- Cognetti F, *see Ferretti G*
- Cohen AM, *see Benson AB III*
- Cohen DS, *see Ajani JA*
- Cohen EEW, Lingen MW, Vokes EE. The Expanding Role of Systemic Therapy in Head and Neck Cancer, 1743
- Cohen HJ, *see Rose JH*
- Cohen MI, *see Silber JH*
- Cohn SL, *see Campbell AD*
see Katzenstein HM
- Coiffier B, *see Hequet O*
- Coiffier B. In Reply (correspondence), 3431
- Coindre J-M, *see Guillou L*
- Coit DG, *see Kammula US*
- Coiteux V, *see de Botton S*
- Colangelo L, *see Gunderson LL*
- Colan SD, *see Adams MJ*
see Lipshultz SD
- Colditz GA, *see Kroenke CH*
- Coleman CN, *see Chan LW*
- Coleman F, *see Peterreit DG*
- Coleman N, *see Okunieff P*
- Coleman R, *see Cuzick J*
- Coleman RE, *see Bottomley A*
see Wahl RL
- Colin P, *see Tournigand C*
- Collette L, van Andel G, Bottomley A, Oosterhof GON, Albrecht W, de Ruijke TM, Fossà SD. Is Baseline Quality of Life Useful for Predicting

- Survival With Hormone-Refractory Prostate Cancer? A Pooled Analysis of Three Studies of the European Organisation for Research and Treatment of Cancer Genitourinary Group, 3877
- Collin F, *see* Guillou L
- Collyar DE, *see* Demmy TL
- Colman M, *see* Morgan PB
- Colman MH, *see* Fife KM
- Colombani P, *see* Cushing B
- Colombatti R, *see* Carli M
- Colombino M, *see* Casula M
- Colombo P, *see* Parra HS
- Colomer R, Viñas G, Beltran M, Izquierdo A, Lluch A, Llombart-Cussac A, Alba E, Munárriz B, Martin M. Validation of the 2001 St Gallen Risk Categories for Node-Negative Breast Cancer Using a Database From the Spanish Breast Cancer Research Group (GEICAM) (correspondence), 961
- Colomo L, *see* Beà S
- Comans EFI, *see* van der Hoeven JJM
- Conde E, *see* de Botton S
see Montalbán C
- Conkling P, *see* Neubauer M
- Connor S, *see* Lutz S
- Conrad CA, *see* Puduvali VK
- Conroy T, *see* Cassidy J
see Rauch P
- Constantinides C, *see* Bamias A
- Constenia M, *see* Czuzick J
- Constine LS, *see* Landier W
- Conta E, *see* Bolis G
- Cook EH, *see* Relling MV
- Cook MG, *see* Dewar DJ
- Cooper DL, *see* Psyrrri A
see Smith BD
- Cooper J, *see* Eifel PJ
- Cooper JS, *see* Garden AS
- Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The Changing Face of Low-Risk Prostate Cancer: Trends in Clinical Presentation and Primary Management, 2141
- Copeland LA, *see* Janz NK
- Coquard R, *see* Gerard J-P
- Cordon-Cardo C. p53 and RB: Simple Interesting Correlates or Tumor Markers of Critical Predictive Nature? (editorial), 975
- Cordonnier C, *see* Ringdén O
- Corless CL, Fletcher JA, Heinrich MC. Biology of Gastrointestinal Stromal Tumors, 3813
- Cormier JN, Huang X, Xing Y, Thall PF, Wang X, Benjamin RS, Pollock RE, Antonescu CR, Maki RG, Brennan MF, Pisters PWT. Cohort Analysis of Patients With Localized, High-Risk, Extremity Soft Tissue Sarcoma Treated at Two Cancer Centers: Chemotherapy-Associated Outcomes, 4567
- Cornelison TL, *see* Okunieff P
- Cornélissen G, *see* Hrushesky W
- Cornu P, *see* Hoang-Xuan K
- Corradini P, Doderio A, Zallio F, Caracciolo D, Casini M, Bregni M, Narni F, Patriarca F, Boccadoro M, Benedetti F, Rambaldi A, Gianni AM, Tarella C. Graft-Versus-Lymphoma Effect in Relapsed Peripheral T-Cell Non-Hodgkin's Lymphomas After Reduced-Intensity Conditioning Followed by Allogeneic Transplantation of Hematopoietic Cells, 2172
- Corradini P, Ladetto M, Zallio F, Astolfi M, Rizzo E, Sametti S, Cuttica A, Rosato R, Farina L, Boccadoro M, Benedetti F, Pileri A, Tarella C. Long-Term Follow-Up of Indolent Lymphoma Patients Treated With High-Dose Sequential Chemotherapy and Autografting: Evidence That Durable Molecular and Clinical Remission Frequently Can Be Attained Only in Follicular Subtypes, 1460
- Cortes JE, *see* Kurzrock R
- Cortese F, *see* Longo R
- Cossu A, *see* Casula M
- Costagliola D, *see* Mary-Krause M
- Costas I, *see* Read WL
- Cote K, *see* D'Amico AV
- Cote RJ, *see* Chatterjee SJ
- Courtney K, *see* Given C
- Couteau C, *see* Tournigand C
- Couwlier C, *see* Leu KM
- Cowan T, *see* Hudson MM
- Cox MC, *see* Sparreboom A
- Cox MC, Figg WD, Thurman PW. No Rational Theory for Drug Pricing (correspondence), 962
- Coylc C, *see* Wei SJ
- Coyne JC, Palmer SC, Shapiro PJ. Prescribing Antidepressants to Advanced Cancer Patients With Mild Depressive Symptoms Is Not Justified (correspondence), 205
- Crane CH, Sargent DJ. Substitution of Oral Fluoropyrimidines for Intravenous Fluorouracil With Radiotherapy: How Much Data Do We Need? (editorial), 2978
- Cranston T, *see* Lipton LR
- Crawford ED, *see* Herr HW
- Crawford J, *see* Lyman GH
see Marks LB
- Cremona F, *see* Izzo F
- Crespin TR, *see* Andersen BL
- Cress RD, Leiserowitz GS. In Reply (correspondence), 379
- Creutzberg CL, van Putten WLJ, Wárlám-Rodenhuis CC, van den Bergh ACM, De Winter KAJ, Koper PCM, Lybeert MLM, Slot A, Lutgens LCHW, Kroese MCS, Beerman H, van Lent M. Outcome of High-Risk Stage IC, Grade 3, Compared With Stage 1 Endometrial Carcinoma Patients: The Postoperative Radiation Therapy in Endometrial Carcinoma Trial, 1234
- Creutzig U, Kaspers GJL. Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia (correspondence), 3432
- Creutzig U, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Lehrnbecher T. Early Death and Treatment-Related Mortality in Children Undergoing Therapy for Acute Myeloid Leukemia: Analysis of the Multicenter Clinical Trials AML-BFM 93 and AML-BFM 98, 4384
- Crinière E, *see* Hoang-Xuan K
- Crinò L, *see* Benedetti G
- Cristofanilli M, Singletary ES, Hortobagyi GN. Inflammatory Breast Carcinoma: The Sphinx of Breast Cancer Research (correspondence), 381
- Cristofani LM, *see* Michalkiewicz E
- Crivellari D, Goldhirsch A, Coates A. Hormonal Treatment Duration in Elderly Patients: An Open Question (correspondence), 1164
- Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, Iznaga-Escobar N, Figueredo R, Koropatnick J, Renginfo E, Fernández E, Álvarez D, Torres O, Ramos M, Leonard I, Pérez R, Lage A. Use of the Humanized Anti-Epidermal Growth Factor Receptor Monoclonal Antibody h-R3 in Combination With Radiotherapy in the Treatment of Locally Advanced Head and Neck Cancer Patients, 1646
- Crooks D, *see* Wright JR
- Crowley J, *see* Durie BGM
see Edelman MJ
- Crown JP, *see* Ooi WS
- Crown WH, *see* Chang S
- Crozet B, *see* Gerard J-P
- Cruz MA, *see* Montalbán C
- Cruz T, *see* Crombet T
- Cufer T, *see* Bottomley A
see Efficace F

- Culine S, *see* Fizazi K
 Cullen J, *see* Figueiredo MI
 Cullen JW, *see* Cushing B
 see Mandelblatt JS
 see Rogers PC
 Cullen JW, Schwartz MD, Lawrence WF, Selby JV, Mandelblatt JS. Short-Term Impact of Cancer Prevention and Screening Activities on Quality of Life, 943
 Culligan M, *see* Friedberg JS
 Cullings HM, *see* Nagasaka T
 Cumming K, *see* Diener-West M
 Cummings B, *see* Meyerhardt JA
 Cummings C, *see* Lipton LR
 Cummings K, *see* Kumar P
 Cumsille MA, *see* Santolaya ME
 Cunningham C, *see* Senzer N
 Cunningham D, *see* Chau I
 see Lal R
 see Rao S
 Cunningham MJ, *see* Berek JS
 Curigliano G, *see* De Pas T
 Curley SA, *see* Izzo F
 Curran W, *see* Meyers CA
 Cusan L, *see* Labrie F
 Cushing B, *see* Rogers PC
 Cushing B, Giller R, Cullen JW, Marina NM, Lauer SJ, Olson TA, Rogers PC, Colombani P, Rescorla F, Billmire DF, Vinocur CD, Hawkins EP, Davis MM, Perlman EJ, London WB, Castleberry RP. Randomized Comparison of Combination Chemotherapy With Etoposide, Bleomycin, and Either High-Dose or Standard-Dose Cisplatin in Children and Adolescents With High-Risk Malignant Germ Cell Tumors: A Pediatric Intergroup Study—Pediatric Oncology Group 9049 and Children’s Cancer Group 8882, 2691
 Cuttica A, *see* Corradini P
 Cuzick J, *see* Fallowfield L
 Cuzick J, Buzdar A, Baum M, Bianco R, Coleman R, Constenia M, Distler W, Dowsett M, Forbes J, Guastalla JP, Houghton J, Williams N, Howell A, Locker G, MacKey J, Sainsbury R, Tobias J. Adjuvant Use of Anastrozole in Breast Cancer (correspondence), 1524
 Cvitkovic E, *see* Yovine A
 Czarnetski B, *see* Agarwala SS
 Czerniecki B, *see* Gimotty PA
 Czerwinski D, *see* Weng W-K
 Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-López AJ. Prolonged Clinical and Molecular Remission in Patients With Low-Grade or Follicular Non-Hodgkin’s Lymphoma Treated With Rituximab Plus CHOP Chemotherapy: 9-Year Follow-Up, 4711
- D**
- Dagovic A, *see* Jeremic B
 Dahl G, *see* Bomgaars L
 Dahl O, *see* Sørbye H
 Dahmen G, *see* Antoch G
 Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM, Wright JJ, Parnes H, Chen CC, Jones E, Parker CE, Linehan WM, Figg WD. Randomized Phase II Trial of Docetaxel Plus Thalidomide in Androgen-Independent Prostate Cancer, 2532
 d’Aiuto M, *see* De Pas T
 Dakhil SR, *see* Jatoi A
 see Perez EA
 Dale DC, *see* Lyman GH
 Daley MD, *see* Raut CP
 Dalgleish AG, *see* Schey SA
 Dalhoff K, *see* Laack E
 Daliani DD, *see* Papandreou CN
 Dalton VK, *see* Waber DP
 Daly MB, *see* Rebbeck TR
 Daly MB. Tailoring Breast Cancer Treatment to Genetic Status: The Challenges Ahead (editorial), 1776
 Damiani S, *see* Benedetti G
 D’Amico AV, *see* Scher HI
 D’Amico AV, Renshaw AA, Cote K, Hurwitz M, Beard C, Loffredo M, Chen M-H. Impact of the Percentage of Positive Prostate Cores on Prostate Cancer–Specific Mortality for Patients With Low or Favorable Intermediate-Risk Disease, 3726
 Damico LA, *see* Johnson DH
 Damokosh AI, *see* Ayers M
 Damon L, *see* Somlo G
 Dancey J, *see* Reyno L
 Dancey JE, *see* Rich JN
 Dancey JE. Epidermal Growth Factor Receptor and Epidermal Growth Factor Receptor Therapies in Renal Cell Carcinoma: Do We Need a Better Mouse Trap? (editorial), 2975
 Danese S, *see* De Placido S
 Danesi R, *see* De Pas T
 Danforth DN, *see* Low JA
 D’Angio GJ, *see* Seibel NL
 Dang NH, Hagemeister FB, Pro B, McLaughlin P, Romaguera JE, Jones D, Samuels B, Samaniego F, Younes A, Wang M, Goy A, Rodriguez MA, Walker PL, Arredondo Y, Tong AT, Fayed L. Phase II Study of Denileukin Diftitox for Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma, 4095
 Darling J, *see* Landier W
 Darnell R. Tumor Immunity in Small-Cell Lung Cancer (editorial), 762
 Darnton SJ, *see* Casson AG
 Darouiche R, *see* Hanna H
 Das PM, Singal R. DNA Methylation and Cancer, 4632
 Das S, *see* Innocenti F
 see Relling MV
 Datar R, *see* Chatterjee SJ
 Datchary J, *see* Bonnetterre J
 Daud AI, *see* Naing A
 Daum SD, Ullrich R, Zeitz M. In Reply (correspondence), 2753
 Davey FR, *see* Byrd JC
 David YB, Gesundheit B, Urkin J, Kapelushnik J. Water Intake and Cancer Prevention, 384
 Davidson NE, *see* Citron ML
 see Perez EA
 see Sparano JA
 Davies AJ, Rohatiner AZS, Howell S, Britton KE, Owens SE, Micallef IN, Deakin DP, Carrington BM, Lawrance JA, Vinnicombe S, Mather SJ, Clayton J, Foley R, Jan H, Kroll S, Harris M, Amess J, Norton AJ, Lister TA, Radford JA. Tositumomab and Iodine I 131 Tositumomab for Recurrent Indolent and Transformed B-Cell Non-Hodgkin’s Lymphoma, 1469
 Davies SM, *see* Ross JA
 Davis FG, *see* Barnholtz-Sloan JS
 Davis JB, *see* Huguenin P
 Davis MM, *see* Cushing B
 see Rogers PC
 Davis MP, Dreicer R, Walsh D, Lagman R, LeGrand SB. Appetite and Cancer-Associated Anorexia: A Review, 1510
 Davis NB, Taber DA, Ansari RH, Ryan CW, George C, Vokes EE, Vogelzang NJ, Stadler WM. Phase II Trial of PS-341 in Patients With Renal Cell Cancer: A University of Chicago Phase II Consortium Study, 115
 Davis TC, *see* Dolan NC
 Davuluri RV, *see* Aldred MA
 Daw NC, *see* Sanders RP

- Daw NC, Santana VM, Iacono LC, Furman WL, Hawkins DR, Houghton PJ, Panetta JC, Gajjar AJ, Stewart CF. Phase I and Pharmacokinetic Study to Topotecan Administered Orally Once Daily for 5 Days for 2 Consecutive Weeks to Pediatric Patients With Refractory Solid Tumors, 829
- Dawkins FW, *see* Adams-Campbell LL
- Dawson NA, *see* Small EJ
- Dawson NV, *see* Rose JH
- Deacon DH, *see* Slingluff CL Jr
- Deakin DP, *see* Davies AJ
- Dean R, *see* Bishop MR
- Deapen D, *see* Johnson TK
- DeArmond G, *see* Repine TB
- Deavers MT, *see* Brown J
- de Baere TJ, *see* Goetz MP
- Debatin JF, *see* Antoch G
- Debernardis D, *see* Aschele C
- DeBiose DA, *see* Thomas CH
- de Bock GH, Bonnema J, van Der Hage J, Kievit J, van de Velde CJH. Effectiveness of Routine Visits and Routine Tests in Detecting Isolated Locoregional Recurrences After Treatment for Early-Stage Invasive Breast Cancer: A Meta-Analysis and Systematic Review, 4010
- De Boeck K, *see* Rossi J-F
- de Boer AGEM, van Lanschot JJB, van Sandick JW, Hulscher JFB, Stalmeier PFM, de Haes JCJM, Tilanus HW, Obertop TH, Sprangers MAG. Quality of Life After Transhiatal Compared With Extended Transthoracic Resection for Adenocarcinomas of the Esophagus, 4202
- de Botton S, Coiteux V, Chevret S, Rayon C, Vilmer E, Sanz M, de La Serna J, Philippe N, Baruchel A, Leverger G, Robert A, San Miguel J, Conde E, Ssotto JJ, Bordessoule D, Fegueux N, Fey M, Parry A, Chomienne C, Degos L, Fenaus P. Outcome of Childhood Acute Promyelocytic Leukemia With All-*Trans*-Retinoic Acid and Chemotherapy, 1404
- Debraud F, *see* Cassidy J
- de Braud F, *see* De Pas T
- de Bruijn HWA, *see* Skates SJ
- Debs RJ, *see* Kashani-Sabet M
- de Carvalho M, *see* Hadley DW
- De Castro J, *see* Casado E
- Deconinck E, *see* Rossi J-F
- De Conno F, *see* Caraceni A
- Dediu M. Should We Discard Vinorelbine Plus Cisplatin From the First-Line Therapy of Advanced Non-Small-Cell Lung Cancer? (correspondence), 1345
- Degnim A, *see* Hartmann LC
- Degos L, *see* de Botton S
- de Graaf PW, *see* Hartgrink HH
- de Gramont A, *see* Rao S
see Tournigand C
- De Grève J, *see* Samyn I
- de Haes H, *see* Efficace F
- de Haes JCJM, *see* de Boer AGEM
- Dehdashti F, *see* Bradley JD
see Grigsby PW
- DeLaat C, *see* Ginsberg JP
- Delaat C, *see* Silber JH
- de La Chapelle A, *see* Aldred MA
- Delaloge S, *see* Andre F
- DeLaney TF, *see* Jagsi R
- Delannoy A, *see* Thomas X
- dela Rosa C, *see* Disis ML
- de La Serna J, *see* de Botton S
- de Las Morenas A, *see* Schlechter BL
- De La Taille A, *see* Patard J-J
- Delattre JY, *see* Hoang-Xuan K
- De Laurentiis M, *see* De Placido S
- del Castillo R, *see* Crombet T
- Deliveliotis C, *see* Bamias A
- Del Vecchio M, Gattinoni L, Lozza L, Bajetta E. Unusual Aspects of Melanoma: Regionally Advanced Nasal Cavity Melanoma, 745
- DeMarco T, *see* Schwartz MD
- De Marinis F, *see* Hanna N
- DeMario M, *see* Dupont J
- Demas W, *see* Garden AS
- de Matteis A, *see* De Placido S
- Demetri GD, *see* Garcia-Carbonero R
- Demicheli R, Bonadonna G, Hrushesky WJM, Retsky MW, Valagussa P. Menopausal Status Dependence of Early Mortality Reduction Due to Diagnosis of Smaller Breast Cancers (T1 v T2-T3): Relevance to Screening, 102
- Demicheli R, Bonadonna G, Valagussa P, Hrushesky WJM, Retsky MW. In Reply (correspondence), 4860
- Demmy TL, Yasko JM, Collyar DE, Katz ML, Krasnov CL, Borwhat MJ, Battershell A, George SL. Managing Accrual in Cooperative Group Clinical Trials, 2997
- Demory J-L, *see* Marchetti M
- Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Calais G. Final Results of the 94-01 French Head and Neck Oncology and Radiotherapy Group Randomized Trial Comparing Radiotherapy Alone With Concomitant Radiochemotherapy in Advanced-Stage Oropharynx Carcinoma, 69
- Dent R, *see* Krzyzanowska MK
- Dent S, *see* Reyno L
- De Paolis M, *see* Bacci G
- De Pas T, Pelosi G, de Braud F, Veronesi G, Curigliano G, Leon ME, Danesi R, Noverasco C, d'Aiuto M, Catalano G, Viale G, Spaggiari L. Modulation of Epidermal Growth Factor Receptor Status by Chemotherapy in Patients with Locally Advanced Non-Small-Cell Lung Cancer Is Rare, 4966
- de Perrot M, Chernenko S, Waddell TK, Shargall Y, Pierre AF, Hutcheon M, Keshavjee S. Role of Lung Transplantation in the Treatment of Bronchogenic Carcinomas for Patients With End-Stage Pulmonary Disease, 4351
- De Placido S, Scambia G, Di Vagno G, Naglieri E, Lombardi AV, Biamonte R, Marinaccio M, Carteni G, Manzione L, Febbraro A, de Matteis A, Gasparini G, Valerio MR, Danese S, Perrone F, Lauria R, De Laurentiis M, Greggi S, Gallo C, Pignata S. Topotecan Compared With No Therapy After Response to Surgery and Carboplatin/Paclitaxel in Patients With Ovarian Cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) Randomized Study, 2635
- Depondt J, *see* Annane D
- De Porre P, *see* Kurzrock R
- Deraco M, *see* Glehen O
- de Reijke TM, *see* Collette L
- De Renzo A, *see* Picardi M
see Zinzani PL
- de Revel T, *see* Toumi N
- DeRosa D, *see* Wright JR
- De Rosa V, *see* Izzo F
- Derynck MK, *see* Oh WK
- de Saint Aubain Somerhausen N, *see* Guillou L
- De Santis M, *see* Potenza L
- De Santis M, Becherer A, Bokemeyer C, Stoiber F, Oechsle K, Sellner F, Lang A, Kletter K, Dohmen BM, Dittrich C, Pont J. 2-¹⁸F-fluoro-deoxy-D-glucose Positron Emission Tomography Is a Reliable Predictor for Viable Tumor in Postchemotherapy Seminoma: An Update of the Prospective Multicentric SEMPET Trial, 1034
- Desch C, *see* Hanna N

AUTHOR INDEX

- des Guetz G, Mariani P, Freneau P, Pouillart P. Paraneoplastic Syndromes in Cancer: Leucocytosis Associated With Liposarcoma Recurrence: Original Presentation of Liposarcoma Recurrence, 2242
- DeSilvio M, *see* Pollack A
- De Simone M, *see* Glehen O
- Detterbeck FC, *see* Fried DB
see Socinski MA
- Deutsch J, *see* Xiong HQ
- Deutsch M, *see* Sevastianos VA
see Taghian A
- deVere White R, *see* Herr HW
- Devi VL, Prabhaskar K, Malathi M, Madhumathi DS, Bapsy PP. Uncommon Manifestations of Common Malignancies: Chronic Lymphocytic Leukemia and Multiple Myeloma in the Same Patient, 3192
- Devine R, *see* Butow P
- Devine S, *see* Hoerr AL
- Devine SM, Flomenberg N, Vesole DH, Liesveld J, Weisdorf D, Badel K, Calandra G, DiPersio JF. Rapid Mobilization of CD34+ Cells Following Administration of the CXCR4 Antagonist AMD3100 to Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma, 1095
- DeVore RF III, *see* Johnson DH
- de Vries EG, *see* Buijs C
- Dewald G, *see* Greenberg PL
see Tallman MS
- Dewar DJ, Newell B, Green MA, Topping AP, Powell BWEM, Cook MG. The Microanatomic Location of Metastatic Melanoma in Sentinel Lymph Nodes Predicts Nonsentinel Lymph Node Involvement, 3345
- De Winter KAJ, *see* Creutzberg CL
- DeWitty RL, *see* Adams-Campbell LL
- Dezube BJ, *see* Doweiko J
see Pantanowitz L
- Dhami MS, *see* Smith BD
- Dhir R, *see* Yu YP
- D'Hombres A, *see* Pommier P
- Diamandis EP, *see* Scorilas A
- Diamond P, *see* Labrie F
- Dianzani C, *see* Vincenzi B
- Diaz J, *see* Miceli M
- Diaz-Rubio E, *see* Cassidy J
- Dickgreber N, *see* Laack E
- Dickman PS, *see* Miser JS
- Dickson J, *see* Lal R
- Dickson L, *see* Hirschowitz EA
- Di Cosimo S, *see* Ferretti G
- Diehl V, *see* Bredenfeld H
see Kiehl MG
- Diehl V. Chemotherapy or Combined Modality Treatment: The Optimal Treatment for Hodgkin's Disease (editorial), 15
- Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, Green DL, Hawkins BS, Hayman J, Jaiyesimi I, Kirkwood JM, Koh W-J, Robertson DM, Shaw JM, Thoma J. Screening for Metastasis From Choroidal Melanoma: The Collaborative Ocular Melanoma Study Group Report 23, 2438
- Diéras V, Fomoleau P, Romieu G, Tubiana-Hulin M, Namer M, Mauriac L, Guastalla J-P, Pujade-Lauraine E, Kerbrat P, Maillart P, Pénault-Llorca F, Buysse M, Pouillart P. Randomized Parallel Study of Doxorubicin Plus Paclitaxel with Doxorubicin Plus Cyclophosphamide As Neoadjuvant Treatment of patients with Breast Cancer, 4958
- Dieringer P, *see* Papandreou CN
- Dierlamm T, *see* Laack E
- Dietrich D, *see* Studer UE
- Dietz K, *see* Bader P
- Diez B, *see* Kellie SJ
- Di Febo G, *see* Biasco G
- Dignam J, *see* Mandelblatt JS
- Diller L, *see* Adams MJ
- Dillon PW, Jones GR, Bagnall-Reeb, HA, Buckley JD, Wiener ES, Haase GM. Prophylactic Urokinase in the Management of Long-Term Venous Access Devices in Children: A Children's Oncology Group Study, 2718
- Dilloo D, *see* Bader P
- Di Maio M, *see* Normanno N
see Perrone F
- Di Maria MV, *see* Hirsch FR
- Dimery I, *see* Howell A
- Dimitrijevic S, *see* Went PT
- Dimofte A, *see* Friedberg JS
- Dimond E, *see* Hadley DW
- Dimopoulos MA, *see* Bamias A
- Ding I, *see* Okunieff P
- Dinndorf P, *see* Lange BJ
- Dinney CP, *see* Patard J-J
- Dinshaw KA, *see* Laskar S
- DiPaola RS, *see* Kaufman HL
see Kumar P
see Oh WK
- DiPersio JF, *see* Devine SM
- Dipersio JF, *see* Hoerr AL
- Dirnhofer S, *see* Went PT
- Dirsch O, *see* Vanhoefer U
- Di Russo A, *see* Bonadonna G
- Disis ML, Schiffman K, Guthrie K, Salazar LG, Knutson KL, Goodell V, dela Rosa C, Cheever MA. Effect of Dose on Immune Response in Patients Vaccinated With an HER-2/neu Intracellular Domain Protein-Based Vaccine, 1916
- Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, Greipp PR, Witzig TE, Lust JA, Rajkumar SV, Fonseca R, Zeldenrust SR, McGregor CGA, Jaffe AS. Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis, 3751
- DiStasio S, *see* Psyrrri A
- Distler W, *see* Cuzick J
- Dittrich C, *see* De Santis M
- Di Vagno G, *see* De Placido S
- Dizon D, *see* Sabbatini P
- Döbert N, *see* Kovács AF
- Dodd M, *see* Miasowski C
- Dodero A, *see* Corradini P
- Dodge RK, *see* Kolitz JE
- Dohmen BM, *see* De Santis M
see Krauss K
- Döhner H, *see* Fröhling S
see Haslinger C
see Schlenk RF
- Döhner K, *see* Fröhling S
see Schlenk RF
- Dolan NC, Ferreira MR, Davis TC, Fitzgibbon ML, Rademaker A, Liu D, Schmitt BP, Gorby N, Wolf M, Bennett CL. Colorectal Cancer Screening Knowledge, Attitudes, and Beliefs Among Veterans: Does Literacy Make a Difference?, 2617
- Dombret H, *see* Thomas X
- Dome JS, *see* Sanders RP
- Dominguez G, *see* Berwick M
- Donahue TF, *see* Amling CL
- Donaldson SS, *see* Hudson MM
see Lieskovsky YE
see Miser JS
see Wharam MD
- Donato B, *see* Ramsey SD
- Donato M, *see* Escalón MP
- Donelan K, *see* Jagsi R

- Donohue JH, *see* Martenson JA Jr
 Donohue K, *see* Aljada IS
 Dooley M, *see* Stefanou A
 Doong S-L, *see* Kuo S-H
 Dorey FJ, *see* Patard J-J
 Dorn J, *see* Scorilas A
 Doroshov JH, *see* Somlo G
 Dostalova J, *see* Rao S
 Douillard J-Y, *see* Negrier S
 Dourakis SP, *see* Sevastianov VA
 Doweiko J, Dezube BJ, Pantanowitz L. Unusual Sites of Hodgkin's Lymphoma: HIV-Associated Hodgkin's Lymphoma of the Stomach, 4227
 Dowell JE, Minna JD. Cancer Chemotherapy Targeted at Reactivating the Expression of Epigenetically Inactivated Genes (editorial), 1353
 Dowell JM, *see* Rich JN
 Downey RJ, Akhurst T, Gonen M, Vincent A, Bains MS, Larson S, Rusch V. Preoperative F-18 Fluorodeoxyglucose-Positron Emission Tomography Maximal Standardized Uptake Value Predicts Survival After Lung Cancer Resection, 3255
 Dowsett M, *see* Cuzick J
 Doyle J, *see* Gassas A
 Doyle JJ, *see* Godder K
 Drake M, *see* Morris C
 Dreicer R, *see* Davis MP
 Dreno B, *see* Agarwala SS
 Dreyer ZA, *see* Zebrack BJ
 Dreyling M, *see* Lenz G
 Drissi R, *see* Sanders RP
 Drivsholm L, *see* Monstad SE
 Drolet Y, *see* Labrie F
 Drucker B, *see* Kondagunta GV
 Druker BJ, *see* Peng B
 Du W, *see* Simon MS
 Duba H-C, *see* Fiegl M
 DuBeshter B, *see* Thigpen JT
 Dubinett SM, Elashoff D, Meyerson M. Assessing Prognosis in Non-Small-Cell Lung Cancer: Avenues to a More Complete Picture? (editorial), 3209
 Dubois S, *see* Wright JR
 DuBois SG, Messina J, Maris JM, Huberty J, Glidden DV, Veatch J, Charon M, Hawkins R, Matthey KK. Hematologic Toxicity of High-Dose Iodine-131-Metaiodobenzylguanidine Therapy for Advanced Neuroblastoma, 2452
 Dubs A, Jacky E, Stahel R, Taverna C, Honegger H. Ototoxicity in Patients With Dose-Intensive Therapy for Cisplatin-Resistant Germ Cell Tumors (correspondence), 1158
 Duda RB, *see* Bober SL
 Dueckers G, *see* Bader P
 Duerst R, *see* Campbell AD
 Duffau H, *see* Hoang-Xuan K
 Dufresne A, *see* Waber DP
 Dufresne J, *see* Labrie F
 Dugan K, *see* Greenberg PL
 Duggan D, *see* Winer EP
 Dukart G, *see* Atkins MB
 Dumon J-C, *see* Mancini I
 Dumontet C, *see* Hequet O
 Dunant A, *see* Andre F
 Dunkel IJ, *see* Kellie SJ
 see Modak S
 Dupont J, *see* Sabbatini P
 Dupont J, Bienvenu B, Aghajanian C, Pezzulli S, Sabbatini P, Vongphrachanh P, Chang C, Perkell C, Ng K, Passe S, Breimer L, Zhi J, DeMario M, Spriggs D, Soignet SL. Phase I and Pharmacokinetic Study of the Novel Oral Cell-Cycle Inhibitor Ro 31-7453 in Patients With Advanced Solid Tumors, 3366
 Dupont J, Tanwar MK, Thaler HT, Fleisher M, Kauff N, Hensley ML, Sabbatini P, Anderson S, Aghajanian C, Holland EC, Spriggs DR. Early Detection and Prognosis of Ovarian Cancer Using Serum YKL-40, 3330
 Dupriez B, *see* Marchetti M
 Dupuis LL, *see* Gassas A
 Durie BGM, Jacobson J, Barlogie B, Crowley J. Magnitude of Response With Myeloma Frontline Therapy Does Not Predict Outcome: Importance of Time To Progression in Southwest Oncology Group Chemotherapy Trials, 1857
 Dürk H, *see* Laack E
 Dutcher J, *see* Rowinsky EK
 Dutcher JP, *see* Atkins MB
 Duvillard P, *see* Toumi N
 Dvorak T, *see* Hanna H
 Dworzak M, *see* Creutzig U
 Dy GK, Bekele L, Hanson LJ, Furth A, Mandrekar S, Sloan JA, Adjei AA. Complementary and Alternative Medicine Use by Patients Enrolled Onto Phase I Clinical Trials, 4810
 Dyczka J, *see* Efficace F
- E**
- Eapen M, *see* Godder K
 Eapen M, Horowitz MM, Klein JP, Champlin RE, Loberiza FR Jr, Ringdén O, Wagner JE. Higher Mortality After Allogeneic Peripheral-Blood Transplantation Compared With Bone Marrow in Children and Adolescents: The Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry, 4872
 Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks JC. Trends in the Aggressiveness of Cancer Care Near the End of Life, 315
 Earle JD, *see* Diener-West M
 see Horning SJ
 Eberhart CG, *see* Fisher PG
 Eckhardt SG, *see* Ratain MJ
 Ecohard R, *see* Saurin J-C
 Edelman MJ, *see* Rudin CM
 Edelman MJ, Chansky K, Gaspar LE, Leigh B, Weiss GR, Taylor SA, Crowley J, Livingston R, Gandara DR. Phase II Trial of Cisplatin/Etoposide and Concurrent Radiotherapy Followed by Paclitaxel/Carboplatin Consolidation for Limited Small-Cell Lung Cancer: Southwest Oncology Group 9713, 127
 Edelson MI, *see* Norton TR
 Edgerton S, *see* Tedesco KL
 Edler L, *see* Laack E
 Edwards CG, *see* Byrd JC
 see Marcucci G
 Edwards JR, *see* Godder K
 Edwards K, *see* Gulec SA
 Efficace F, *see* Bottomley A
 Efficace F, Therasse P, Piccart MJ, Coens C, Van Steen K, Welnicka-Jaskiewicz M, Cufer T, Dyczka J, Lichinitser M, Shepherd L, de Haes H, Sprangers MA, Bottomley A. Health-Related Quality of Life Parameters As Prognostic Factors in a Nonmetastatic Breast Cancer Population: An International Multicenter Study, 3381
 Eftekhari Sadat AT, *see* Lipton LR
 Egberts ACG, *see* Graaf MR
 Ehninger G, *see* Kiehl MG
 see Schlenk RF
 Eickhoff J, *see* King, DM
 Eifel PJ, Winter K, Morris M, Levenback C, Grigsby PW, Cooper J, Rotman M, Gershenson D, Mutch DG. Pelvic Irradiation With Concurrent

AUTHOR INDEX

- Chemotherapy Versus Pelvic and Para-Aortic Irradiation for High-Risk Cervical Cancer: An Update of Radiation Therapy Oncology Group Trial (RTOG) 90–01, 872
- Eigentler TK, *see* Leiter U
- Eigentler TK, Buettner PG, Leiter U, Garbe C. Impact of Ulceration in Stages I to III Cutaneous Melanoma As Staged by the American Joint Committee on Cancer Staging System: An Analysis of the German Central Malignant Melanoma Registry, 4376
- Eilers KM, *see* Fromme EK
- Einhorn L, *see* Hanna N
- Einhorn LH, *see* Fisch MJ
see Houck W
see Schneider BP
- Einzig A, *see* Sparano JA
- Eisen A, *see* Metcalfe K
- Eisenberger CF, *see* Stoecklein NH
- Eisenberger M, *see* Scher HI
- Eisenberg PD, *see* Meyers CA
- Eisenfeld AJ, *see* Sabbatini P
- Eisenhauer E, *see* Bezzak A
- Eisenreich B, *see* Herold R
- Ejlertsen B, Mouridsen HT, Langkjer ST, Andersen J, Sjöström J, Kjaer M. Phase III Study of Intravenous Vinorelbine in Combination With Epirubicin Versus Epirubicin Alone in Patients With Advanced Breast Cancer: A Scandinavian Breast Group Trial (SB9403), 2313
- Ekeberg Ø, *see* Hem E
- Elashoff D, *see* Dubinett SM
see Freedland SJ
see Takeuchi H
- Elashoff R, *see* Takeuchi H
- Elder D, *see* Gimotty PA
- Elenitsas R, *see* Gimotty PA
- Elias D, *see* Glehen O
- Elkin EB, Schnitt SJ. In Reply (correspondence), 4232
- Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC. HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis, 854
- Elledge R, *see* Howell A
- Elliott P, *see* Papandreou CN
- Ellis J, *see* Palmer DH
- Ellis LM, Hoff PM. Targeting the Epidermal Growth Factor Receptor: An Important Incremental Step in the Battle Against Colorectal Cancer (editorial), 1177
- Ellis M, Ballman K. Trawling for Genes That Predict Response to Breast Cancer Adjuvant Therapy (editorial), 2267
- Ellis N, *see* Pasche B
- Ellis PA, *see* Hagerty RG
- Elsayem A, Swint K, Fisch MJ, Palmer JL, Reddy S, Walker P, Zhukovsky D, Knight P, Bruera E. Palliative Care Inpatient Service in a Comprehensive Cancer Center: Clinical and Financial Outcomes, 2008
- Elson P, *see* Alatrash G
- Emanuel EJ, *see* Schneider EC
- Emery CF, *see* Andersen BL
- Endoh H, Tomida S, Yatabe Y, Konishi H, Osada H, Tajima K, Kuwano H, Takahashi T, Mitsudomi T. Prognostic Model of Pulmonary Adenocarcinoma by Expression Profiling of Eight Genes As Determined by Quantitative Real-Time Reverse Transcriptase Polymerase Chain Reaction, 811
- Eng C, *see* Aldred MA
- Engelhardt LR, *see* Cheng JD
- Engelholm SA, *see* Gronlund B
- Engelking C, *see* Benson AB III
- Engel-Riedel W, *see* Laack E
- Engert A, *see* Bredenfeld H
- Ennis M, *see* Goodwin PJ
- Ennis RD. Uncertainties Regarding Pelvic Radiotherapy for Prostate Cancer (correspondence), 2254
- Ensor CM, *see* Izzo F
- Epstein AM, *see* Schneider EC
- Erazo A, *see* Keller AM
- Erbersdobler A, *see* Stoecklein NH
- Erikstein B, *see* Brandberg Y
- Erlichman C, *see* Alberts SR
- Ermani M, *see* Brandes AA
- Ernst E, *see* Roffe L
- Erwin BA, Sullivan PA, Ten Have TR. Trial of Antidepressants for Mildly Depressed Cancer Patients Should Have Been Reported in a Manner Allowing Independent Evaluation on Investigators' Claims (correspondence), 753
- Escalón MP, Champlin RE, Saliba RM, Acholonu SA, Hosing C, Fayad L, Giralt S, Ueno NT, Maadani F, Pro B, Donato M, McLaughlin P, Khouri IF. Nonmyeloablative Allogeneic Hematopoietic Transplantation: A Promising Salvage Therapy for Patients With Non-Hodgkin's Lymphoma Whose Disease Has Failed a Prior Autologous Transplantation, 2419
- Escudier B, *see* Negrier S
- Esfahanian S, *see* Smith BD
- Eshelman DA, *see* Landier W
- Esper P, *see* Kent E
- Espina B, *see* Levine AM
- Espinouse D, *see* Hequet O
- Esseltine D, *see* Papandreou CN
- Essner R, *see* Lee JH
- Estevan R, *see* Fernández-Martos C
- Estey EH, *see* Kurzrock R
- Etienne PL, *see* Bouché O
- Ettenberg SA, *see* Tan AR
- Ettinger DS, *see* Loehrer PJ Sr
- Etzel CJ, *see* Pytynia KB
- Etzioni RD, *see* Ramsey SD
- Evans DB, *see* Kouvaraki MA
- Evans GR, *see* Rebbeck TR
- Evans WK, *see* Gagliardi A
- Everett AD, *see* Ren H
- Eychmueller S, *see* Glare PA

F

- Fabi A, *see* Ferretti G
- Fabiani B, *see* Mounier N
- Fabris G, *see* Scartozzi M
- Faderl SH, *see* Kurzrock R
- Fahs M, *see* Mandelblatt JS
- Faiss S, Pape U-F, Wiedenmann B. In Reply (correspondence), 574
- Faivre S, *see* Raymond E
- Falcone A, *see* Marchetti M
- Faldum A, *see* Simon T
- Falini B, *see* Zinzani PL
- Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A. Quality of Life of Postmenopausal Women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial, 4261
- Famoni MF, *see* Spentzos D
- Fan DSP, *see* Liu DTL
- Fandi A, *see* Giaccone G
see Herbst RS
- Faquin WC, *see* French CA
- Farahmand BY, *see* Lens MB
- Fardig J, *see* Kent E

AUTHOR INDEX

- Fargeot P, *see* Bonnetterre J
see Bottomley A
- Fargeot P, Bonnetterre J, Roché H, Lortholary A, Campone M, Van Praagh I, Monnier A, Namer M, Schraub S, Barats J-C, Guastalla J-P, Goudier M-J, Chapelle-Marcillac I. Disease-Free Survival Advantage of Weekly Epirubicin Plus Tamoxifen Versus Tamoxifen Alone as Adjuvant Treatment of Operable, Node-Positive, Elderly Breast Cancer Patients: 6-Year Follow-Up Results of the French Adjuvant Study Group 08 Trial, 4674
- Farina L, *see* Corradini P
- Farrar WB, *see* Andersen BL
- Farrell MA, *see* Goetz MP
- Farruggio A, *see* Montella L
- Fattori PP, *see* Zinzani PL
- Faulhaber PF, *see* Sodee DB
- Faulkner JR, *see* Herr HW
- Fauser AA, *see* Kiehl MG
- Fayad L, *see* Escalón MP
- Fayed L, *see* Dang NH
- Fayers PM, *see* Sundstrøm S
- Fazio N, Oberg K. Prospective, Randomized, Multicenter Trial on the Antiproliferative Effect of Lanreotide, Interferon Alfa, and Their Combination for Therapy of Metastatic Neuroendocrine Gastroenteropancreatic Tumors (correspondence), 573
- Fearon B, *see* Vickers AJ
- Fearon ER, *see* Mehlen P
- Febbraro A, *see* De Placido S
- Fedenko KM, *see* Dahut WL
- Fegueux N, *see* de Botton S
see Thomas X
- Fehn K, *see* Wadler S
- Fehrenbacher L, *see* Johnson DH
- Feig B, *see* Ajani JA
- Feig BW, *see* Chen AM
see Pisters PWT
see Raut CP
- Feig S, *see* Lange BJ
- Feld J, *see* Michael M
- Feldman BM, *see* Sung L
- Feliu J, *see* Casado E
- Fenaux P, *see* de Botton S
see Thomas X
- Fenger C, *see* Bardi G
- Feng L, *see* Lu C
see Ren H
- Feng W, *see* Yen Y
- Fereshetian A, *see* Rockwell L
- Fermin E, *see* Somlo G
- Fernández-Aramburo A, *see* Alba E
- Fernández E, *see* Crombet T
- Fernández-Martos C, Aparicio J, Bosch C, Torregrosa M, Campos JM, Garcera S, Vicent JM, Maestu I, Climent MA, Mengual JL, Tormo A, Hernandez A, Estevan R, Richart JM, Viciano V, Uribe N, Campos J, Puchades R, Arlandis F, Almenar D. Preoperative Uracil, Tegafur, and Concomitant Radiotherapy in Operable Rectal Cancer: A Phase II Multicenter Study With 3 Years' Follow-Up, 3016
- Fernandez-Teijeiro A, Betensky RA, Sturla LM, Kim JYH, Tamayo P, Pomeroy SL. Combining Gene Expression Profiles and Clinical Parameters for Risk Stratification in Medulloblastomas, 994
- Fernberg O, *see* Cheng JD
- Ferrari A, *see* Potenza L
- Ferreira CMM, *see* Kashani-Sabet M
- Ferreira MR, *see* Dolan NC
- Ferreri AJ, *see* Brandes AA
- Ferreri AJM, *see* Reni M
- Ferretti G, Di Cosimo S, Giannarelli D, Carlini P, Papaldo P, Alimonti A, Fabi A, Mandalà M, Milella M, Ruggeri EM, Cognetti F. *HER2/neu* Expression and Hormonal Therapy in Early Breast Cancer: Can Muddy Waters Become Clear? (correspondence), 568
- Ferry D, *see* Casson AG
- Fervers B, *see* Burgers JS
- Fetting JH, *see* Meyskens FL Jr
- Feugier P, *see* Mounier N
- Feusner J, *see* Lange BJ
- Fey M, *see* de Botton S
- Ficarra V, *see* Patard J-J
- Fidler IJ, *see* Mathew P
- Fiegl M, Haun M, Massoner A, Krugmann J, Müller-Holzner E, Hack R, Hilbe W, Marth C, Duba H-C, Gastl G, Grünewald K. Combination of Cytology, Fluorescence In Situ Hybridization for Aneuploidy, and Reverse-Transcriptase Polymerase Chain Reaction for Human Mammaglobin/Mammaglobin B Expression Improves Diagnosis of Malignant Effusions, 474
- Fields P, *see* Schey SA
- Fiere D, *see* Thomas X
- Fife KM, Colman MH, Stevens GN, Firth IC, Moon D, Shannon KF, Harman R, Petersen-Schaefer K, Zacest AC, Besser M, Milton GW, McCarthy WH, Thompson JF. Determinants of Outcome in Melanoma Patients With Cerebral Metastases, 1293
- Figer A, *see* Cassidy J
- Figg WD, *see* Chan LW
see Cox MC
see Dahut WL
see Sparreboom A
see Tan AR
- Figlin R, *see* Rowinsky EK
- Figlin RA, *see* Patard J-J
- Figueiredo B, *see* Michalkiewicz E
- Figueiredo MI, Cullen J, Hwang Y-T, Rowland JH, Mandelblatt JS. Breast Cancer Treatment in Older Women: Does Getting What You Want Improve Your Long-Term Body Image and Mental Health?, 4002
- Figueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L. Adjuvant Therapy for Stage II Colon Cancer: A Systematic Review From the Cancer Care Ontario Program in Evidence-Based Care's Gastrointestinal Cancer Disease Site Group, 3395
- Figueredo AT, *see* Benson AB III
- Figueredo R, *see* Crombet T
- Figuerola BE, Brown JR, Nascimento A, Fisher DC, Tuli S. Unusual Sites of Hodgkin's Lymphoma: Hodgkin's Lymphoma of the CNS Masquerading As Meningioma, 4228
- Filippa DA, *see* Chang DZ
- Finch C, *see* Schwartz MD
- Findlay BP, *see* Goldberg RM
- Fine HA. Toward a Glioblastoma Vaccine: Promise and Potential Pitfalls (editorial), 4240
- Fine S, *see* Bull SB
- Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA. Patient Beliefs and Tamoxifen Discontinuance in Older Women With Estrogen Receptor-Positive Breast Cancer, 3309
- Fink U, *see* Wieder HA
- Finke J, *see* Alatrash G
- Finkelstein JS, *see* Smith MR
- Finkelstein S, *see* Yu YP
- Finkler N, *see* Berek JS
- Finklestein JZ, *see* Seibel NL
- Finlay J, *see* Hilden JM
- Finlay JL, *see* Chi SN
see Kellie SJ
see Modak S
- Finley D, *see* Chang S
- Firth IC, *see* Fife KM

AUTHOR INDEX

- Fischer JJ, *see* Smith BD
 Fischer L, *see* Kiewe P
 Fisch MJ, *see* Bruera E
 see Elsayem A
 Fisch MJ, Kristeller JL, Passik S, Loehrer PJ, Einhorn LH. In Reply (correspondence), 206, 754
 Fisher B, *see* Martenson JA Jr
 see Roa W
 Fisher DC, *see* Figueroa BE
 see Ghia KK
 Fisher EZ, *see* Racz LE
 Fisher-Malloy MJ, *see* Given C
 Fisher PG, Burger PC, Eberhart CG. Biologic Risk Stratification of Medulloblastoma: The Real Time Is Now (editorial), 971
 Fisher RI, *see* Lyman GH
 Fisher S, *see* Lipton LR
 Fitch TR, *see* Alberts SR
 see Perez EA
 Fitzgerald TJ, *see* Wharam MD
 Fitzgibbon J, *see* Last KW
 Fitzgibbon ML, *see* Dolan NC
 Fizazi K, Culine S, Kramar A, Amato RJ, Bouzy J, Chen I, Droz J-P, Logothetis CJ. Early Predicted Time to Normalization of Tumor Markers Predicts Outcome in Poor-Prognosis Nonseminomatous Germ Cell Tumors, 3868
 Flaherty L, *see* Simon MS
 Flamm AL, *see* Hwang JP
 Flatt SW, *see* Rock CL
 Fleischauer A, *see* Ladas EJ
 Fleisher M, *see* Dupont J
 Fleming GF, *see* Winer EP
 Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, Kline R, Burger RA, Goodman A, Burks RT. Phase III Trial of Doxorubicin Plus Cisplatin With or Without Paclitaxel Plus Filgrastim in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study, 2159
 Flens MJ, *see* Jongbloed MRM
 Flesh M, *see* Tournigand C
 Flessa HC, *see* Gear RB
 Fletcher DM, *see* Oliveira AM
 Fletcher JA, *see* Corless CL
 see French CA
 Fletcher RH, *see* Ayanian JZ
 Flinn IW, *see* Chan ATC
 Flomenberg N, *see* Devine SM
 Flores E, *see* Montalbán C
 Flynn PJ, *see* Benson AB III
 Focan C, *see* Hrushesky W
 Foekens JA, *see* Span PN
 Fokstuen T, *see* Sørbye H
 Foley JP, *see* Amling CL
 Foley R, *see* Davies AJ
 Folwaczny, *see* Glas J
 Fontaine C, *see* Samyn I
 Foody T, *see* Hirschowitz EA
 Foon KA, *see* Rowinsky EK
 Forastiere AA, *see* Argiris A
 see Armanios M
 see Garden AS
 Forbes J, *see* Cuzick J
 Ford HER, *see* Chau I
 Ford J, *see* Peng B
 Ford PA, *see* Ballen KK
 Forman S, *see* Somlo G
 Fornander T, *see* Sverrisdóttir A
 Fornara P, *see* Atzpodien J
 Forni C, *see* Bacci G
 Forsberg G, *see* Cheng JD
 Forsyth P, *see* Roa W
 Forte KJ, *see* Landier W
 Fossà SD, *see* Collette L
 Fossati R, *see* Johnson FE
 Fossella FV, *see* Hanna N
 Foster NR, *see* Alberts SR
 Foster T, *see* Su YB
 Fouad MN, *see* Ayanian JZ
 Fouladi M, *see* Stewart CF
 Fouladi M, Chintagumpala M, Laningham FH, Ashley D, Kellie SJ, Langston JW, McCluggage CW, Woo S, Kocak M, Krull K, Kun LE, Mulhern RK, Gajjar A. White Matter Lesions Detected by Magnetic Resonance Imaging After Radiotherapy and High-Dose Chemotherapy in Children With Medulloblastoma or Primitive Neuroectodermal Tumor, 4551
 Foulkes WD, *see* Metcalfe K
 Fountzilias G, *see* Bamias A
 Fourcade L, *see* Leclair M-D
 Fourquet A, *see* Louis-Sylvestre C
 Foussard C, *see* Rossi J-F
 Fowler CJF, *see* Peterit DG
 Fowler DH, *see* Bishop MR
 Fra J, *see* Avril MF
 Franchi M, *see* Bolis G
 Francini G, *see* Gill S
 Francis S, *see* Fallowfield L
 Frankel P, *see* Somlo G
 Franklin J, *see* Bomgaars L
 see Bredenfeld H
 Franklin WA, *see* Hirsch FR
 Fraschini G, *see* Thomas E
 Fraser R, *see* Socinski MA
 Frassoni F, *see* Ringdén O
 Frati L, *see* Gradilone A
 Fratkin M, *see* Hillner BE
 Freedland SJ, Aronson WJ, Kane CJ, Presti JC Jr, Amling CL, Elashoff D, Terris MK. Impact of Obesity on Biochemical Control After Radical Prostatectomy for Clinically Localized Prostate Cancer: A Report by the Shared Equal Access Regional Cancer Hospital Database Study Group, 446
 Freeman C, *see* Hébert-Croteau N
 Freeman CR, *see* Landier W
 Freeman JK, *see* Rockwell L
 French CA, Kutok JL, Faquin WC, Toretzky JA, Antonescu CR, Griffin CA, Nose V, Vargas SO, Moschovi M, Tzortzatos-Stathopoulou F, Miyoshi I, Perez-Atayde AR, Aster JC, Fletcher JA. Midline Carcinoma of Children and Young Adults With *NUT* Rearrangement, 4135
 Freneau P, *see* des Guetz G
 Freudenberg LS, *see* Antoch G
 Frickhofen N, *see* Zander AR
 Friebe T, *see* Rebeck TR
 Fried DB, Morris DE, Poole C, Rosenman JG, Halle JS, Detterbeck FC, Hensing TA, Socinski MA. Systematic Review Evaluating the Timing of Thoracic Radiation Therapy in Combined Modality Therapy for Limited-Stage Small-Cell Lung Cancer, 4837
 Friedberg J, *see* Lyman GH
 Friedberg JS, Mick R, Stevenson JP, Zhu T, Busch TM, Shin D, Smith D, Culligan M, Dimofte A, Glatstein E, Hahn SM. Phase II Trial of Pleural Photodynamic Therapy and Surgery for Patients With Non-Small-Cell Lung Cancer With Pleural Spread, 2192
 Friederichs J, *see* Gertler R
 Friedlander M, *see* Hogg R
 Friedlander ML, *see* Phillips K-A

AUTHOR INDEX

- Friedli C, *see* Huguenin P
 Friedman AH, *see* Rich JN
 Friedman DL, *see* Landier W
 Friedman HS, *see* Rich JN
 Friedmann AM, *see* Hudson MM
 Fries S, *see* Bredenfeld H
 Fritsch JC, *see* Madersbacher S
 Fröhling S, Schlenk RF, Stolze I, Bihlmayr J, Benner A, Kreitmeier S, Tobis K, Döhner H, Döhner K. *CEBPA* Mutations in Younger Adults With Acute Myeloid Leukemia and Normal Cytogenetics: Prognostic Relevance and Analysis of Cooperating Mutations, 624
 Fromme EK, Eilers KM, Mori M, Hsieh Y-C, Beer TM. How Accurate Is Clinician Reporting of Chemotherapy Adverse Effects? A Comparison With Patient-Reported Symptoms From the Quality-of-Life Questionnaire C30, 3485
 Froz J-P, *see* Fizazi K
 Frye DK, *see* Thomas E
 Fryer CJH, *see* Miser JS
 Fuchs CS, *see* Goldberg RM
 see Meyerhardt JA
 Fujimoto A, *see* Takeuchi H
 Fulham MJ, *see* Viney RC
 Fuller C, *see* Gajjar A
 Fulton D, *see* Roa W
 Fumoleau P, *see* Bonnetterre J
 see Diéras V
 Furman WL, *see* Aquino VM
 see Daw NC
 see Wagner LM
 Furth A, *see* Dy GK
 Furth AF, *see* Garrity MM
- G**
- Gaa J, *see* Kovács AF
 Gabert J, *see* Thomas X
 Gable P, *see* Small EJ
 Gafni A, *see* Simunovic M
 see Wright JR
 Gagliardi A, Grunfeld E, Evans WK. Evaluation of Diagnostic Assessment Units in Oncology: A Systematic Review, 1126
 Gagnon B, *see* Jatoi A
 Gagnon B, Mayo NE, Hanley J, MacDonald N. Pattern of Care at the End of Life: Does Age Make a Difference in What Happens to Women With Breast Cancer?, 3458
 Gahrton G, *see* Morris C
 Gajdos P, *see* Annane D
 Gajewski TF, *see* Zimmerman TM
 Gajewski TF. Temozolomide for Melanoma: New Toxicities and New Opportunities (editorial), 580
 Gajjar A, *see* Fouladi M
 see Stewart CF
 Gajjar A, Hernan R, Kocak M, Fuller C, Lee Y, McKinnon PJ, Wallace D, Lau C, Chintagumpala M, Ashley DM, Kellie SJ, Kun L, Gilbertson RJ. Clinical, Histopathologic, and Molecular Markers of Prognosis: Toward a New Disease Risk Stratification System for Medulloblastoma, 984
 Gajjar AJ, *see* Daw NC
 Galecki A, *see* Given C
 Gale RP, *see* Godder K
 Gallagher G, *see* Guillou L
 Gallion HH, Brunetto VL. In Reply (correspondence), 2972
 Gallo C, *see* De Placido S
 see Perrone F
 Gallo L, *see* Aschele C
 Gamucci T, *see* Bottomley A
 Gan J, *see* King, DM
 Gandara DR, *see* Edelman MJ
 Ganem G, *see* Tournigand C
 Ganser A, *see* Kiehl MG
 see Schlenk RF
 Ganz PA, *see* Lippman SM
 see Tannock IF
 Gao F, *see* Hoerr AL
 Gao L, *see* Liu DTL
 Garaud P, *see* Denis F
 Garaventa A, *see* Carli M
 Garay CA, *see* Kemeny N
 Garbe C, *see* Eigentler TK
 see Leiter U
 Garber JE, *see* Lippman SM
 see Rebbbeck TR
 Garber JE, Hartman A-R. Prophylactic Oophorectomy and Hormone Replacement Therapy: Protection at What Price? (editorial), 978
 Garcera S, *see* Fernández-Martos C
 Garcia-Carbonero R, Supko JG, Manola J, Seiden MV, Harmon D, Ryan DP, Quigley MT, Merriam P, Canniff J, Goss G, Matulonis U, Maki RG, Lopez T, Puchalski TA, Sancho MA, Gomez J, Guzman C, Jimeno J, Demetri GD. Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients With Progressive Sarcomas of Soft Tissues Refractory to Chemotherapy, 1480
 García JF, *see* Montalbán C
 García-Laraña J, *see* Montalbán C
 García-Manero G, *see* Kurzrock R
 García-Sanz R, *see* Montalbán C
 Garden AS, Harris J, Vokes EE, Forastiere AA, Ridge JA, Jones C, Horwitz EM, Glisson BS, Nabell L, Cooper JS, Demas W, Gore E. Preliminary Results of Radiation Therapy Oncology Group 97-03: A Randomized Phase II Trial of Concurrent Radiation and Chemotherapy for Advanced Squamous Cell Carcinomas of the Head and Neck, 2856
 Gardner S, *see* Modak S
 Gardner SL, *see* Chi SN
 Garewal HS, *see* Schrag D
 Gargiulo G, *see* Picardi M
 Garin A, *see* Reyno L
 Garris J, *see* Tisman G
 Garrity MM, Burgart LJ, Mahoney MR, Windschitl HE, Salim M, Wiesenfeld M, Krook JE, Michalak JC, Goldberg RM, O'Connell MJ, Furth AF, Sargent DJ, Murphy LM, Hill E, Riehle DL, Meyers CH, Witzig TE. Prognostic Value of Proliferation, Apoptosis, Defective DNA Mismatch Repair, and p53 Overexpression in Patients With Resected Dukes' B2 or C Colon Cancer: A North Central Cancer Treatment Group Study, 1572
 Garst J, *see* Marks LB
 Garvin JH Jr, *see* Godder K
 Gaskins M, *see* Adams-Campbell LL
 Gasparini G, *see* De Placido S
 see Longo R
 Gaspar LE, *see* Edelman MJ
 see Meyers CA
 Gassas A, Grant R, Richardson S, Dupuis LL, Doyle J, Allen U, Ablu O, Sung L. Predictors of Viridans Streptococcal Shock Syndrome in Bacteremic Children With Cancer and Stem-Cell Transplant Recipients, 1222
 Gasser T, *see* Studer UE
 Gastl G, *see* Fiegl M
 Gatsonis CG, *see* Wahl RL
 Gattinoni L, *see* Del Vecchio M
 Gatzemeier U, *see* Giaccone G
 see Hanna N
 Gaudreault J, *see* Johnson DH

- Gaur S, Aish LS, Oo TH. Difficult Diagnostic and Therapeutic Cases: Presentation of Prostate Cancer With Cervical Adenopathy, 957
- Gautam A, *see* Bepler C
- Gautschi O, Bigosch C, Huegli B, Jermann M, Marx A, Chassé E, Ratschiller D, Weder W, Joerger M, Betticher DC, Stahel RA, Ziegler A. Circulating Deoxyribonucleic Acid As Prognostic Marker in Non-Small-Cell Lung Cancer Patients Undergoing Chemotherapy, 4157
- Gazzaniga P, *see* Gradilone A
- Gazzard B, *see* Stebbing J
- Gea-Banacloche JC, *see* Bishop MR
- Gear RB, Heffelfinger S, Flessa HC. Unusual Lymphoma Manifestations: Natural Killer Cell Leukemia With Dermal Erythema and Vascular Epidermal Growth Factor Production, 557
- Gebhardt MC, *see* Miser JS
- Gee C, *see* Chatterjee SJ
- Géhanno P, *see* Annane D
- Geissler G, *see* Campbell AD
- Gelber RD, *see* Waber DP
- Gelber S, *see* Partridge AH
- Geletneký K, *see* Steiner HH
- Geller JI, Santana VM. Tumor Rupture and Mitotic Index in Pediatric Sex Cord-Stromal Tumors (correspondence), 2032
- Gelmon K, *see* Reyno L
- Genevay M, *see* Guillou L
- Gennarelli N, *see* Picardi M
- Gentilini P, *see* Zinzani PL
- Gentili S, *see* Marchetti M
- George B, *see* Chatterjee SJ
- George C, *see* Davis NB
- George J, *see* Banerjee M
- George SL, *see* Demmy TL
see Kolitz JE
- Georgoulas V, Ardavanis A, Agelidou A, Agelidou M, Chandrinou V, Tsaroucha E, Toumbis M, Kouroussis C, Syrigos K, Polyzos A, Samaras N, Papakotoulas P, Christofilakis C, Ziras N, Alegakis A. Docetaxel Versus Docetaxel Plus Cisplatin As Front-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer: A Randomized Multi-center Phase III Trial, 2602
- Georgoulas VA, *see* Keller AM
- Gerard J-P, Chapet O, Nemoz C, Hartweg J, Romestaing P, Coquard R, Barbet N, Maingon P, Mahe M, Baulieux J, Partensky C, Papillon M, Glehen O, Crozet B, Grandjean J-P, Adeleine P. Improved Sphincter Preservation in Low Rectal Cancer With High-Dose Preoperative Radiotherapy: The Lyon R96-02 Randomized Trial, 2404
- Gerber LH, *see* Okunieff P
- Gerbing R, *see* Lange BJ
- Germain T, *see* Denis F
- Gerritsen W, *see* Palmer DH
- Gersh BJ, *see* Perez EA
- Gershenson D, *see* Eifel PJ
- Gershenson DM, *see* Brown J
see Slomovitz BM
- Gertler R, Rosenberg R, Stricker D, Friederichs J, Hoos A, Werner M, Ulm K, Holzmann B, Nekarda H, Siewert J-R. Telomere Length and Human Telomerase Reverse Transcriptase Expression As Markers for Progression and Prognosis of Colorectal Carcinoma, 1807
- Gertz MA, *see* Dispenzieri A
- Gervais R, *see* Hanna N
- Gesundheit B, *see* David YB
- Gettinger S, Shapira I, Scheinfeld N, Grossbard M. Complications of Therapy in Cancer Patients. Case 2. Scrotal Ulceration During All-Trans-Retinoic Acid Therapy for Acute Promyelocytic Leukemia, 4648
- Gevargez A, *see* Goetz MP
- Geyer JR, *see* Bomgaars L
- Ghadirian P, *see* Metcalfe K
- Ghesani M, *see* Harandi A
- Ghia KK, Chen Y, Milner DA Jr, Fisher DC. Challenging Manifestations of Malignancies: Langerhans Cell Histiocytosis Presenting With a Skin Rash, 3640
- Ghiorzo P, *see* Casula M
- Gholam D, Lotz J-P, Atallah D, Theodore C. Germ Cell Tumors: Unusual Course of Pure Testicular Seminoma, 1755
- Ghossein R, *see* Kammula US
- Giaccone G, *see* Herbst RS
- Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH. Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non-Small-Cell Lung Cancer: A Phase III Trial—INTACT 1, 777
- Giannantoni P, *see* Longo R
- Giannarelli D, *see* Ferretti G
- Gianni AM, *see* Corradini P
- Gianni L, *see* Bonadonna G
- Gieseler F, *see* Laack E
- Gika D, *see* Bamias A
- Gilbert MR, *see* Puduvali VK
- Gilbertson RJ, *see* Gajjar A
- Gilde K, *see* Avril MF
- Giles FJ, *see* Kurzrock R
- Giles GG, *see* Phillips K-A
- Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Seitz JF, Labianca R, Chen W, Cha SS, Heldebrandt MP, Goldberg RM. Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?, 1797
- Gillen M, *see* Senzer N
- Giller R, *see* Cushing B
- Giller RH, *see* Rogers PC
- Gillies SD, *see* King, DM
- Gilliland DG, *see* Sternberg DW
- Gilliland FD, *see* Johnson TK
- Gilly FN, *see* Glehen O
- Gimm O, *see* Aldred MA
- Gimotty PA, Guerry DP, Ming ME, Elenitsas R, Xu X, Czerniecki B, Spitz F, Schuchter L, Elder D. Thin Primary Cutaneous Malignant Melanoma: A Prognostic Tree for 10-Year Metastasis Is More Accurate Than American Joint Committee on Cancer Staging, 3668
- Ginsberg J, *see* Blaney SM
- Ginsberg JP, Cnaan A, Zhao H, Clark BJ, Paridon SM, Chin AJ, Rychik J, Hogarty AN, Barber G, Rutkowski M, Kimball TR, DeLaat C, Steinerherz LJ, Silber JH. Using Health-Related Quality of Life Measures to Predict Cardiac Function in Survivors Exposed to Anthracyclines, 3149
- Giovannini M, *see* Bouché O
- Giralt S, *see* Escalón MP
- Gisselbrecht C, *see* Mounier N
- Given B, *see* Given C
- Given C, Given B, Rahbar M, Jeon S, McCorkle R, Cimprich B, Galecki A, Kozachik S, Brady A, Fisher-Malloy MJ, Courtney K, Bowie E. Effect of a Cognitive Behavioral Intervention on Reducing Symptom Severity During Chemotherapy, 507
- Glanzmann C, *see* Huguenin P
- Glare PA, Eychmueller S, McMahon P. Diagnostic Accuracy of the Palliative Prognostic Score in Hospitalized Patients With Advanced Cancer, 4823
- Glaser R, *see* Andersen BL
- Glas J, Török H-P, Schneider A, Brünner G, Kopp R, Albert ED, Stolte M, Folwaczny C. Allele 2 of the Interleukin-2 Receptor Antagonist Gene Is Associated With Early Gastric Cancer, 4746
- Glatstein E, *see* Friedberg JS
see Goffman TE

- Glehen O, *see* Gerard J-P
- Glehen O, Gilly FN. In Reply (correspondence), 203
- Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, Barone R, Yonemura Y, Cavaliere F, Quenet F, Gutman M, Tentles AAK, Lorimier G, Bernard JL, Bereder JM, Porcheron J, Gomez-Portilla A, Shen P, Deraco M, Rat P. Cytoreductive Surgery Combined With Perioperative Intraperitoneal Chemotherapy for the Management of Peritoneal Carcinomatosis From Colorectal Cancer: A Multi-Institutional Study, 3284
- Glick JH, *see* Horning SJ
- Glidden DV, *see* DuBois SG
- Glimelius B, *see* Sørbye H
- Glisson BS, *see* Garden AS
- Gluckman E, *see* Ringdén O
- Glusac EJ, *see* Smith BD
- Gning I, *see* Anderson KO
- Gobbi M, *see* Zinzani PL
- Göbel U, *see* Schneider DT
- Godder K, Eapen M, Laver JH, Zhang M-J, Camitta BM, Wayne AS, Gale RP, Doyle JJ, Yu LC, Chen AR, Garvin JH Jr, Sandler ES, Yeager AM, Edwards JR, Horowitz MM. Autologous Hematopoietic Stem-Cell Transplantation for Children With Acute Myeloid Leukemia in First or Second Complete Remission: A Prognostic Factor Analysis, 3798
- Goebell PJ, *see* Chatterjee SJ
- Goetz MP, Callstrom MR, Charboneau JW, Farrell MA, Maus TP, Welch TJ, Wong GY, Sloan JA, Novotny PJ, Petersen IA, Beres RA, Regge D, Capanna R, Saker MB, Grönemeyer DHW, Gevarguez A, Ahrar K, Choti MA, de Baere TJ, Rubin J. Percutaneous Image-Guided Radiofrequency Ablation of Painful Metastases Involving Bone: A Multicenter Study, 300
- Goffman TE, Glatstein E. Hypofractionation Redux?, 589
- Gold R, *see* Ströbel P
- Goldberg RM, *see* Garrity MM
- see* Gill S
- see* Grothey A
- see* Gunderson LL
- see* Martenson JA Jr
- Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR. A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer, 23
- Golden-Kreutz DM, *see* Andersen BL
- Goldfarb SL, *see* Janz NK
- Goldhirsch A, *see* Crivellari D
- Goldsmith SJ, *see* Milowsky MI
- Goldstein D, *see* Hagerty RG
- Goldstein LJ, *see* Tedesco KL
- Goldwasser MA, *see* Waber DP
- Goley E, *see* Chan LW
- Golob JA, *see* Rowinsky EK
- Golub RM, Bennett CL, Stinson T, Venta L, Morrow M. Cost Minimization Study of Image-Guided Core Biopsy Versus Surgical Excisional Biopsy for Women With Abnormal Mammograms, 2430
- Golubeva A, *see* Schlechter BL
- Gomez F, *see* Pommier P
- Gomez J, *see* Garcia-Carbonero R
- see* Miller VA
- Gomez-Portilla A, *see* Glehen O
- Gonen C, *see* Altundag O
- Gonen M, *see* Brenner B
- see* Downey RJ
- González-Barón M, *see* Casado E
- González-Camacho L, *see* Montalbán C
- Gonzalez Larriba JL, *see* Avril MF
- Goodell V, *see* Disis ML
- Goode M, *see* Smith MR
- Gooding R, *see* Adams-Campbell LL
- Goodin S, *see* Kumar P
- Goodin S, Kane MP, Rubin EH. Epothilones: Mechanism of Action and Biologic Activity, 2015
- Goodman A, *see* Fleming GF
- Goodnough LT, *see* Hoerr AL
- Goodwin PJ, Ennis M, Bordeleau LJ, Pritchard KI, Trudedau ME, Koo J, Hood N. Health-Related Quality of Life and Psychosocial Status in Breast Cancer Prognosis: Analysis of Multiple Variables, 4184
- Goodwin PJ. Support Groups in Breast Cancer: When a Negative Result Is Positive (editorial), 4244
- Gorbunova V, *see* Reyno L
- Gorby N, *see* Dolan NC
- Gordon A, *see* Berek JS
- Gordon GB, *see* Lippman SM
- Gore E, *see* Garden AS
- Gore M, *see* Agarwala SS
- see* Hancock BW
- Gore ME, *see* Hess V
- Gorin N-C, *see* Ringdén O
- Gorni G, *see* Caraceni A
- Goss G, *see* Garcia-Carbonero R
- Gotlib V, *see* Haque B
- Goto K, *see* Minami H
- Goudas L, *see* McNicol E
- Goudier M-J, *see* Bonnetterre J
- see* Fargeot P
- Gouma DJ, *see* Hartgrink HH
- Govindan R, *see* Bradley JD
- see* Read WL
- Gown AM, *see* Yaziji H
- Goy A, *see* Dang NH
- see* Schlette EJ
- Graaf MR, Beiderbeck AB, Egberts ACG, Richel DJ, Guchelaar H-J. The Risk of Cancer in Users of Statins, 2388
- Gradilone A, Gazzaniga P, Ribuffo D, Scarpa S, Cigna E, Vasaturo F, Bottoni U, Innocenzi D, Calvieri S, Scuderi N, Frati L, Aglianò AM. In Reply (correspondence), 2752
- Gradishar WJ, *see* Citron ML
- see* Sparano JA
- see* Tedesco KL
- Gradishar WJ, Meza LA, Amin B, Samid D, Hill T, Chen Y-M, Lower EE, Marcom PK. Capecitabine Plus Paclitaxel As Front-Line Combination Therapy for Metastatic Breast Cancer: A Multicenter Phase II Study, 2321
- Graeven U, *see* Laack E
- Graf N, *see* Reinhard H
- Graham ML, *see* Winer EP
- Grande C, *see* Montalbán C
- Grandjean J-P, *see* Gerard J-P
- Grant JR, *see* Pytynia KB
- Grant R, *see* Gassas A
- Greco FA, *see* Burris H III
- Green DL, *see* Diener-West M
- Green DM, *see* Landier W, *see* Seibel NL
- Green DM. The Treatment of Stages I-IV Favorable Histology Wilms' Tumor, 1366
- Green MA, *see* Dewar DJ
- Green MR, *see* Lima CMR
- Green S. Do Estimates of Long-Term Survival Tell Us Whether Patients Diagnosed With Breast Cancer Before Age 50 Years Are Ever Cured? (editorial), 392
- Greenbaum N, *see* Adams MJ

- Greenberg ML, *see* Spiegel BJ
see Sung L
- Greenberg PL, Lee SJ, Advani R, Tallman MS, Sikic BI, Letendre L, Dugan K, Lum B, Chin DL, Dewald G, Paietta E, Bennett JM, Rowe JM. Mitoxantrone, Etoposide, and Cytarabine With or Without Valspodar in Patients With Relapsed of Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome: A Phase III Trial (E2995), 1078
- Greendale GA, *see* Ursin G
- Greene FL, Stewart AK, Norton HJ. New Tumor-Node-Metastasis Staging Strategy for Node-Positive (stage III) Rectal Cancer: An Analysis, 1778
- Greggi S, *see* De Placido S
- Greil J, *see* Bader P
- Gress R, *see* Bishop MR
- Gridelli C, *see* Perrone F
- Grier HE, *see* Mack JW
see Miser JS
- Griffin CA, *see* French CA
- Grigsby PW, *see* Eifel PJ
- Grigsby PW, Siegel BA, Dehdashti F, Rader J, Zoberi I. Posttherapy [¹⁸F] Fluorodeoxyglucose Positron Emission Tomography in Carcinoma of the Cervix: Response and Outcome, 2167
- Grilli C, *see* Vincenzi B
- Grillo-López AJ, *see* Czuczman MS
- Grob JJ, *see* Avril MF
- Groen H, *see* van Westreenen HL
- Grogan TM, *see* Hehn ST
- Grönemeyer DHW, *see* Goetz MP
- Gronlund B, Høgdall C, Hilden J, Engelholm SA, Høgdall EVS, Hansen HH. Should CA-125 Response Criteria Be Preferred to Response Evaluation Criteria in Solid Tumors (RECIST) for Prognostication During Second-Line Chemotherapy of Ovarian Carcinoma?, 4051
- Groschen S, *see* Chatterjee SJ
- Grosh WW, *see* Slingluff CL Jr
- Grossbard M, *see* Gettinger S
- Grossi A, *see* Marchetti M
- Grossman HB, *see* Herr HW
- Grossmann J, *see* Cassidy J
- Grothey A, Sargent D, Goldberg RM, Schmoll H-J. Survival of Patients With Advanced Colorectal Cancer Improves With the Availability of Fluorouracil-Leucovorin, Irinotecan, and Oxaliplatin in the Course of Treatment, 1209
- Grous J, *see* Giaccone G
see Herbst RS
- Groves MD, *see* Puduvali VK
- Gruhn B, *see* Bader P
- Gruia G, *see* Lima CMR
- Grundy PE, *see* Seibel NL
- Grünewald K, *see* Fiegl M
- Grunfeld E, *see* Gagliardi A
- Gu X, *see* Spentzos D
- Guadagnoli E, *see* Fink AK
- Guardigni L, *see* Zinzani PL
- Guarnerio P, *see* Bolis G
- Guarrera S, *see* Berwick M
- Guastalla JP, *see* Cuzick J
- Guastalla J-P, *see* Diéras V
see Fargeot P
- Guchelaar H-J, *see* Graaf MR
- Guérin-Meyer V, *see* Bouché O
- Guerry DP, *see* Gimotty PA
- Guha C, *see* Senzer N
- Guibon O, *see* Rossi J-F
- Guillemin F, *see* Rauch P
- Guillou L, Benhattar J, Bonichon F, Gallagher G, Terrier P, Stauffer E, de Saint Aubain Somerhausen N, Michels J-J, Jundt G, Vince DR, Taylor S, Genevay M, Collin F, Trassard M, Coindre J-M. Histologic Grade, But Not SYT-SSX Fusion Type, Is an Important Prognostic Factor in Patients With Synovial Sarcoma: A Multicenter, Retrospective Analysis, 4040
- Gulavita S, *see* Roa W
- Gulec SA, Beller M, Edwards K, Lizotte P, O'Day S. Uncommon Presentations of Cancer Patients. Case 3. Positron Emission Tomography-Computed Tomography Diagnosis of Metastatic Melanoma With Intussusception, 4854
- Gulley JL, *see* Dahut WL
- Gulyas S, *see* Rinehart J
- Gunderson LL, *see* Ajani JA
see Martenson JA Jr
- Gunderson LL, Sargent DJ, Tepper JE, Wolmark N, O'Connell MJ, Begovic M, Allmer C, Colangelo L, Smalley SR, Haller DG, Martenson JA, Mayer RJ, Rich TA, Ajani JA, MacDonald JS, Willett CG, Goldberg RM. Impact of T and N Stage and Treatment on Survival and Relapse in Adjuvant Rectal Cancer: A Pooled Analysis, 1785
- Gupta S, *see* Kemeny N
- Gupta T, *see* Laskar S
- Gurley D, *see* Rose JH
- Gurney JG, *see* Zebrack BJ
- Gurtler J, *see* Kemeny N
- Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, Lynch TJ, Neuberg DS, Christiani DC. XPD and XRCC1 Genetic Polymorphisms Are Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients Treated With Platinum Chemotherapy, 2594
- Gururangan S, *see* Mulhern RK
- Gurwitz J, *see* Fink AK
- Guthrie K, *see* Disis ML
- Gutknecht C, *see* Saurin J-C
- Gutman M, *see* Glehen O
- Guzman C, *see* Garcia-Carbonero R

H

- Haas N, *see* Rowinsky EK
- Haas P, *see* Nevalainen MT
- Haas P, Kononen J, Sauter G, Rui H. Signal Transducer and Activator of Transcription-5 Activation and Breast Cancer Prognosis, 2053
- Haase GM, *see* Dillon PW
see Seibel NL
- Habermann TM, *see* Horning SJ
- Habig T, *see* Schirrmeyer H
- Hack R, *see* Fiegl M
- Hadley DW, Jenkins JF, Dimond E, de Carvalho M, Kirsch I, Palmer CGS. Colon Cancer Screening Practices After Genetic Counseling and Testing for Hereditary Nonpolyposis Colorectal Cancer, 39
- Haferlach T, *see* Kern W
see Lenz G
- Haffty BG, *see* Choi DH
see Psyrrri A
- Hagemeyer FB, *see* Dang NH
- Hagerty RG, Butow PN, Ellis PA, Lobb EA, Pendlebury S, Leigh N, Goldstein D, Lo SK, Tattersall MHN. Cancer Patient Preferences for Communication of Prognosis in the Metastatic Setting, 1721
- Hahnfeld S, *see* Al-Batran S-E
- Hahn SM, *see* Friedberg JS
- Haider S, *see* Shahab N
- Haines PT, *see* Wright JR
- Hainsworth J, *see* Burris H III
- Haion C, *see* Mounier N
- Hakulinen T, *see* Brenner H
- Halabi S, *see* Scher HI

- see Small EJ
- Halberg F, *see* Hrushesky W
- Halbert CH, *see* Schwartz MD
- Haldorsen T, *see* Hem E
- Hall R, *see* Keith B
- Halle JS, *see* Fried DB
see Socinski MA
- Haller DG, *see* Armanios M
see Benson AB III
see Gill S
see Gunderson LL
see Houldin AD
- Haller DG. *JCO's* Special Series: More Is Better (editorial), 3207
- Haller DG. Of Looking Back and Looking Forward (editorial), 1
- Hallman D, *see* Kemeny N
- Hallmans G, *see* Stattin P
- Halpern AC, Marghoob AA. Thin Melanoma: Still "Excellent Prognosis" Disease? (editorial), 3651
- Halpern S, *see* Modak S
- Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone Imaging in Metastatic Breast Cancer, 2942
- Hamel MB, *see* Rose JH
- Hamid O, *see* Rinehart J
- Hamilton AS, *see* Johnson TK
- Hammond DB. What ASCO Does for Its Members (correspondence), 2251
- Hammond LA, *see* Pérez-Soler R
- Hammond ME, *see* Pollack A
- Hampshire M, *see* Wei SJ
- Han J, *see* Kim H
see Kim JS
- Han K-R, *see* Patard J-J
- Hanada K, *see* Minami H
- Hanauske A, *see* Raymond E
- Hancock BW, Wheatley K, Harris S, Ives N, Harrison G, Horsman JM, Middleton MR, Thatcher N, Lorigan PC, Marsden JR, Burrows L, Gore M. Adjuvant Interferon in High-Risk Melanoma: The AIM HIGH Study—United Kingdom Coordinating Committee on Cancer Research Randomized Study of Adjuvant Low-Dose Extended-Duration Interferon Alfa-2a in High-Risk Resected Malignant Melanoma, 53
- Handgretinger R, *see* Bader P
see Simon T
- Hank JA, *see* King, DM
- Hanks GE, *see* Pollack A
- Hanks SP, *see* Little SE
- Hanley J, *see* Gagnon B
- Hanna H, Benjamin R, Chatzinikolaou I, Alakech B, Richardson D, Mansfield P, Dvorak T, Munsell MF, Darouiche R, Kantarjian H, Raad I. Long-Term Silicone Central Venous Catheters Impregnated With Minocycline and Rifampin Decrease Rates of Catheter-Related Bloodstream Infection in Cancer Patients: A Prospective Randomized Clinical Trial, 3163
- Hanna N, *see* Senzer N
- Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Chang T, Tsao Y, Pless M, Muller T, Lim H-L, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr. Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy, 1589
- Hanna WM, *see* Bull SB
- Hanselmann S, *see* Studer UE
- Hansen HH, *see* Gronlund B
- Hansen HH, Bajorin DF, Muss HB, Purkalne G, Schrijvers D, Stahel R. Recommendations for a Global Core Curriculum in Medical Oncology, 4616
- Hanson LJ, *see* Dy GK
- Hao C, *see* Roa W
- Haque B, Gotlib V, Bolla S, Bloomfield K, Patel A. Unusual Presentations of Hematologic Malignancies: Primary Central Nervous System B-Cell Lymphoma of Marginal Zone B-Cell Type in a Neurosyphilis Patient, 1333
- Harandi A, Ghesani M, Polosajian L, Tupper T, Sara G. Value of Positron Emission Tomography Scan in Staging Cancers and an Unusual Presentation of Acute Myeloid Leukemia: Demonstration of CNS Lymphoma by Positron Emission Tomography Scan Affects Management, 2964
- Harbeck N, *see* Scorilas A
- Harker-Murray A, *see* Thompson MA
- Harlin H, *see* Zimmerman TM
- Harman R, *see* Fife KM
- Harmon D, *see* Garcia-Carbonero R
- Harms D, *see* Schuck A
- Harper P, Plunkett T, Khayat D. In Reply (correspondence), 1347
- Harrington DP, *see* Ayanian JZ
- Harrington K, *see* Hess V
- Harris J, *see* Garden AS
- Harris LN, *see* Winer EP
- Harris M, *see* Davies AJ
- Harrison G, *see* Hancock BW
- Harris PA, *see* Palmer DH
- Harris S, *see* Hancock BW
- Harstrick A, *see* Vanhoefer U
- Hartgrink HH, van de Velde CJH, Putter H, Bonenkamp JJ, Kranenborg EK, Songun I, Welvaart K, van Krieken JHJM, Meijer S, Plukker JTM, van Elk PJ, Obertop H, Gouma DJ, van Lanschot JJB, Taat CW, de Graaf PW, von Meyenfeldt MF, Tilanus H, Sasako M. Extended Lymph Node Dissection for Gastric Cancer: Who May Benefit? Final Results of the Randomized Dutch Gastric Cancer Group Trial, 2069
- Hartman A-R, *see* Garber JE
- Hartmann JT, *see* Kollmannsberger C
see Rick O
- Hartmann LC, Degnim A, Schaid DJ. Prophylactic Mastectomy for BRCA1/2 Carriers: Progress and More Questions (editorial), 981
- Hartmann M, *see* Rick O
- Hartmann O, *see* Leclair M-D
- Hartmann R, *see* Herold R
- Hartweg J, *see* Gerard J-P
- Harvey S, *see* Aljada IS
- Hasegawa Y, *see* Kumasaka R
- Hasford J, *see* Lenz G
- Haslinger C, Schweifer N, Stilgenbauer S, Döhner H, Lichter P, Kraut N, Stratowa C, Abseher R. Microarray Gene Expression Profiling of B-Cell Chronic Lymphocytic Leukemia Subgroups Defined by Genomic Aberrations and VH Mutation Status, 3937
- Hatlevoll R, *see* Sundström S
- Hatschek T, *see* Liljegren A
- Hatton A, *see* Kissane DW
- Haugen M, *see* Monstad SE
- Haugh M, *see* Burgers JS
- Haun M, *see* Fiegl M
- Haura E, *see* Bepler G
- Hauri D, *see* Studer UE
- Hauschild A, *see* Avril MF
- Haut PR, *see* Campbell AD
see Katzenstein HM
- Havrilesky LJ, *see* Skates SJ
- Hawk E, *see* Lippman SM
- Hawkins BS, *see* Diener-West M
- Hawkins D, *see* Arndt C
- Hawkins DR, *see* Daw NC
- Hawkins EP, *see* Cushing B

AUTHOR INDEX

- Hawkins R, *see* DuBois SG
- Hayes DF, *see* Schott A
- Hayes M, *see* Peng B
- Hayes MM, *see* Chia SK
- Hayman J, *see* Diener-West M
- Heald PW, *see* Smith BD
- Hébert-Croteau N, Brisson J, Latreille J, Rivard M, Abdelaziz N, Martin G.
Compliance With Consensus Recommendations for Systemic Therapy Is Associated With Improved Survival of Women With Node-Negative Breast Cancer, 3685
- Hébert-Croteau N, Freeman C, Latreille J, Brisson J. Delay of Radiation Therapy and Outcomes of Breast Cancer (correspondence), 1342
- Hecht JR, *see* Rinehart J
- Hedley D, *see* Michael M
- Heelan RT, *see* Miller VA
- Heerema NA, *see* Marcucci G
- Heffelfinger S, *see* Gear RB
- Hegewisch-Becker S, *see* Al-Batran S-E
- Hehn ST, Grogan TM, Miller TP. Utility of Fine-Needle Aspiration As a Diagnostic Technique in Lymphoma, 3046
- Heil G, *see* Schlenk RF
- Heimans JJ, *see* Klein M
- Heim S, *see* Bardi G
- Heinrich MC, *see* Corless CL
- Hejna G, *see* Muler JH
- Heldebrant MP, *see* Gill S
- Heller G, *see* Scher HI
- Heloury Y, *see* Leclair M-D
- Helton S, *see* Mulhern RK
- Hem E, Loge JH, Haldorsen T, Ekeberg Ø. Suicide Risk in Cancer Patients From 1960 to 1999, 4209
- Hemminki K, Rawal R, Bermejo JL. Mammographic Screening Is Dramatically Changing Age-Incidence for Breast Cancer (correspondence), 4652
- Hendershot EI, *see* Sung L
- Henderson IC, *see* Keller AM
see Winer EP
- Henry DH, *see* Ballen KK
see Sparano JA
- Hensing TA, *see* Fried DB
see Socinski MA
- Hensley ML, *see* Dupont J
- Hensley ML, Spriggs DR. Cancer Screening: How Good Is Enough? (editorial), 4037
- Henze G, *see* Bader P
see Herold R
- Heo DS, *see* Yun YH
- Hequet O, Le QH, Moullet I, Pauli E, Salles G, Espinouse D, Dumontet C, Thieblemont C, Arnaud P, Antal D, Bouafia F, Coiffier B. Subclinical Late Cardiomyopathy After Doxorubicin Therapy for Lymphoma in Adults, 1864
- Herbst RS, *see* Giaccone G
see Johnson DH
- Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH. Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: A Phase III Trial—INTACT 2, 785
- Herida M, *see* Mary-Krause M
- Herman J, *see* Kent E
- Hernan R, *see* Gajjar A
- Hernandez A, *see* Fernández-Martos C
- Hernandez E, *see* Norton TR
- Herndon JE, *see* Marks LB
- Herndon JE II, *see* Patz EF Jr
see Rich JN
- Hero B, *see* Simon T
- Herold-Mende C, *see* Steiner HH
- Herold R, von Stackelberg A, Hartmann R, Eisenreich B, Henze G. Acute Lymphoblastic Leukemia-Relapse Study of the Berlin-Frankfurt-Münster Group (ALL-REZBFM) Experience: Early Treatment Intensity Makes the Difference (correspondence), 569
- Herraiz M, *see* Sangro B
- Herrera R, *see* Rinehart J
- Herr HW, Faulkner JR, Grossman HB, Natale RB, deVere White R, Sarosdy MF, Crawford ED. Surgical Factors Influence Bladder Cancer Outcomes: A Cooperative Group Report, 2781
- Herrero I, *see* Sangro B
- Hertenstein B, *see* Kiehl MG
- Hess K, *see* Ayers M
- Hess KR, *see* Puduvalli VK
- Hess V, A'Hern R, Nasiri N, King DM, Blake PR, Barton DPJ, Shepherd JH, Ind T, Bridges J, Harrington K, Kaye SB, Gore ME. Mucinous Epithelial Ovarian Cancer: A Separate Entity Requiring Specific Treatment, 1040
- Hester AL, *see* Landier W
- Hetzel J, *see* Schirrmeyer H
- Hetzel M, *see* Schirrmeyer H
- Hetzel P, *see* Rockwell L
- Heuvel JJTM, *see* Span PN
- Hewitt SM, *see* Tan AR
- Heynemann H, *see* Atzpodien J
- Hibbitts S, *see* Slingluff CL Jr
- Hicks JE, *see* Okunieff P
- Hidalgo J, *see* Hoerr AL
- Hidalgo M, *see* Atkins MB
see Soulieres D
- Hidalgo M. New Target, New Drug, Old Paradigm (editorial), 2270
- Hiddemann W, *see* Kern W
see Lenz G
- Higano C, *see* Scher HI
- Hilbe W, *see* Fiegl M
- Hildebrandt B, Rau B, Gellermann J, Wust P, Riess H. Hyperthermic Intraperitoneal Chemotherapy in Patients With Peritoneal Carcinosis (correspondence), 1527
- Hilden J, *see* Gronlund B
- Hilden JM, Meerbaum S, Burger P, Finlay J, Janss A, Scheithauer BW, Walter AW, Rorke LB, Biegel JA. Central Nervous System Atypical Teratoid/Rhabdoid Tumor: Results of Therapy in Children Enrolled in a Registry, 2877
- Hill E, *see* Garrity MM
- Hill M, *see* Chau I
see Lal R
- Hillman DW, *see* Perez EA
- Hillner BE, Tunuguntla R, Fratkin M. Clinical Decisions Associated With Positron Emission Tomography in a Prospective Cohort of Patients With Suspected or Known Cancer at One United States Center, 4147
- Hill S, *see* Palmer DH
- Hill T, *see* Gradishar WJ
- Hiratsuka M, *see* Sano T
- Hirsch FR, Varella-Garcia M, Bunn PA Jr, Di Maria MV, Veve R, Bremnes RM, Baron AE, Zeng C, Franklin WA. In Reply (correspondence), 3646
- Hirschowitz EA, Foody T, Kryscio R, Dickson L, Sturgill J, Yannelli J. Autologous Dendritic Cell Vaccines for Non-Small-Cell Lung Cancer, 2808
- Ho WM, *see* Yeo W
- Hoang-Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H, Lejeune J, Polivka M, Crinière E, Marie Y, Mokhtari K, Carpentier AF, Laigle F, Simon JM, Cornu P, Broët P, Sanson M, Delattre JY. Temozolomide As Initial Treatment for Adults With Low-Grade Oligodendrogliomas or

- Oligoastrocytomas and Correlation With Chromosome 1p Deletions, 3133
- Hoang-Xuan K, Delattre JY. In Reply (correspondence), 1167
- Hobbs KB, *see* Shaw HS
- Hochster H, *see* Kemeny N
- Hochster H, Plimack ER, Runowicz CD, Speyer J, Wallach RC, Sorich J, Mandeli J, Wadler S, Wright J, Muggia FM. Biweekly 72-Hour 9-Aminocamptothecin Infusion As Second-Line Therapy for Ovarian Carcinoma: Phase II Study of the New York Gynecology Group and the Eastern Cooperative Oncology Group, 120
- Hodgson SV, *see* Lipton LR
- Hoekstra OS, *see* van der Hoeven JJM
- Hoekstra-Weebers JEHM, *see* van Roosmalen MS
- Hoelle W, *see* Bader P
- Hoelzer D, *see* Kiehl MG
- Hoerr AL, Gao F, Hidalgo J, Tiwari D, Blum KA, Mathews V, Adkins DR, Blum W, Devine S, Vij R, Goodnough LT, Dipersio JF, Khoury HJ. Effects of Pretransplantation Treatment With Rituximab on Outcomes of Autologous Stem-Cell Transplantation for Non-Hodgkin's Lymphoma, 4561
- Hofer S, *see* Kühne M
- Hoff P, *see* Kouvaraki MA
- Hoff PM, *see* Ellis LM
see Shirao K
- Hoff PM, Pazdur R, Lassere Y, Carter S, Samid D, Polito D, Abbruzzese JL. Phase II Study of Capecitabine in Patients With Fluorouracil-Resistant Metastatic Colorectal Carcinoma, 2078
- Hoffman PC, *see* Rudin CM
- Hoffman RM, *see* Johnson TK
- Hogarty AN, *see* Ginsberg JP
see Silber JH
- Høgdall C, *see* Gronlund B
- Høgdall EVS, *see* Gronlund B
- Hogg R, Friedlander M. Biology of Epithelial Ovarian Cancer: Implications for Screening Women at High Genetic Risk, 1315
- Hohloch K, *see* Kollmannsberger C
- Hoke E, *see* Kolitz JE
- Hoke LA, *see* Bober SL
- Holcenberg J, *see* Reid JM
- Holland EC, *see* Dupont J
- Holland JF, *see* Citron ML
- Hollander SL. Uncommon Presentations of Hodgkin's Disease: Hodgkin's Disease of the Nasopharynx, 195
- Hollema H, *see* Buijs C
- Hollenbach KA, *see* Rock CL
- Hollis DR, *see* Meyerhardt JA
- Holm S, *see* Whitworth MK
- Holmes FA, *see* Thomas E
- Holmes MD, *see* Kroenke CH
- Holmgren E, *see* Johnson DH
- Holtsberg FW, *see* Izzo F
- Holzmann B, *see* Gertler R
- Homesley HD, *see* Thigpen JT
- Hon C, Ma ESK, Au WY. Unusual Sites of Metastatic Malignancy. Case 3. Acute Leukemia Presenting As Bilateral Proptosis, 5015
- Honda N, *see* Tisman G
- Honegger H, *see* Dubs A
see Lukaschek J
- Hong WK, *see* Lu C
see Ren H
- Hong YS, *see* Yun YH
- Hood N, *see* Goodwin PJ
- Hoogerbrugge N, *see* van Roosmalen MS
- Hoogerbrugge N, Bult P, Brunner H. In Reply (correspondence), 1161
- Hoon DSB, *see* Takeuchi H
- Hoos A, *see* Gertler R
- Hopper JL, *see* Phillips K-A
- Horick N, *see* Skates SJ
- Horne M, *see* Palmer DH
- Horning SJ, *see* Advani R
- Horning SJ, Weller E, Kim KM, Earle JD, O'Connell MJ, Habermann TM, Glick JH. Chemotherapy With or Without Radiotherapy in Limited-Stage Diffuse Aggressive Non-Hodgkin's Lymphoma: Eastern Cooperative Oncology Group Study 1484, 3032
- Horowitz MM, *see* Eapen M
see Godder K
- Horsman JM, *see* Hancock BW
- Hortobagyi GN, *see* Ayers M
see Chen AM
see Cristofanilli M
see Hamaoka T
see Navo MA
see Thomas E
- Hortobagyi GN. What Is the Role of High-Dose Chemotherapy in the Era of Targeted Therapies? (editorial), 2263
- Horton T, *see* Blaney SM
- Horwich A. Radiotherapy in Stage I Seminoma of the Testis (editorial), 585
- Horwitz EM, *see* Garden AS
- Hosch SB, *see* Stoecklein NH
- Hosing C, *see* Escalón MP
- Hossfeld DK, *see* Laack E
- Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Meta-Analysis of Randomized Clinical Trials Comparing Cisplatin to Carboplatin in Patients With Advanced Non-Small-Cell Lung Cancer, 3852
- Hotta K, Mtsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Role of Adjuvant Chemotherapy in Patients With Resected Non-Small-Cell Lung Cancer: Reappraisal With a Meta-Analysis of Randomized Controlled Trials, 3860
- Hou N, *see* Pasche B
- Houck W, Abonour R, Vance G, Einhorn LH. Secondary Leukemias in Refractory Germ Cell Tumor Patients Undergoing Autologous Stem-Cell Transplantation Using High-Dose Etoposide, 2155
- Houghton J, *see* Cuzick J
- Houghton PJ, *see* Daw NC
see Stewart CF
- Houldin AD, Naylor MD, Haller DG. Physician-Nurse Collaboration in Research in the 21st Century, 774
- Houlston RS, *see* Popat S
- Houston G, *see* Burris H III
- Howard BV, *see* Chlebowski RT
- Howard S, *see* Hudson MM
see Relling MV
- Howard SP, *see* Peteret DG
- Howell A, *see* Cuzick J
see Fallowfield L
- Howell A, Robertson JFR, Abram P, Lichinitser MR, Elledge R, Bajetta E, Watanabe T, Morris C, Webster A, Dimery I, Osborne CK. Comparison of Fulvestrant Versus Tamoxifen for the Treatment of Advanced Breast Cancer in Postmenopausal Women Previously Untreated With Endocrine Therapy: A Multinational, Double-Blind, Randomized Trial, 1605
- Howell S, *see* Davies AJ
- Howlader N, *see* Ramsey SD
- Hrushesky W, Wood P, Levi F, von Roemeling R, Bjarnason G, Focan C, Meier K, Cornélissen G, Halberg F. A Recent Illustration of Some Essentials of Circadian Chronotherapy Study Design (correspondence), 2971
- Hrushesky WJM, *see* Demicheli R
- Hryniuk W, *see* Banerjee M
- Hryniuk W, Ragaz J, Peters W. Dose Density by Any Other Name (correspondence), 750

AUTHOR INDEX

Hsieh L, *see* Temple LKF
 Hsieh YC, *see* Roberts SS
 Hsieh Y-C, *see* Fromme EK
 Hsu FJ, *see* Weng W-K
 Hsu H-C, *see* Kuo S-H
 Huang EH, Tucker SL, Strom EA, McNeese MD, Kuerer HM, Buzdar AU, Valero V, Perkins GH, Schechter NR, Hunt KK, Sahin AA, Hortobagyi GN, Buchholz TA. Postmastectomy Radiation Improves Local-Regional Control and Survival for Selected Patients With Locally Advanced Breast Cancer Treated With Neoadjuvant Chemotherapy and Mastectomy, 4691
 Huang J, *see* MacKillop WJ
 Huang X, *see* Cormier JN
 Huang Y, *see* Aldred MA
 Huberman M, *see* Pérez-Soler R
 Huberty J, *see* DuBois SG
 Hubscher S, *see* Palmer DH
 Hudes GR, *see* Atkins MB
 Hudis C, *see* Citron ML
 see Winer EP
 Hudson MM, *see* Landier W
 Hudson MM, Krasin M, Link MP, Donaldson SS, Billups C, Merchant TE, Kun L, Billet AL, Kaste S, Tarbell NJ, Howard S, Friedmann AM, Hurwitz CA, Young JA, Marcus KC, Rai S, Cowan T, Weinstein HJ. Risk-Adapted, Combined-Modality Therapy With VAMP/COP and Response-Based, Involved-Field Radiation for Unfavorable Pediatric Hodgkin's Disease, 4541
 Huegli B, *see* Gautschi O
 Huguenin P, Beer KT, Allal A, Rufibach K, Friedli C, Davis JB, Pestalozzi B, Schmid S, Thöni A, Ozsahin TM, Bernier J, Töpfer M, Kann R, Meier UR, Thum P, Bieri S, Nottter M, Lombriser N, Glanzmann C. Concomitant Cisplatin Significantly Improves Locoregional Control in Advanced Head and Neck Cancers Treated With Hyperfractionated Radiotherapy, 4665
 Huguet F, *see* Thomas X
 Hui EP, *see* Chan ATC
 Hull D, *see* Palmer DH
 Hulscher JFB, *see* de Boer AGEM
 Humblet Y, *see* Rao S
 see Van Cutsem E
 Hunt KK, *see* Chen AM
 see Huang EH
 see Pisters PWT
 see Raut CP
 Huober J, *see* Krauss K
 Hurd D, *see* Citron ML
 Hurd DD, *see* Kolitz JE
 Hurley J, *see* Anderson KO
 Hurwitz CA, *see* Hudson MM
 Hurwitz M, *see* D'Amico AV
 Husain S, *see* Roa W
 Huser AK, *see* Okunieff P
 Hussey D, *see* Thomas CH
 Hutcheon M, *see* de Perrot M
 Hutson TE, *see* Alatrash G
 Hwang JP, Smith ML, Flamm AL. Challenges in Outpatient End-of-Life Care: Wishes to Avoid Resuscitation, 4643
 Hwang Y-T, *see* Figueiredo MI
 Hyodo I, *see* Shirao K

I

Iacobelli S, *see* Morris C
 Iacono LC, *see* Daw NC

see Stewart CF
 Ibrahim N, *see* Ayers M
 Ichinose Y, *see* Kubota K
 Ikin J, *see* Kissane DW
 Ilariucci F, *see* Marchetti M
 Ilegbodu D, *see* Neubauer M
 Illes A, *see* Rao S
 Illidge T, *see* Meyers CA
 Ilson DH, *see* Brenner B
 Imisch P, *see* Weber A
 Ind T, *see* Hess V
 Ingle JN, *see* Citron ML
 see Perez EA
 see Sparano JA
 Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramirez J, Rudin CM, Vokes EE, Ratain MJ. Genetic Variants in the *UDP-glucuronosyltransferase 1A1* Gene Predict the Risk of Severe Neutropenia of Irinotecan, 1382
 Innocenzi D, *see* Gradilone A
 Isaacs C, *see* Rebbeck TR
 see Schwartz MD
 Isobe T, *see* Kubota K
 Ives N, *see* Hancock BW
 Iveson T, *see* Rao S
 Iyer L, *see* Innocenti F
 Izatt L, *see* Lipton LR
 Izbicki JR, *see* Stoecklein NH
 Iznaga-Escobar N, *see* Crombet T
 Izquierdo A, *see* Colomer R
 Izzo F, Marra P, Beneduce G, Castello G, Vallone P, De Rosa V, Cremona F, Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA, Ng C, Curley SA. Pegylated Arginine Deiminase Treatment of Patients With Unresectable Hepatocellular Carcinoma: Results From Phase I/II Studies, 1815

J

Jablons DM, *see* Johnson DH
 Jackson M, *see* Butow P
 Jacky E, *see* Dubs A
 Jacobs A, *see* Sabbatini P
 Jacobs JJ, *see* Skates SJ
 Jacobson J, *see* Durie BGM
 Jacobson JS, *see* Ladas EJ
 Jacobson MG, *see* Pisters PWT
 Jacobsson H, *see* Sverrisdóttir A
 Jaeger D, *see* Al-Batran S-E
 Jaeger E, *see* Al-Batran S-E
 Jaffé AS, *see* Dispenzieri A
 see Perez EA
 Jaffe N. Metachronous Skeletal Osteosarcoma After Therapy (correspondence), 1524
 Jaggi R, DeLaney TF, Donelan K, Tarbell NJ. Real-Time Rationing of Scarce Resources: The Northeast Proton Therapy Center Experience, 2246
 Jahnke K, *see* Kiewe P
 Jaiyesimi I, *see* Diener-West M
 James ND, *see* Palmer DH
 Jan H, *see* Davies AJ
 Jan J-S, *see* Lin J-C
 Janakiraman N, *see* Khalid I
 Jänicke F, *see* Zander AR
 Janik JS, *see* Trobaugh-Lotario AD
 Janisch L, *see* Innocenti F
 Janjan N, *see* Ajani JA

AUTHOR INDEX

- see* Lutz S
- Jansen SJT, Otten W, Stiggelbout AM. Review of Determinants of Patients' Preferences for Adjuvant Therapy in Cancer, 3181
- Janss A, *see* Hilden JM
- Janz NK, Wren PA, Copeland LA, Lowery JC, Goldfarb SL, Wilkins EG. Patient-Physician Concordance: Preferences, Perceptions, and Factors Influencing the Breast Cancer Surgical Decision, 3091
- Jara C, *see* Alba E
- Jaramillo E, *see* Liljegren A
- Jassem J, *see* Reyno L
- Jass JR, *see* Nagasaka T
- Jatkoe T, *see* Wang Y
- Jatoi A, Rowland K, Loprinzi CL, Sloan JA, Dakhil SR, MacDonald N, Gagnon B, Novotny PJ, Mailliard JA, Bushey TIL, Nair S, Christensen B. An Eicosapentaenoic Acid Supplement Versus Megestrol Acetate Versus Both for Patients With Cancer-Associated Wasting: A North Central Cancer Treatment Group and National Cancer Institute of Canada Collaborative Effort, 2469
- Jatoi I, Soballe PW, Anderson WF. Delayed Benefit of Mammography Screening in Premenopausal Women (correspondence), 4860
- Javle MM, *see* Palesty JA
- Jayson GC, *see* Whitworth MK
- Jean-Christophe S, Béatrice P, Driffa M. In Reply (correspondence), 3836
- Jeffrey GM, *see* Lima CMR
- Jenkins J, *see* Michalkiewicz E
- Jenkins JF, *see* Hadley DW
- Jenkins MA, *see* Phillips K-A
- Jenkins RB, *see* Adem C
- Jeong J-H, *see* Taghian A
- Jeon S, *see* Given C
- Jeremic B, Milicic B, Dagovic A, Vaskovic Z, Tadic L. Radiation Therapy With or Without Concurrent Low-Dose Daily Chemotherapy in Locally Advanced, Nonmetastatic Squamous Cell Carcinoma of the Head and Neck, 3540
- Jerman M, *see* Weder W
- Jermann M, *see* Gautschi O
- Jhiang S, *see* Aldred MA
- Jiang J, *see* Wang Y
- Jimeno J, *see* Garcia-Carbonero R
see Yovine A
- Jing L, *see* Yu YP
- Joerger M, *see* Gautschi O
- Johannessen DC, *see* Sundström S
- Johansson B, *see* Bardi G
- Johnson DH, *see* Azzoli CG
see Giaccone G
see Herbst RS
see Langer CJ
see Loehrer PJ Sr
see Pfister DG
see Tedesco KL
- Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF III, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F. Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer, 2184
- Johnson FE, Virgo KS, Fossati R. Follow-Up for Patients With Colorectal Cancer After Curative-Intent Primary Treatment (editorial), 1363
- Johnson JL, Moscinski L, Zuckerman K. Value of Positron Emission Tomography Scan in Staging Cancers and an Unusual Presentation of Acute Myeloid Leukemia: Acute Myeloid Leukemia Presenting With Lytic Bone Lesions, 2968
- Johnson PJ, *see* Chan ATC
see Yeo W
- Johnson SA, *see* Rossi J-F
- Johnson TK, Gilliland FD, Hoffman RM, Deapen D, Penson DF, Stanford JL, Albertsen PC, Hamilton AS. Racial/Ethnic Differences in Functional Outcomes in the 5 Years After Diagnosis of Localized Prostate Cancer, 4193
- Johnson V, *see* Lipton LR
- Johnston PG. Of What Value Genomics in Colorectal Cancer? Opportunities and Challenges (editorial), 1538
- Jolivet J, *see* Labrie F
- Jonas U, *see* Atzpodien J
- Jonat W, *see* Zander AR
- Jones C, *see* Garden AS
see Little SE
- Jones D, *see* Dang NH
see Mathew P
- Jones E, *see* Dahut WL
- Jones G, *see* Oh WK
- Jones GR, *see* Dillon PW
- Jones HA, *see* Wei SJ
- Jones-Jackson L, *see* Miceli M
- Jones KL, *see* Navo MA
- Jones LA, *see* Rock CL
- Jones RB, *see* Ueno NT
- Jones S, *see* Burris H III
- Jongbloed MRM, Kanen BLJ, Visser M, Niessen H, Flens MJ, Loffeld RJLF. Unusual Sites of Metastatic Involvement: Intracardiac Metastasis From a Merkel Cell Carcinoma, 1153
- Joseph M, *see* Spentzos D
- Joshi V, *see* Kretschmar CS
- Josting A, *see* Bredenfeld H
- Jouet J-P, *see* Ringdén O
- Junck L, *see* Puduvali VK
- Jundt G, *see* Guillou L
- Jürgens H, *see* Bielack SS

K

- Kaaks R, *see* Stattin P
- Kaasa S, *see* Sundström S
- Kabbaj O, *see* Andre F
- Kabbinavar F, *see* Johnson DH
- Kadziola Z, *see* Kakkar AK
- Kaelin WG, *see* Kim WY
- Kager L, Zoubek A, Bielack S. In Reply (correspondence), 5017
- Kahatt C, *see* Yovine A
- Kahn KL, *see* Ayanian JZ
see Schneider EC
- Kairys J, *see* Berd D
- Kakinuma R, *see* Minami H
- Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, Rustin G, Thomas M, Quigley M, Williamson RCN. Low Molecular Weight Heparin, Therapy With Dalteparin, and Survival in Advanced Cancer: The Fragmin Advanced Malignancy Outcome Study (FAMOUS), 1944
- Kaklamani V, *see* Pasche B
- Kalapurakal J, *see* Campbell AD
- Kaldjian EP, *see* Rinehart J
- Kalish D, *see* Anderson KO
- Kalofonos C, *see* Bamias A
- Kam M, *see* Chan ATC
- Kamanabrou D, *see* Avril MF
- Kambara T, *see* Nagasaka T
- Kameyama T, *see* Osoegawa A
- Kaminsky MC, *see* Bouché O
- Kammula US, Ghossein R, Bhattacharya S, Coit DG. Serial Follow-Up and

- the Prognostic Significance of Reverse Transcriptase-Polymerase Chain Reaction–Staged Sentinel Lymph Nodes From Melanoma Patients, 3989
- Kane CJ, *see* Freedland SJ
- Kane MP, *see* Goodin S
- Kanen BLJ, *see* Jongbloed MRM
- Kann R, *see* Huguenin P
- Kantarjian H, *see* Hanna H
- Kantarjian HM, *see* Kurzrock R
- Kantoff P, *see* Scher HI
- Kantoff PW, *see* Oh WK
- Kanz L, *see* Kollmannsberger C
- Kao JC, *see* Rich JN
- Kapelushnik J, *see* David YB
- Kaplan E, *see* Small EJ
- Kaplan S, *see* Mulhern RK
- Kapur D, *see* Smith BD
- Karasek P, *see* Van Cutsem E
- Kardinal CG, *see* Perez EA
- Karlan B. Profiling the Perpetrator (editorial), 4663
- Karlan BY, *see* Liede A
- Karnauskas R, *see* Rudin CM
- Karp D, *see* Pérez-Soler R
- Karrison T, *see* Innocenti F
see Zimmerman TM
- Kashani-Sabet M, Shaikh L, Miller JR III, Nosrati M, Ferreira CMM, Debs RJ, Sagebiel RW. NF- κ B in the Vascular Progression of Melanoma, 617
- Kaspers GJL, *see* Creutzig U
- Kassar M, *see* Psyrri A
- Kasten-Sportes C, *see* Bishop MR
- Kaste S, *see* Hudson MM
- Kaste SC, *see* Relling MV
- Kastritis E, *see* Bamias A
- Katakami N, *see* Kubota K
- Kattan MW, *see* Scher HI
- Katzenstein HM, Cohn SL, Shore RM, Bardo DME, Haut PR, Olszewski M, Schmoldt J, Liu D, Rademaker AW, Kletzel M. Scintigraphic Response by ¹²³I-Metaiodobenzylguanidine Scan Correlates With Event-Free Survival in High-Risk Neuroblastoma, 3909
- Katz ML, *see* Demmy TL
- Kauff N, *see* Dupont J
- Kaufman HL, Wang W, Manola J, DiPaola RS, Ko Y-J, Sweeney C, Whiteside TL, Schlom J, Wilding G, Weiner LM. Phase II Randomized Study of Vaccine Treatment of Advanced Prostate Cancer (E7897): A Trial of the Eastern Cooperative Oncology Group, 2122
- Kaufman M, *see* Keller AM
- Kaufman PA, *see* Perez EA
- Kaur L, *see* Petereit DG
- Kavanagh JJ, *see* Navo MA
- Kawachi I, *see* Kroenke CH
- Kawahara M, *see* Kubota K
- Kaye SB, *see* Hess V
- Keith B, Hall R, Scholnik A. Improved Outcome With Dose-Dense Chemotherapy (correspondence), 749
- Kelalis PP, *see* Seibel NL
- Keller AM, Mennel RG, Georgoulas VA, Nabholz J-M, Erazo A, Lluch A, Vogel CL, Kaufmann M, von Minckwitz G, Henderson IC, Mellars L, Alland L, Tandler C. Randomized Phase III Trial of Pegylated Liposomal Doxorubicin Versus Vinorelbine or Mitomycin C Plus Vinblastine in Women With Taxane-Refractory Advanced Breast Cancer, 3893
- Kellie SJ, *see* Fouladi M
see Gajjar A
see Stewart CF
- Kellie SJ, Boyce H, Dunkel IJ, Diez B, Rosenblum M, Brualdi L, Finlay JL. Primary Chemotherapy for Intracranial Nongerminomatous Germ Cell Tumors: Results of the Second International CNS Germ Cell Study Group Protocol, 846
- Kelly KM, *see* Ladas EJ
- Kelly SJ, *see* Olivotto IA
- Kelly WK, *see* Scher HI
- Kelsen DP, *see* Brenner B
- Kemeny N, Garay CA, Gurtler J, Hochster H, Kennedy P, Benson A, Brandt DS, Polikoff J, Wertheim M, Shumaker G, Hallman D, Burger B, Gupta S. Randomized Multicenter Phase II Trial of Bolus Plus Infusional Fluorouracil/Leucovorin Compared With Fluorouracil/Leucovorin Plus Oxaliplatin as Third-Line Treatment of Patients with Advanced Colorectal Cancer, 4753
- Kemp B, *see* Lu C
- Kendra K, *see* King, DM
- Kennedy DD, *see* Ladas EJ
- Kennedy P, *see* Kemeny N
- Kenny PM, *see* Viney RC
- Kent E, Sandler H, Montie J, Lee C, Herman J, Esper P, Fardig J, Smith DC. Combined-Modality Therapy With Gemcitabine and Radiotherapy As a Bladder Preservation Strategy: Results of a Phase I Trial, 2540
- Kepner JL, *see* Aquino VM
- Kerbrat P, *see* Bonnetterre J
see Diéras V
- Keresztes R, *see* Winer EP
- Kern W, Haferlach T, Schnittger S, Hiddemann W, Schoch C. Prognosis in Therapy-Related Acute Myeloid Leukemia and Impact of Karyotype (correspondence), 2510
- Kerr DJ, *see* Palmer DH
- Kerr J, *see* Mano M
- Keshavjee S, *see* de Perrot M
- Kesler KA, *see* Schneider BP
- Kessel IL, *see* Morgan PB
- Kestenholz P, *see* Weder W
- Khalid I, Rival J, Salama ME, Banghar PK, Janakiraman N. Unusual Presentations of Hematologic Malignancies: Precursor B-Cell Lymphoblastic Lymphoma Presenting As Spinal Cord Compression, 1331
- Khandwala HM, Mirchandani D, Chibbar R, Chow V. Uncommon Presentations of Cancer Patients. Case 1. Metastatic Breast Cancer Presenting With Panhypopituitarism, 4851
- Khan RB, *see* Merchant TE
see Mulhern RK
- Khayat D, *see* Harper P
- Khor L-Y, *see* Pollack A
- Khoury IF, *see* Escalón MP
- Khoury HJ, *see* Hoerr AL
- Khoury T, *see* Aljada IS
- Khuri FR, *see* Lu C
see Ren H
- Khuri FR, Lotan R. Retinoids in Lung Cancer: Friend, Foe, or Fellow Traveler? (editorial), 3435
- Kiefe CI, *see* Ayanian JZ
- Kiefer R, *see* Ströbel P
- Kiehl MG, Kraut L, Schwerdtfeger R, Hertenstein B, Remberger M, Kroeger N, Stelljes M, Bornhaeuser M, Martin H, Scheid C, Ganser A, Zander AR, Kienast J, Ehninger G, Hoelzer D, Diehl V, Fauser AA, Ringden O. Outcome of Allogeneic Hematopoietic Stem-Cell Transplantation in Adult Patients With Acute Lymphoblastic Leukemia: No Difference in Related Compared With Unrelated Transplant in First Complete Remission, 2816
- Kienast J, *see* Kiehl MG
- Kiessling M, *see* Steiner HH
- Kievit J, *see* de Bock GH
see van den Brink M
- Kiewe P, Korfel A, Loddenkemper C, Fischer L, Jahnke K, Notter M, Mühr-Wilkenshoff F, Stein H, Thiel E. Unusual Sites of Hodgkin's

AUTHOR INDEX

- Lymphoma: Cholemic Nephrosis in Hodgkin's Lymphoma With Liver Involvement, 4230
- Kiffmeyer WR, *see* Ross JA
- Kim D-H, *see* Kim H
see Kim JS
- Kim H, *see* Kim JS
- Kim H, Kwon YM, Kim JS, Lee H, Park J-H, Shim YM, Han J, Park J, Kim D-H. Tumor-Specific Methylation in Bronchial Lavage for the Early Detection of Non-Small-Cell Lung Cancer, 2363
- Kim HL, *see* Patard J-J
- Kim HT, *see* Tallman MS
- Kim J, *see* Papandreou CN
- Kim JH, *see* Shariat SF
- Kim JS, *see* Kim H
see Yun YH
- Kim JS, Lee H, Kim H, Shim YM, Han J, Park J, Kim D-H. Promoter Methylation or Retinoic Acid Receptor Beta 2 and the Development of Second Primary Lung Cancers in Non-Small-Cell Lung Cancer, 3443
- Kim JYH, *see* Fernandez-Teijeiro A
- Kim KM, *see* Horning SJ
see King, DM
- Kim S-J, *see* Mathew P
- Kim S-y, *see* Yun YH
- Kim T, *see* Seibel NL
- Kim WY, Kaelin WG. Role of *VHL* Gene Mutation in Human Cancer, 4991
- Kimball TR, *see* Ginsberg JP
see Silber JH
- Kimura K, *see* Nagasaka T
- King A, *see* Chan ATC
- King DM, *see* Hess V
- King DM, Albertini MR, Schalch H, Hank JA, Gan J, Surfus J, Mahvi D, Schiller JH, Warner T, Kim KM, Eickhoff J, Kendra K, Reisfeld R, Gillies SD, Sondel P. Phase I Clinical Trial of the Immunocytokine EMD 273063 in Melanoma Patients, 4463
- King MT, *see* Viney RC
- King S, *see* Moore DH
- King-Underwood L, *see* Little SE
- Kinoshita T, *see* Sano T
- Kirchner H, *see* Atzpodien J
- Kirkwood JM, *see* Agarwala SS
see Diener-West M
see Moschos SJ
- Kirsch I, *see* Hadley DW
- Kirshner JA, *see* Winer EP
- Kirstein MN, *see* Stewart CF
- Kissane DW, Love A, Hatton A, Bloch S, Smith G, Clarke DM, Miach P, Ikin J, Ranieri N, Snyder RD. Effect of Cognitive-Existential Group Therapy on Survival in Early-Stage Breast Cancer, 4255
- Kitchen B, *see* Blaney SM
- Kiura K, *see* Hotta K
- Kjaer M, *see* Ejlertsen B
- Klein CA, *see* Stoecklein NH
- Klein JP, *see* Eapen M
- Klein M, Heimans JJ. The Measurement of Cognitive Functioning in Low-Grade Glioma Patients After Radiotherapy (correspondence), 966
- Klencke B, *see* Chan ATC
- Klenke R, *see* Bomgaars L
- Klenke RA, *see* Chintagumpala M
- Klepp O, *see* Sundström S
- Kletter K, *see* De Santis M
- Kletzel M, *see* Campbell AD
see Katzenstein HM
see Kretschmar CS
- Klimstra DS, *see* Brenner B
- Kline R, *see* Fleming GF
- Klingebl T, *see* Bader P
- Knietig R, *see* Schuck A
- Knight P, *see* Elsayem A
- Knight RD, *see* Schey SA
- Knoefel WT, *see* Stoecklein NH
- Knopp EA, *see* Chi SN
- Knudsen K, *see* Partridge AH
- Knuth A, *see* Al-Batran S-E
see Laack E
- Knutson KL, *see* Disis ML
- Ko PC-I, *see* Tsai M-S
- Ko Y-J, *see* Kaufman HL
- Kocak M, *see* Fouladi M
see Gajjar A
- Kocherginsky M, *see* Innocenti F
- Koch P, Liersch R, Berdel WE. Intestinal Non-Hodgkin's Lymphoma (correspondence), 2752
- Kodish ED, *see* Simon CM
- Koduru PRK, *see* Byrd JC
see Marcucci G
- Koenigsmann M, *see* Zander AR
- Kogut N, *see* Somlo G
- Koh W-J, *see* Diener-West M
- Kohorn EI. Problems With Nomenclature and Pharmacodynamics in Trophoblastic Disease (correspondence), 203
- Kolitz JE, *see* Marcucci G
- Kolitz JE, George SL, Dodge RK, Hurd DD, Powell BL, Allen SL, Velez-Garcia E, Moore JO, Shea TC, Hoke E, Caligiuri MA, Vardiman JW, Bloomfield CD, Larson RA. Dose Escalation Studies of Cytarabine, Daunorubicin, and Etoposide With and Without Multidrug Resistance Modulation With PSC-833 in Untreated Adults With Acute Myeloid Leukemia Younger Than 60 Years: Final Induction Results of Cancer and Leukemia Group B Study 9621, 4290
- Kollmannsberger C, Beyer J, Liersch R, Schoeffski P, Metzner B, Rick O, Hartmann JT, Stengele K, Hohloch K, Spott C, Kanz L, Bokemeyer C. Combination Chemotherapy With Gemcitabine Plus Oxaliplatin in Patients With Intensively Pretreated or Refractory Germ Cell Cancer: A Study of the German Testicular Cancer Study Group, 108
- Kondagunta GV, Drucker B, Schwartz L, Bacik J, Marion S, Russo P, Mazumdar M, Motzer RJ. Phase II Trial of Bortezomib for Patients With Advanced Renal Cell Carcinoma, 3720
- Kondagunta GV, Sheinfeld J, Mazumdar M, Mariani TV, Bajorin D, Bacik J, Bosl GJ, Motzer RJ. Relapse-Free and Overall Survival in Patients With Pathologic Stage II Nonseminomatous Germ Cell Cancer Treated With Etoposide and Cisplatin Adjuvant Chemotherapy, 464
- Konishi H, *see* Endoh H
- Kononen J, *see* Nevalainen MT
see Went PT
- Konstantinopoulos PA, *see* Moschos SJ
- Koo J, *see* Goodwin PJ
- Koo P, *see* Miaskowski C
- Kopans D.. Get the Facts Straight (correspondence), 4859
- Koper PCM, *see* Creutzberg CL
- Kopit J, *see* Saltz LB
- Kopp R, *see* Glas J
- Korfel A, *see* Kiewe P
- Kornblau SM, *see* Benson AB III
- Kornblith A, *see* Winer EP
- Korones DN. In Reply (correspondence), 2259
- Koropatnick J, *see* Crombet T
- Korth-Bradley J, *see* Raymond E
- Kortsik C, *see* Laack E
- Koscielniak E, *see* Carli M
see Schuck A
- Kosmidis P, *see* Bamias A

- Kostakoglu L, *see* Milowsky MI
- Kosty MP. PC-SPES: Hope or Hype? (editorial), 3657
- Kottaridis PD, *see* Chatterjee R
- Kourousis C, *see* Bamias A
- Kouroussis C, *see* Georgoulas V
- Kourteva G, *see* Rao S
- Koutras A, *see* Bamias A
- Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, Yao JC. Fluorouracil, Doxorubicin, and Streptozocin in the Treatment of Patients With Locally Advanced and Metastatic Pancreatic Endocrine Carcinomas, 4762
- Kovács AF, Döbert N, Gaa J, Menzel C, Bitter K. Positron Emission Tomography in Combination With Sentinel Node Biopsy Reduces the Rate of Elective Neck Dissections in the Treatment of Oral and Oropharyngeal Cancer, 3973
- Kovacsovics T, *see* Thomas X
- Kovar A, *see* Vanhoefler U
- Kozachik S, *see* Given C
- Kozloff M, *see* Rudin CM
- Krahl R, *see* Schlenk RF
- Krailo M, *see* Aquino VM
see Blaney SM
- Krailo MD, *see* Miser JS
see Reid JM
- Krak NC, *see* van der Hoeven JJM
- Kramar A, *see* Fizazi K
- Kramer BS, *see* Lippman SM
- Kramer K, *see* Kushner BH
- Kramer MHH, *see* Rossi J-F
- Kranenbarg EK, *see* Hartgrink HH
see van Beek J
see van den Brink M
- Krasin M, *see* Hudson MM
- Krasin MJ, *see* Merchant TE
- Krasnov CL, *see* Demmy TL
- Kraus DH, *see* Wreesmann VB
- Kraushaar T, *see* Ströbel P
- Krauss K, Aydeniz B, Dohmen BM, Wehrmann M, Wallwiener D, Huober J. Value of Positron Emission Tomography Scan in Staging Cancers and an Unusual Presentation of Acute Myeloid Leukemia: Detection of an Appendiceal Carcinoma by Whole-Body Positron Emission Tomography After Caesarean Section, 2966
- Kraut L, *see* Kiehl MG
- Kraut MJ. Pathologic Complete Response and Survival Advantage in Esophageal Cancer: Old News (correspondence), 2513
- Kraut N, *see* Haslinger C
- Krauter J, *see* Schlenk RF
- Krebs AD, *see* Herbst RS
- Kreienberg R, *see* Zander AR
- Krein A, *see* Ströbel P
- Kreitmeier S, *see* Fröhling S
- Kremens B, *see* Bader P
- Kremer P, *see* Steiner HH
- Krenning EP, *see* Teunissen JJM
- Kretschmar CS, Kletzel M, Murray K, Thorner P, Joshi V, Marcus R, Smith EI, London WB, Castleberry R. Response to Paclitaxel, Topotecan, and Topotecan-Cyclophosphamide in Children With Untreated Disseminated Neuroblastoma Treated in an Upfront Phase II Investigational Window: A Pediatric Oncology Group Study, 4119
- Kreyenberg H, *see* Bader P
- Kris MG, *see* Miller VA
- Kristeller JL, *see* Fisch MJ
- Kroeger N, *see* Kiehl MG
- Kroenke CH, Rosner B, Chen WY, Kawachi I, Colditz GA, Holmes MD. Functional Impact of Breast Cancer by Age at Diagnosis, 1849
- Kroese MCS, *see* Creutzberg CL
- Kröger N, *see* Zander AR
- Kroll DJ, *see* Shaw HS
- Kroll S, *see* Davies AJ
- Krook JE, *see* Garrity MM
see Perez EA
- Krown SE, *see* Su YB
- Krown SE. Highly Active Antiretroviral Therapy in AIDS-Associated Kaposi's Sarcoma: Implications for the Design of Therapeutic Trials in Patients With Advanced, Symptomatic Kaposi's Sarcoma, 399
- Krug LM, *see* Miller VA
- Krüger W, *see* Zander AR
- Krugmann J, *see* Fiegl M
- Krull K, *see* Fouladi M
- Krystio R, *see* Hirschowitz EA
- Krzyzanowska MK, *see* Benson AB III
- Krzyzanowska MK, Pintilie M, Brezden-Masley C, Dent R, Tannock IF. Quality of Abstracts Describing Randomized Trials in the Proceedings of American Society of Clinical Oncology Meetings: Guidelines for Improved Reporting, 1993
- Kubota K, *see* Minami H
- Kubota K, Watanabe K, Kunitoh H, Noda K, Ichinose Y, Katakami N, Sugiyama T, Kawahara M, Yokoyama A, Yokota S, Yoneda S, Matsui K, Kudo S, Shibuya M, Isobe T, Segawa Y, Nishiaki Y, Ohashi Y, Niitani H. Phase III Randomized Trial of Docetaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin in Patients With Stage IV Non-Small-Cell Lung Cancer: The Japanese Taxotere Lung Cancer Study Group, 254
- Kudo S, *see* Kubota K
- Kuehl H, *see* Antoch G
- Kuerer HM, *see* Chen AM
see Huang EH
see Raut CP
- Kufe D, *see* Senzer N
- Kugler JW, *see* Armanios M
- Kuhn JA, *see* Lewis D
- Kuhn JG, *see* Puduvali VK
- Kühne M, Sidler D, Hofer S, Lugli A, Ludwig C. Challenging Manifestations of Malignancies: Polycythemia and High Serum Erythropoietin Level As a Result of Hemangioblastoma, 3639
- Kujas M, *see* Hoang-Xuan K
- Kulp B, *see* Markman M
- Kumar P, Perrotti M, Weiss R, Todd M, Goodin S, Cummings K, DiPaola RS. Phase I Trial of Weekly Docetaxel With Concurrent Three-Dimensional Conformal Radiation Therapy in the Treatment of Unfavorable Localized Adenocarcinoma of the Prostate, 1909
- Kumar S, Witzig TE, Rajkumar SV. Thalidomide: Current Role in the Treatment of Non-Plasma Cell Malignancies, 2477
- Kumasaka R, Nakamura N, Shirato K, Osawa H, Takanashi S, Hasegawa Y, Yamabe H, Nakamura M, Tamura M, Okumura K. Side Effects of Therapy: Nephrotic Syndrome Associated With Gefitinib Therapy, 2504
- Kun L, *see* Gajjar A
see Hudson MM
- Kun LE, *see* Fouladi M
see Merchant TE
- Kunitoh H, *see* Kubota K
- Kunkler I, *see* Meyers CA
- Kuntz KM, *see* Elkin EB
- Kunz DS, *see* Schuck A
- Kunze S, *see* Steiner HH
- Kuo C, *see* Takeuchi H
- Kuo S-H, Chen L-T, Yeh K-H, Wu M-S, Hsu H-C, Yeh P-Y, Mao T-L, Chen C-L, Doong S-L, Lin J-T, Cheng A-L. Nuclear Expression of BCL10 or Nuclear Factor Kappa B Predicts *Helicobacter pylori*-Independent Status of Early-Stage, High-Grade Gastric Mucosa-Associated Lymphoid Tissue Lymphomas, 3491

- Kurita A, *see* Sano T
- Kurzrock R, Albitar M, Cortes JE, Estey EH, Faderl SH, Garcia-Manero G, Thomas DA, Giles FJ, Ryback ME, Thibault A, De Porre P, Kantarjian HM. Phase II Study of R115777, a Farnesyl Transferase Inhibitor, in Myelodysplastic Syndrome, 1287
- Kuse R, *see* Alpen B
- Kushner BH, Kramer K, LaQuaglia MP, Modak S, Yataghene K, Cheung N-KV. Reduction From Seven to Five Cycles of Intensive Induction Chemotherapy in Children with High-Risk Neuroblastoma, 4888
- Kusuda L, *see* Amling CL
- Kutikova L, *see* Chang S
- Kutok JL, *see* French CA
- Kuttesch J, *see* Reid JM
- Kuttesch JF, *see* Chintagumpala M
- Kuwano H, *see* Endoh H
- Kwan WH, *see* Chan ATC
- Kwekkeboom DJ, *see* Teunissen JJM
- Kwiatkowski F, *see* Glehen O
- Kwok A, *see* Meyerhardt JA
- Kwok CCH, *see* Kwong DLW
- Kwon YM, *see* Kim H
- Kwong DLW, Sham JST, Au GKH, Chua DTT, Kwong PWK, Cheng ACK, Wu PM, Law MWM, Kwok CCH, Yau CC, Wan KY, Chan RTT, Choy DDK. Concurrent and Adjuvant Chemotherapy for Nasopharyngeal Carcinoma: A Factorial Study, 2643
- Kwong M, *see* Psyryi A
- Kwong PWK, *see* Kwong DLW
- Kyle RA, *see* Dispenzieri A
- L**
- Laack E, Dickgreber N, Müller T, Knuth A, Benk J, Lorenz C, Gieseler F, Dürk H, Engel-Riedel W, Dalhoff K, Kortsik C, Graeven U, Burk M, Dierlamm T, Welte T, Burkholder I, Edler L, Hossfeld DK. Randomized Phase III Study of Gemcitabine and Vinorelbine Versus Gemcitabine, Vinorelbine, and Cisplatin in the Treatment of Advanced Non-Small-Cell Lung Cancer: From the German and Swiss Lung Cancer Study Group, 2348
- Labianca R, *see* Gill S
- Labopin M, *see* Ringdén O
- Labrie C, *see* Labrie F
- Labrie F, Champagne P, Labrie C, Roy J, Laverdière J, Provencher L, Potvin M, Drolet Y, Pollak M, Penasci L, L'Espérance B, Dufresne J, Latreille J, Robert J, Samson B, Jolivet J, Yelle L, Cusan L, Diamond P, Candas B. Activity and Safety of the Antiestrogen EM-800, the Orally Active Precursor of Acolbifene, in Tamoxifen-Resistant Breast Cancer, 864
- Lacasa C, *see* Sangro B
- Lacerda L, *see* Michalkiewicz E
- La Cesa A, *see* Vincenzi B
- Lacy MQ, *see* Dispenzieri A
- Ladas EJ, Jacobson JS, Kennedy DD, Teel K, Fleischauer A, Kelly KM. Antioxidants and Cancer Therapy: A Systematic Review, 517
- Ladetto M, *see* Corradini P
- Lage A, *see* Crombet T
- Lagman R, *see* Davis MP
- Lai CKC, *see* Chan W-M
- Lai K, *see* Chan ATC
- Lai M, *see* Chan ATC
- Lai P, *see* Barnholtz-Sloan JS
- Lai R, *see* Schlette EJ
- Lai R. Association Between *TGFBR1*6A* and Cancer: Is There Any Evidence? (correspondence), 2754
- Laigle F, *see* Hoang-Xuan K
- Lal R, Dickson J, Cunningham D, Chau I, Norman AR, Ross PJ, Topham C, Middleton G, Hill M, Oates J. A Randomized Trial Comparing Defined-Duration With Continuous Irinotecan Until Disease Progression in Fluoropyrimidine and Thymidylate Synthase Inhibitor-Resistant Advanced Colorectal Cancer, 3023
- Lam DSC, *see* Chan W-M
see Liu DTL
- Lam JS, *see* Patarad J-J
- Lam KC, *see* Yeo W
- Lamb DJ, *see* Shariat SF
- Lambert P, *see* Wadler S
- Lammertsma AA, *see* van der Hoeven JJM
- Lamont JP, *see* Lewis D
- Lamy T, *see* Nimubona S
- Lance RS, *see* Amling CL
- Landi B, *see* Tournigand C
- Landier W, Bhatia S, Eshelman DA, Forte KJ, Sweeney T, Hester AL, Darling J, Armstrong FD, Blatt J, Constine LS, Freeman CR, Friedman DL, Green DM, Marina N, Meadows AT, Neglia JP, Oeffinger KC, Robison LL, Ruccione KS, Sklar CA, Hudson MM. Development of Risk-Based Guidelines for Pediatric Cancer Survivors: The Children's Oncology Group Long-Term Follow-Up Guidelines From the Children's Oncology Group Late Effects Committee and Nursing Discipline, 4979
- Landrum MB, *see* Earle CC
- Landsittel D, *see* Yu YP
- Lang A, *see* De Santis M
- Lang B, *see* Monstad SE
- Lang FF, Yung WKA. In Reply (correspondence), 1345
- Lang P, *see* Bader P
- Lange B, *see* Sung L
- Lange BJ, Dinndorf P, Smith FO, Arndt C, Barnard D, Feig S, Feusner J, Seibel N, Weiman M, Aplenc R, Gerbing R, Alonzo TA. Pilot Study of Idarubicin-Based Intensive-Timing Induction Therapy for Children With Previously Untreated Acute Myeloid Leukemia: Children's Cancer Group Study 2941, 150
- Lange PH, *see* Scher HI
- Lange PH, Lin DW. Does the Who and How of Surgery in Bladder Cancer Matter? (editorial), 2762
- Langendijk JA, Leemans CR, Buter J, Berkhof J, Slotman BJ. The Additional Value of Chemotherapy to Radiotherapy in Locally Advanced Nasopharyngeal Carcinoma: A Meta-Analysis of the Published Literature, 4604
- Langer C, *see* Cheng JD
- Langer CJ, *see* Argiris A
see Johnson DH
- Langer CJ, Stephenson P, Thor A, Vangel M, Johnson DH. Trastuzumab in the Treatment of Advanced Non-Small-Cell Lung Cancer: Is There a Role? Focus on Eastern Cooperative Oncology Group Study 2598, 1180
- Langer EK, *see* Ross JA
- Langkjer ST, *see* Ejlertsen B
- Langston JW, *see* Fouladi M
- Laningham FH, *see* Fouladi M
- Lanzi G, *see* Longo R
- Lapidus J, *see* Roberts SS
- Laprie A, *see* Leclair M-D
- LaQuaglia MP, *see* Kushner BH
- Lardinois D, *see* Weder W
- Larrache J, *see* Sangro B
- Larson PS, *see* Schlechter BL
- Larson RA, *see* Byrd JC
see Kolitz JE
see Marcucci G
see Zimmerman TM
- Larson S, *see* Downey RJ
- Laskar S, Gupta T, Vimal S, Muckaden MA, Saikia TK, Pai SK, Naresh KN,

- Dinshaw KA. Consolidation Radiation After Complete Remission in Hodgkin's Disease Following Six Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Chemotherapy: Is There a Need?, 62
- Lassere Y, *see* Hoff PM
- Lasset C, *see* Negrier S
- Last KW, Rohatiner AZS, Fitzgibbon J, Lister TA. In Reply (correspondence), 3430
- Latreille J, *see* Hébert-Croteau N
see Labrie F
- Lau C, *see* Gajjar A
- Lau J, *see* McNicol E
- Lauer SJ, *see* Cushing B
see Rogers PC
- Laufer M, *see* Partridge AH
- Lauria R, *see* De Placido S
- Lauta VM, *see* Zinzani PL
- Laverdière J, *see* Labrie F
- Laver JH, *see* Godder K
- Lavolé A, *see* Mary-Krause M
- Law MWM, *see* Kwong DLW
- Lawrance JA, *see* Davies AJ
- Lawrence HJ, *see* Nguyen VH
- Lawrence R, *see* Rose JH
- Lawrence T, *see* Muler JH
- Lawrence W, *see* Mandelblatt JS
see Schwartz MD
- Lawrence WF, *see* Cullen J
- Lawton CA, *see* Pollack A
- Le QH, *see* Hequet O
- Le Blanc K, *see* Ringdén O
- Le Bousse-Kerdiles MC, *see* Marchetti M
- Lebwohl D, *see* Reyno L
- Leclair M-D, Hartmann O, Heloury Y, Fourcade L, Laprie A, Mechinaud F, Munzer C, Rubie H. Localized Pelvic Neuroblastoma: Excellent Survival and Low Morbidity With Tailored Therapy—The 10-Year Experience of the French Society of Pediatric Oncology, 1689
- Lecocke M, *see* Ayers M
- Lee, H., *see* Kim JS
- Lee AK, *see* Zagars GK
- Lee C, *see* Kent E
see Steer CJ
- Lee CG, *see* Yun YH
- Lee H, *see* Kim H
see Smith MR
- Lee JH, Essner R, Torisu-Itakura H, Wanek L, Wang H, Morton DL. Factors Predictive of Tumor-Positive Nonsentinel Lymph Nodes After Tumor-Positive Sentinel Lymph Node Dissection for Melanoma, 3677
- Lee JJ, *see* Ren H
see Yeo W
- Lee JS, *see* Yun YH
- Lee JS-J, *see* Leu KM
- Lee KS, *see* Yun YH
- Lee MH, *see* Choi DH
- Lee P, *see* Shuch B
- Lee S, *see* Sparano JA
- Lee SJ, *see* Greenberg PL
- Lee S-w, *see* Yun YH
- Lee Y, *see* Gajjar A
- Leemans CR, *see* Langendijk JA
- Legay R, *see* Lukaschek J
- Leggett BA, *see* Nagasaka T
- LeGrand SB, *see* Davis MP
- Lehrnbecher T, *see* Creutzig U
- Lei KIK, *see* Yeo W
- Leigh B, *see* Edelman MJ
- Leighl N, *see* Hagerty RG
- Leighl NB, Butow PN, Tattersall MHN. Treatment Decision Aids in Advanced Cancer: When the Goal Is Not Cure and the Answer Is Not Clear, 1759
- Leipprand E, *see* Maier BO
- Leiserowitz GS, *see* Cress RD
- Leisinger H-J, *see* Studer UE
- Leister C, *see* Raymond E
- Leiter U, *see* Eigentler TK
- Leiter U, Buettner PG, Eigentler TK, Garbe C. Prognostic Factors of Thin Cutaneous Melanoma: An Analysis of the Central Malignant Melanoma Registry of the German Dermatological Society, 3660
- Leitman S, *see* Bishop MR
- Lejeune J, *see* Hoang-Xuan K
- Lekakis L, *see* Psyrris A
- Lemoine NR, *see* Kakkar AK
- Lens MB, Rosdahl I, Ahlbom A, Farahmand BY, Synnerstad I, Boeryd B, Bishop JAN. Effect of Pregnancy on Survival in Women With Cutaneous Malignant Melanoma, 4369
- Lenz G, Dreyling M, Schiegnitz E, Haferlach T, Hasford J, Unterhalt M, Hiddemann W. Moderate Increase of Secondary Hematologic Malignancies After Myeloblastic Radiochemotherapy and Autologous Stem-Cell Transplantation in Patients With Indolent Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group, 4926
- Lenz H-J. The Use and Development of Germline Polymorphisms in Clinical Oncology (editorial), 2519
- Leonard I, *see* Crombet T
- Leong L, *see* Somlo G
- Leon ME, *see* De Pas T
see Pastorino U
- Lepper ER, *see* Tan AR
- Lerman C, *see* Schwartz MD
- Lerner SP, *see* Shariat SF
- L'Espérance B, *see* Labrie F
- Lesperance ML, *see* Olivotto IA
- Letendre L, *see* Greenberg PL
- Leubke AM, *see* Stoecklein NH
- Leu KM, Ostruszka LJ, Shewach D, Zalupski M, Sondak V, Biermann JS, Lee JS-J, Couwlier C, Palazzolo K, Baker LH. Laboratory and Clinical Evidence of Synergistic Cytotoxicity of Sequential Treatment With Gemcitabine Followed by Docetaxel in the Treatment of Sarcoma, 1706
- Leung EH, *see* Citron ML
- Leung SF, *see* Chan ATC
- Leung TWT, *see* Yeo W
- Leung TW-T, *see* Chan ATC
- Leuschner I, *see* Reinhard H
- Lev DC, Onn A, Melinkova VO, Miller C, Stone V, Ruiz M, McGary EC, Ananthaswamy HN, Price JE, Bar-Eli M. Exposure of Melanoma Cells to Dacarbazine Results in Enhanced Tumor Growth and Metastasis In Vivo, 2092
- Levenback C, *see* Eifel PJ
- Leverger G, *see* de Botton S
- Levi F, *see* Hrushesky W
- Levin B, *see* Lippman SM
- Levine AM, Tulpule A, Espina B, Sherrod A, Boswell WD, Lieberman RD, Nathwani BN, Welles L. Liposome-Encapsulated Doxorubicin in Combination With Standard Agents (cyclophosphamide, vincristine, prednisone) in Patients With Newly Diagnosed AIDS-Related Non-Hodgkin's Lymphoma: Results of Therapy and Correlates of Response, 2662
- Levine DA, *see* Spentzos D
- Levine EA, *see* Glehen O
see Shen P
- Levine M, *see* Simunovic M

AUTHOR INDEX

- Levine MN, *see* Kakkar AK
see Wright JR
- Levin VA, *see* Puduvali VK
- Levitt ML, *see* Pfeffer MR
- Levitz JS, Sugarbaker PH, Lichtman SM, Brun EA. Unusual Abdominal Tumors: Pseudomyxoma Peritonei: Response to Capecitabine, 1518
- Levy AS, *see* Chi SN
- Levy DE, *see* Waber DP
- Levy R, *see* Weng W-K
- Lewis D, McCarty TM, Kuhn JA, Lamont JP. Uncommon Presentations of Cancer Patients. Case 2. Colon Cancer Presenting With Intestinal Intussusception, 4853
- Lewis VO, *see* Pisters PWT
- Lh eritier V, *see* Thomas X
- Li C, *see* Merchant TE
- Li R, *see* Pollack A
- Li S, *see* Seibel NL
- Li T, *see* Sparano JA
- Li Y, *see* Argiris A
- Li Y-P, *see* Rowinsky EK
- Liang R, *see* Chim CS
- Liang X, *see* Trobaugh-Lotario AD
- Liao S, *see* Thigpen JT
- Liberati AM, *see* Ascani S
- Liebermann TA, *see* Spentzos D
- Lichinitser M, *see* Efficace F
see Howell A
- Lichter P, *see* Haslinger C
- Lichtman SM, *see* Levitz JS
- Licitra L, Bossi PF, Locati LF, Zunino F. Cisplatin and Fluorouracil Concurrent to Radiotherapy in Nasopharyngeal Cancer: Is the Schedule Compatible? (correspondence), 377
- Licitra L, Suardi S, Bossi P, Locati LD, Mariani L, Quattrone P, Lo Vullo S, Oggionni M, Olmi P, Cant  G, Pierotti MA, Pilotti S. Prediction of *TP53* Status for Primary Cisplatin, Fluorouracil, and Leucovorin Chemotherapy in Ethmoid Sinus Intestinal-Type Adenocarcinoma, 4901
- Lidbrink E, *see* Brandberg Y
- Lieberman F, *see* Puduvali VK
- Lieberman RD, *see* Levine AM
- Liebmann J, *see* Meyers CA
- Liede A, Karlan BY, Narod SA. Cancer Risks for Male Carriers of Germline Mutations in *BRCA1* or *BRCA2*: A Review of the Literature, 735
- Liersch R, *see* Koch P
see Kollmannsberger C
- Lieskovsky YE, Donaldson SS, Torres MA, Wong RM, Amylon MD, Link MP, Agarwal R. High-Dose Therapy and Autologous Hematopoietic Stem-Cell Transplantation for Recurrent or Refractory Pediatric Hodgkin's Disease: Results and Prognostic Indices, 4532
- Liesveld J, *see* Devine SM
- Liljegren A, Lindgren G, Brandberg Y, Rotstein S, Nilsson B, Hatschek T, Jaramillo E, Lindblom A. Individuals With an Increased Risk of Colorectal Cancer: Perceived Benefits and Psychological Aspects of Surveillance by Means of Regular Colonoscopies, 1736
- Lim D, *see* Somlo G
- Lim H-L, *see* Hanna N
- Lima CMR, Green MR, Rotche R, Miller WH Jr, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G, Miller LL. Irinotecan Plus Gemcitabine Results in No Survival Advantage Compared With Gemcitabine Monotherapy in Patients With Locally Advanced or Metastatic Pancreatic Cancer Despite Increased Tumor Response Rate, 3776
- Limentani SA, *see* Socinski MA
- Lin DW, *see* Lange PH
- Lin J-C, Jan J-S. In Reply (correspondence), 377
- Lin J-T, *see* Kuo S-H
- Lin NU, Bellon JR, Winer EP. CNS Metastases in Breast Cancer, 3618
- Lin PP, *see* Pisters PWT
- Lin TY, Chiu KM, Chien CY, Wang MJ, Chu SH. Unusual Sites of Metastatic Involvement: Right Ventricular Outflow Obstruction Caused by Metastatic Hepatocellular Carcinoma, 1152
- Lin Y-C, *see* Chang G-C
- Lindblom A, *see* Liljegren A
- Linden HM, Ramsey S, Anderson N. An Ounce of Prevention or a Pound of Cure? Investing to Improve Breast Cancer Outcomes for African American Women (editorial), 2517
- Lindgren G, *see* Liljegren A
- Linehan WM, *see* Dahut WL
- Lingen MW, *see* Cohen EEW
- Link MP, *see* Hudson MM
see Lieskovsky YE
see Miser JS
- Liou S-H, *see* Atkins MB
- Lipkowitz S, *see* Tan AR
- Lippman ME, *see* Low JA
- Lippman SM, Levin B, Brenner DE, Gordon GB, Aldige CR, Kramer BS, Garber JE, Hawk E, Ganz PA, Somerfield MR. Cancer Prevention and the American Society of Clinical Oncology, 3848
- Lipscomb J, *see* Ayanian JZ
- Lipshultz SE, *see* Adams MJ
- Lipshultz SE, Colan SD. Cardiovascular Trials in Long-Term Survivors of Childhood Cancer (editorial), 769
- Lipsitz SR, *see* Adams MJ
- Lipton LR, Johnson V, Cummings C, Fisher S, Risby P, Eftekhari Sadat AT, Cranston T, Izatt L, Sasieni P, Hodgson SV, Thomas HJW, Tomlinson IPM. Refining the Amsterdam Criteria and Bethesda Guidelines: Testing Algorithms for the Prediction of Mismatch Repair Mutation Status in the Familial Cancer Clinic, 4934
- Lissia A, *see* Casula M
- Lister TA, *see* Davies AJ
see Last KW
see Rossi J-F
- Little SE, Hanks SP, King-Underwood L, Jones C, Rapley EA, Rahman N, Pritchard-Jones K. Frequency and Heritability of *WT1* Mutations in Nonsyndromic Wilm's Tumor Patients: A UK Children's Cancer Study Group Study, 4140
- Littlewood TJ, *see* Rossi J-F
- Liu D, *see* Dolan NC
see Katzenstein HM
- Liu DTL, *see* Chan W-M
- Liu DTL, Fan DSP, Chan W-M, Choi PCL, Gao L, Lam DSC. Challenging Problems in Malignancy: Chronic Lymphocytic Leukemia With Ocular Complications and Superior Vena Cava Obstruction, 3830
- Liu G, *see* Gurubhagavatula S
- Liu L, *see* Yu YP
- Liu V, *see* Puduvali VK
- Liu Y, *see* Dahut WL
- Livingston PO, *see* Su YB
- Livingston R, *see* Citron ML
see Edelman MJ
- Liyanarchchi S, *see* Aldred MA
- Lizotte P, *see* Gulec SA
- Llanos M, *see* Montalb n C
- Lledo G, *see* Bouch  O
see Tournigand C
- Llewellyn-Thomas HA, *see* Sung L
- Lloid ME, *see* Robien K
- Llombart-Cussac A, *see* Colomer R
- Lloyd P, *see* Peng B
- Lluch A, *see* Colomer R
see Keller AM
- Lo SK, *see* Haggerty RG

AUTHOR INDEX

- Lo YMD, *see* Chan ATC
 Lobb EA, *see* Hagerty RG
 Lobel B, *see* Patard J-J
 Lobello R, *see* Picardi M
 Loberiza FR Jr, *see* Eapen M
 Loblaw DA, Mendelson DS, Talcott JA, Virgo KS, Somerfield MR, Ben-Josef E, Middleton R, Porterfield H, Sharp SA, Smith TJ, Taplin ME, Vogelzang NJ, Wade JL Jr, Bennett CL, Scher HI. American Society of Clinical Oncology Recommendations for the Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer, 2927
 LoBuglio A, *see* Xiong HQ
 Locati LD, *see* Licitra L
 Locati LF, *see* Licitra L
 Lockbaum P, *see* Rowinsky EK
 Locker G, *see* Cuzick J
 see Fallowfield L
 Locketz AJ, *see* Thompson MA
 Loddenkemper C, *see* Kiewe P
 Loeffler JS, *see* Chakravarti A
 Loehrer PJ, *see* Fisch MJ
 see Shirao K
 Loehrer PJ Sr, *see* Saltz LB
 Loehrer PJ Sr, Wang W, Johnson DH, Ettinger DS. Octreotide Alone or With Prednisone in Patients With Advanced Thymoma and Thymic Carcinoma: An Eastern Cooperative Oncology Group Phase II Trial, 293
 Loening SA, *see* Atzpodien J
 Loewen G, *see* Aljada IS
 Loffeld RJLF, *see* Jongbloed MRM
 Loffredo M, *see* D'Amico AV
 Logan TF, *see* Atkins MB
 Loge JH, *see* Hem E
 Loggie BW, *see* Shen P
 Logothetis C, *see* Mathew P
 see Scher HI
 Logothetis CJ, *see* Fizazi K
 see Papandreou CN
 Lombardi AV, *see* De Placido S
 Lombriser N, *see* Huguenin P
 Lonardi S, *see* Aschele C
 London WB, *see* Cushing B
 see Kretschmar CS
 see Rogers PC
 Longhi A, *see* Bacci G
 Longo R, Mocini D, Santini M, Giannantoni P, Carillio G, Torino F, Auriti A, Marcello R, Lanzi G, Cortese F, Gasparini G. Unusual Sites of Metastatic Malignancy. Case 1. Cardiac Metastasis in Hepatocellular Carcinoma, 5012
 Long SR, *see* Chang S
 Look KY, *see* Fleming GF
 Loong F, *see* Chim CS
 López-Guillermo A, *see* Beà S
 López JD, *see* Repine TB
 Lopez T, *see* Garcia-Carbonero R
 Loprinzi C, *see* Shanafelt TD
 Loprinzi CL, *see* Gill S
 see Jatoi A
 Lordick F, *see* Wieder HA
 Lorenz C, *see* Laack E
 Lorigan PC, *see* Hancock WB
 Lorimier G, *see* Glehen O
 Lortholary A, *see* Fargeot P
 Lorusso P, *see* Simon MS
 LoRusso PM, *see* Rinehart J
 Lotan R, *see* Khuri FR
 see Lu C
 Lotz J-P, *see* Gholam D
 Louis-Sylvestre C, Clough K, Asselain B, Vilcoq JR, Salmon RJ, Campana F, Fourquet A. Axillary Treatment in Conservative Management of Operable Breast Cancer: Dissection or Radiotherapy? Results of a Randomized Study With 15 Years of Follow-Up, 97
 Louvet C, *see* Tournigand C
 Love A, *see* Kissane DW
 Lovell MA, *see* Trobaugh-Lotario AD
 Lo Vullo S, *see* Licitra L
 Lower EE, *see* Gradishar WJ
 Lowery JC, *see* Janz NK
 Low JA, Berman AW, Steinberg SM, Danforth DN, Lippman ME, Swain SM. Long-Term Follow-Up for Locally Advanced and Inflammatory Breast Cancer Patients Treated With Multimodality Therapy, 4067
 Low V, *see* Kakkar AK
 Lozano R, *see* Kouvaraki MA
 Lozza L, *see* Del Vecchio M
 Lu C, Soria J-C, Tang X, Xi X-C, Wang L, Mao L, Lotan R, Kemp B, Bekele BN, Feng L, Hong WK, Khuri FR. Prognostic Factors in Resected Stage I Non-Small-Cell Lung Cancer: A Multivariate Analysis of Six Molecular Markers, 4575
 Lu KH, *see* Slomovitz BM
 Lubeck DP, *see* Cooperberg MR
 Ludwig C, *see* Kühne M
 Lugli A, *see* Kühne M
 see Went PT
 Lukaschek J, Nufer M, Maurer D, Asanger M, Honegger H, Widmer L, Malet-Martino M, Legay R, Martino R. Cardiotoxicity and Neurotoxicity of High-Dose Continuous Fluorouracil As a Result of Degradation Compounds in the Drug Vials (correspondence), 5022
 Lum B, *see* Greenberg PL
 Luo J-H, *see* Yu YP
 Luppi M, *see* Potenza L
 Lustig RH, *see* Merchant TE
 Lutgens LCHW, *see* Creutzberg CL
 Lutz S, Spence C, Chow E, Janjan N, Connor S. Survey on Use of Palliative Radiotherapy in Hospice Care, 3581
 Lybeert MLM, *see* Creutzberg CL
 Lyden ER, *see* Walterhouse DO
 Lynch CF, *see* Potosky AL
 Lynch GR, *see* Anderson KO
 Lynch HT, *see* Metcalfe K
 see Rebeck TR
 Lynch P, *see* Velikova G
 Lynch PM, *see* Ajani JA
 Lynch TJ, *see* Gurubhagavatula S

M

- Ma BBY, *see* Chan ATC
 Ma ESK, *see* Hon C
 Ma Y, *see* Van Cutsem E
 Maadani F, *see* Escalón MP
 Mabbott DJ, *see* Spiegler BJ
 MacDonald D, *see* Tisman G
 MacDonald JS, *see* Gunderson LL
 see Meyerhardt JA
 Macdonald JS, *see* Meyerhardt JA
 MacDonald N, *see* Gagnon B
 see Jatoi A
 Machtay M. Phase I's, Photons, and Philosophies: New Tactics for Exploratory Clinical Trials of Concurrent Chemoradiation (editorial), 214

AUTHOR INDEX

- MacKey J, *see* Cuzick J
- MacKillop WJ, Huang J, Barbera L, Brouwers M, Browman G. In Reply (correspondence), 1343
- Mack JW, Grier HE. The Day One Talk, 563
- MacNeil M, *see* Reyno L
- MacPhee DG, *see* Nagasaka T
- Macro M, *see* Mounier N
- Madden T, *see* Papandreou CN
- Madersbacher S, Thalmann GN, Fritsch JC, Studer UE. Is Eligibility for a Chemotherapy Protocol a Good Prognostic Factor for Invasive Bladder Cancer After Radical Cystectomy?, 4103
- Madewell JE, *see* Hamaoka T
- Madhumathi DS, *see* Devi VL
- Maehara Y, *see* Osoegawa A
- Maestu I, *see* Fernández-Martos C
- Maghfoor I, *see* Al-Thenayan E
- Magnant C, *see* Schwartz MD
- Maguire HC Jr, *see* Berd D
- Mahe M, *see* Gerard J-P
- Mahfouz T, *see* Miceli M
- Mahoney MR, *see* Garrity MM
- Mahvi D, *see* King, DM
- Maier BO, von Scheidt W, Siuk J, Sumer C, Leipprand E, Schlimok G, Sandherr M. Cardiac Involvement in Malignancies: Primary Cardiac Diffuse Large B-Cell Lymphoma: Diagnosis by Transesophageal Echocardiography-Guided Transvenous Biopsy, 2745
- Mailänder V, *see* Bredenfeld H
- Maillart P, *see* Diéras V
- Mailliard JA, *see* Jatoi A
see Martenson JA Jr
see Perez EA
- Main D, *see* Schwartz MD
- Maingon P, *see* Gerard J-P
- Makin W, *see* Whitworth MK
- Maki RG, *see* Cormier JN
see Garcia-Carbonero R
- Makower D, *see* Wadler S
- Malathi M, *see* Devi VL
- Malet-Martino M, *see* Lukaschek J
- Malfetano J, *see* Thigpen JT
- Malin JL, *see* Ayanian JZ
see Schneider EC
- Malin JL. Bridging the Divide: Intergrating Cancer-Directed Therapy and Palliative Care (editorial), 3438
- Maloney AM, *see* Sung L
- Maltoni M, *see* Caraceni A
- Mamounas E, *see* Taghian A
- Manalo J, *see* Sparano JA
- Manca A, *see* Casula M
- Mancini I, Dumon J-C, Body J-J. Efficacy and Safety of Ibandronate in the Treatment of Opioid-Resistant Bone Pain Associated With Metastatic Bone Disease: A Pilot Study, 3587
- Mandalà M, *see* Ferretti G
- Mandalia S, *see* Stebbing J
- Mandelblatt JS, *see* Cullen J
see Figueiredo MI
- Mandelblatt JS, Schechter CB, Yabroff KR, Lawrence W, Dignam J, Muenig P, Chavez Y, Cullen J, Fahs M. Benefits and Costs of Interventions to Improve Breast Cancer Outcomes in African American Women, 2554
- Mandeli J, *see* Hochster H
- Mandel K, Atkinson S, Barr RD, Pencharz P. Skeletal Morbidity in Childhood Acute Lymphoblastic Leukemia, 1215
- Mandelli F, *see* Breccia M
- Manders P, *see* Span PN
- Mandolesi A, *see* Scartozzi M
- Mandrekar S, *see* Dy GK
- Manegold C, *see* Giaccone G
see Hanna N
see Herbst RS
- Mangialaio S, *see* Went PT
- Mangili G, *see* Bolis G
- Mani S, *see* Senzer N
- Manne SL, *see* Norton TR
- Mann RB, *see* Chan ATC
- Manola J, *see* Garcia-Carbonero R
see Kaufman HL
- Mano M, Kerr J. Optimal Therapy for Relapsed Carcinoma of the Cervix After Primary Chemoradiation (correspondence), 5021
- Mansfield P, *see* Hanna H
- Mansfield PF, *see* Ajani JA
- Mansfield PF. Lymphadenectomy for Gastric Cancer (editorial), 2759
- Mantelli M, *see* Casula M
- Manzione L, *see* De Placido S
- Mao L, *see* Lu C
see Ren H
- Mao T-L, *see* Kuo S-H
- Mapara MY, Sykes M. Tolerance and Cancer: Mechanisms of Tumor Evasion and Strategies for Breaking Tolerance, 1136
- Marcello R, *see* Longo R
- Marchetti M, Barosi G, Balestri F, Viarengo G, Gentili S, Barulli S, Demory J-L, Ilariucci F, Volpe A, Bordessoule D, Grossi A, Le Bousse-Kerdiles MC, Caenazzo A, Pecci A, Falcone A, Broccia G, Bendotti C, Bauduer F, Buccisano F, Dupriez B. Low-Dose Thalidomide Ameliorates Cytopenias and Splenomegaly in Myelofibrosis With Myeloid Metaplasia: A Phase II Trial, 424
- Marchigiani D, *see* Bishop MR
- Marcom PK, *see* Gradishar WJ
- Marcucci G., *see* Perrotti D
- Marcucci G, Mrózek K, Ruppert AS, Archer KJ, Pettenati MJ, Heerema NA, Carroll AJ, Koduru PRK, Koltitz JE, Sterling LJ, Edwards CG, Anastasi J, Larson RA, Bloomfield CD. Abnormal Cytogenetics at Date of Morphologic Complete Remission Predicts Short Overall and Disease-Free Survival, and Higher Relapse Rate in Adult Acute Myeloid Leukemia: Results From Cancer and Leukemia Group B Study 8461, 2410
- Marcus KC, *see* Hudson MM
- Marcus R, *see* Kretschmar CS
- Marcus RE, *see* Rossi J-F
- Marghoob AA, *see* Halpern AC
- Margolin K, *see* Somlo G
- Mariani L, *see* Licitra L
- Mariani P, *see* des Guetz G
- Mariani TV, *see* Kondagunta GV
- Marie Y, *see* Hoang-Xuan K
- Marijnen CAM, *see* van den Brink M
- Marinaccio M, *see* De Placido S
- Marina N, *see* Landier W
see See Rogers PC
- Marina NM, *see* Cushing B
- Marion S, *see* Kondagunta GV
see Motzer RJ
- Maris JM, *see* DuBois SG
- Markman J, *see* Markman M
- Markman M. Intraperitoneal Hyperthermic Chemotherapy As Treatment of Peritoneal Carcinomatosis of Colorectal Cancer (correspondence), 1527
- Markman M, Markman J, Webster K, Zanotti K, Kulp B, Peterson G, Belinson J. Duration of Response to Second-Line, Platinum-Based Chemotherapy for Ovarian Cancer: Implications for Patient Management and Clinical Trial Design, 3120
- Markowitz S, *see* Wei SJ

AUTHOR INDEX

- Marks LB, Garst J, Socinski MA, Sibley G, Blackstock AW, Herndon JE, Zhou S, Shafman T, Tisch A, Clough R, Yu X, Turrisi A, Anscher M, Crawford J, Rosenman J. Carboplatin/Paclitaxel or Carboplatin/Vinorelbine Followed by Accelerated Hyperfractionated Conformal Radiation Therapy: Report of a Prospective Phase I Dose Escalation Trial From the Carolina Conformal Therapy Consortium, 4329
- Marks R, *see* Shanafelt TD
- Marlin S, *see* Reyno L
- Maroun J, *see* Benson AB III
see Figueredo A
- Marques R, *see* Michalkiewicz E
- Marra P, *see* Izzo F
- Marsden JR, *see* Hancock BW
- Marshall B, *see* Atkins MB
- Marshall GD Jr, *see* Raut CP
- Marsiglia H, *see* Andre F
- Martelli M, *see* Zinzani PL
- Martenson JA, *see* Gunderson LL
- Martenson JA Jr, *see* Benson AB III
- Martenson JA Jr, Willett CG, Sargent DJ, Mailliard JA, Donohue JH, Gunderson LL, Thomas CR Jr, Fisher B, Benson AB III, Myerson R, Goldberg RM. Phase III Study of Adjuvant Chemotherapy and Radiation Therapy Compared With Chemotherapy Alone in the Surgical Adjuvant Treatment of Colon Cancer: Results of Intergroup Protocol 0130, 3277
- Marth C, *see* Fiegl M
- Martin C, *see* Yovine A
- Martinelli V, *see* Picardi M
- Martínez R, *see* Montalbán C
- Martin G, *see* Hébert-Croteau N
- Martin H, *see* Kiehl MG
- Martini C, *see* Caraceni A
- Martin M, *see* Colomer R
- Martin M, *see* Alba E
- Martino R, *see* Lukaschek J
- Martino S, *see* Citron ML
see Perez EA
- Marvin V, *see* Stebbing J
- Marx A, *see* Gautschi O
see Ströbel P
- Mary-Krause M, Herida M, Costagliola D, Lavolé A, Cadranel J. In Reply (correspondence), 1349
- Marymount M, *see* Campbell AD
- Massimo L, *see* Caprino D
- Massoner A, *see* Fiegl M
- Mastrangelo MJ, *see* Berd D
- Matakidou A, *see* Popat S
- Matejić D, *see* Steiner HH
- Materman E, *see* Raymond E
- Mather SJ, *see* Davies AJ
- Mathew P, Thall PF, Jones D, Perez C, Bucana C, Troncoso P, Kim S-J, Fidler IJ, Logothetis C. Platelet-Derived Growth Factor Receptor Inhibitor Imatinib Mesylate and Docetaxel: A Modular Phase I Trial in Androgen-Independent Prostate Cancer, 3323
- Mathews R, *see* Roberts SS
- Mathews V, *see* Hoerr AL
- Mathias C, *see* Bruera E
- Matloff E, *see* Rebbeck TR
- Matsubara N, *see* Nagasaka T
- Matsui K, *see* Kubota K
- Matsukura S, *see* Nakajima H
- Matsuo K, *see* Hotta K
- Matthay KK, *see* DuBois SG
- Matthews B, *see* Ballen KK
- Mattke AC, *see* Schuck A
- Matullo G, *see* Berwick M
- Matulonis U, *see* Garcia-Carbonero R
- Mauch P, *see* Adams MJ
- Maurer D, *see* Lukaschek J
- Mauriac L, *see* Diéras V
- Maus TP, *see* Goetz MP
- Mautner V, *see* Palmer DH
- Mautz W, *see* Waber DP
- Mayer RJ, *see* Byrd JC
see Gunderson LL
see Meyerhardt JA
see Saltz LB
- Mayo NE, *see* Gagnon B
- Mazumdar M, *see* Kondagunta GV
see Motzer RJ
- Mazzolini G, *see* Sangro B
- McAllister P, *see* Benson AB III
- McCabe MS, *see* Anderson BD
- McCallum R, *see* Benson AB III
- McCarthy J, *see* Tisman G
- McCarthy WH, *see* Fife KM
- McCarty TM, *see* Lewis D
- McCaughan BC, *see* Viney RC
- McCluggage CW, *see* Fouladi M
- McCollum AD, *see* Meyerhardt JA
- McCorkle R, *see* Given C
- McCready DR, *see* Bull SB
- McCredie MRE, *see* Phillips K-A
- McDonald C, *see* Yu YP
- McGary EC, *see* Lev DC
- McGehee R, *see* Morris M
- McGinn CJ, *see* Muler JH
- McGovern FJ, *see* Smith MR
- McGovren JP, *see* Meyerhardt JA
- McGregor CGA, *see* Dispenzieri A
- McIlwain M, *see* Auerbach M
- McKenna P, *see* Myers DA
- McKinnon PJ, *see* Gajjar A
- McLaughlin P, *see* Dang NH
see Escalón MP
- McLaughlin PW, *see* Thomas CH
- McLean JM, *see* Viney RC
- McLendon RE, *see* Rich JN
- McLennan J, *see* Metcalfe K
- McLeod DG, *see* Amling CL
- McLeod HL, *see* Wang Y
- McLeod HL, Watters JW. Irinotecan Pharmacogenetics: Is It Time to Intervene? (editorial), 1356
- McIlwain M, *see* Auerbach M
- McMahon P, *see* Glare PA
- McNeese MD, *see* Chen AM
see Huang EH
see Thomas E
- McNicol E, Strassels S, Goudas L, Lau J, Carr D. Nonsteroidal Anti-Inflammatory Drugs, Alone or Combined With Opioids, for Cancer Pain: A Systematic Review, 1975
- McNuff JM, *see* Smith BD
- McQuellon RP, *see* Moore DH
- McTiernan A, *see* Chlebowski RT
- Meadows AT, *see* Landier W
- Mears A, *see* Socinski MA
- Mechinaud F, *see* Leclair M-D
- Medeiros LJ, *see* Schlette EJ
- Meerbaum S, *see* Hilden JM
- Meerwaldt J, *see* Meyers CA

- Mehdi A, *see* Sabbatini P
- Mehlen P, Fearon ER. Role of the Dependence Receptor DCC in Colorectal Cancer Pathogenesis, 3420
- Mehta J. Myeloid Growth Factors Should Not Be Administered Routinely After Allogeneic Hematopoietic Stem-Cell Transplantation (correspondence), 4429
- Mehta MP, *see* Meyers CA
see Peterit DG
see Puduvali VK
- Mehta SS, *see* Cooperberg MR
- Meier K, *see* Hrushesky W
- Meier UR, *see* Huguenin P
- Meijer CJLM, *see* van Beek J
- Meijer S, *see* Hartgrink HH
see van der Hoeven JJM
- Mekhail T, *see* Alatrash G
- Melero I, *see* Sangro B
- Melinkova VO, *see* Lev DC
- Mellado B, *see* Cao MG
- Mellars L, *see* Keller AM
- Melpignano M, *see* Bolis G
- Memoli N, *see* Miller VA
- Ménard C, *see* Chan LW
- Mendelson DS, *see* Loblaw DA
- Mendenhall WM. Mandibular Osteoradionecrosis (editorial), 4867
- Méndez M, *see* Montalbán C
- Mendoza TR, *see* Anderson KO
- Menetrier-Caux C, *see* Negrier S
- Meng MV, *see* Cooperberg MR
- Mengual JL, *see* Fernández-Martos C
- Mennel RG, *see* Keller AM
- Menu Y, *see* Avril MF
- Menzel C, *see* Kovács AF
- Merchant TE, *see* Hudson MM
- Merchant TE, Mulhern RK, Krasin MJ, Kun LE, Williams T, Li C, Xiong X, Khan RB, Lustig RH, Boop FA, Sanford RA. Preliminary Results From a Phase II Trial of Conformal Radiation Therapy and Evaluation of Radiation-Related CNS Effects for Pediatric Patients With Localized Ependymoma, 3156
- Meric-Bernstam F, *see* Chen AM
see Raut CP
- Merkel DE, *see* Tedesco KL
- Meropol NJ, *see* Saltz LB
- Meropol NJ, Castel LD, Schulman KA, Weinfurt KP. In Reply (correspondence), 572
- Merriam P, *see* Garcia-Carbonero R
- Merrill P, *see* Slingluff CL Jr
- Mertens A, *see* Zebrack BJ
- Mertens AC, *see* Ross JA
- Merx H, *see* Arndt V
- Mery-Mignard D, *see* Tournigand C
- Messina J, *see* DuBois SG
- Messina JL, *see* Naing A
- Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, Olopade OI, Eisen A, Weber B, McLennan J, Sun P, Foulkes WD, Narod SA. Contralateral Breast Cancer in *BRCA1* and *BRCA2* Mutation Carriers, 2328
- Metivier J, *see* Ayers M
- Metz JM, *see* Wei SJ
- Metzger V, *see* Waber DP
- Metzner B, *see* Atzpodien J
see Kollmannsberger C
see Zander AR
- Meunier C, *see* Nimubona S
- Meyer MB, *see* Rinehart J
- Meyer W, *see* Arndt C
- Meyer WH, *see* Walterhouse DO
see Wharam MD
- Meyerhardt JA, Kwok A, Ratain MJ, McGovren JP, Fuchs CS. Relationship of Baseline Serum Bilirubin to Efficacy and Toxicity of Single-Agent Irinotecan in Patients With Metastatic Colorectal Cancer, 1439
- Meyerhardt JA, Tepper JE, Niedzwiecki D, Hollis DR, McCollum AD, Brady D, O'Connell MJ, Mayer RJ, Cummings B, Willett C, Macdonald JS, Benson AB III, Fuchs CS. Impact of Body Mass Index on Outcomes and Treatment-Related Toxicity in Patients With Stage II and III Rectal Cancer: Findings From Intergroup Trial 0114, 648
- Meyerhardt JA, Tepper JE, Niedzwiecki D, Hollis DR, Schrag D, Ayanian JZ, O'Connell MJ, Weeks JC, Mayer RJ, Willett CG, MacDonald JS, Benson AB III, Fuchs CS. Impact of Hospital Procedure Volume on Surgical Operation and Long-Term Outcomes in High-Risk Curatively Resected Rectal Cancer: Findings From the Intergroup 0114 Study, 166
- Meyers CA, *see* Puduvali VK
- Meyers CA, Smith JA, Bezjak A, Mehta MP, Liebmann J, Illidge T, Kunkler I, Caudrelier J-M, Eisenberg PD, Meerwaldt J, Siemers R, Carrie C, Gaspar LE, Curran W, Phan S-C, Miller RA, Renschler MF. Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III Trial, 157
- Meyers CH, *see* Garrity MM
- Meyers PA, *see* Miser JS
- Meyerson M, *see* Dubinett SM
- Meyskens FL Jr, Fetting JH. Pulling the Trigger, 3644
- Meza J, *see* Wharam MD
- Meza LA, *see* Gradishar WJ
- Miach P, *see* Kissane DW
- Miaskowski C, Dodd M, West C, Schumacher K, Paul SM, Tripathy D, Koo P. Randomized Clinical Trial of the Effectiveness of a Self-Care Intervention to Improve Cancer Pain Management, 1713
- Micallef IN, *see* Davies AJ
- Miceli M, Atoui R, Thertulien R, Barlogie B, Anaissie E, Walker R, Jones-Jackson L. Deep Septic Thrombophlebitis: An Unrecognized Cause of Relapsing Bacteremia in Patients With Cancer (correspondence), 1529
- Miceli M, Atoui R, Walker R, Mahfouz T, Mirza N, Diaz J, Tricot G, Barlogie B, Anaissie E. Diagnosis of Deep Septic Thrombophlebitis in Cancer Patients by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Scanning: A Preliminary Report, 1949
- Michael M, Brittain MA, Nagai J, Feld R, Hedley D, Oza A, Siu L, Moore MJ. Phase II Study of Activated Charcoal to Prevent Irinotecan-Induced Diarrhea, 4410
- Michaelson MD, Rosenthal DI, Smith MR. Long-Term Bisphosphonate Treatment of Bone Metastases From Renal Cell Carcinoma (correspondence), 4233
- Michaelson RA, *see* Winer EP
- Michalak JC, *see* Garrity MM
- Michalkiewicz E, Sandrini R, Figueiredo B, Miranda ECM, Caran E, Oliveria-Filho AG, Marques R, Pianovski MAD, Lacerda L, Cristofani LM, Jenkins J, Rodriguez-Galindo C, Ribeiro RC. Clinical and Outcome Characteristics of Children With Adrenocortical Tumors: A Report From the International Pediatric Tumor Registry, 838
- Michalopoulos G, *see* Yu YP
- Michalski J, *see* Wharam MD
- Michaud L, *see* Navo MA
- Michels J-J, *see* Guillou L
- Michelson H, *see* Brandberg Y
- Mick R, *see* Friedberg JS
- Middeldorp JM, *see* van Beek J
- Middleton G, *see* Lal R
- Middleton MR, *see* Hancock BW
- Middleton R, *see* Loblaw DA
- Mikhail M, *see* Shuch B

AUTHOR INDEX

- Milan C, *see* Bouché O
- Milella M, *see* Ferretti G
- Milicic B, *see* Jeremic B
- Miller C, *see* Lev DC
- Miller DC, *see* Chi SN
see Modak S
- Miller DS, *see* Moore DH
- Miller JR III, *see* Kashani-Sabet M
- Miller LL, *see* Lima CMR
- Miller RA, *see* Meyers CA
- Miller TP, *see* Hehn ST
- Miller TP. The Limits of Limited Stage Lymphoma (editorial), 2982
- Miller V, *see* Giaccone G
see Herbst RS
- Miller VA, *see* Sherman EJ
- Miller VA, Kris MG, Shah N, Patel J, Azzoli C, Gomez J, Krug LM, Pao W, Rizvi N, Pizzo B, Tyson L, Vehkatraman E, Ben-Porat L, Memoli N, Zakowski M, Rusch V, Heelan RT. Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non-Small-Cell Lung Cancer, 1103
- Miller WH Jr, *see* Lima CMR
- Millikan RE, *see* Papandreou CN
- Milne RL, *see* Phillips K-A
- Milner DA Jr, *see* Ghia KK
- Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith JS, Bander NH. Phase I Trial of Yttrium-90-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Androgen-Independent Prostate Cancer, 2522
- Milton GW, *see* Fife KM
- Minami H, Ohe Y, Niho S, Goto K, Ohmatsu H, Kubota K, Kakinuma R, Nishiwaki Y, Nokihara H, Sekine I, Saijo N, Hanada K, Ogata H. Comparison of Pharmacokinetics and Pharmacodynamics of Docetaxel and Cisplatin in Elderly and Non-Elderly Patients: Why Is Toxicity Increased in Elderly Patients?, 2901
- Ming ME, *see* Gimotty PA
- Minna JD, *see* Dowell JE
- Minsky BD, *see* Brenner B
- Mintun MA, *see* Bradley JD
- Miny J, *see* Rauch P
- Miranda ECM, *see* Michalkiewicz E
- Mirchandani D, *see* Khandwala HM
- Miree C, *see* Simon MS
- Mirlacher M, *see* Went PT
- Mirza D, *see* Palmer DH
- Mirza M, *see* Miceli M
- Miser JS, Krailo MD, Tarbell NJ, Link MP, Fryer CJH, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA, Donaldson SS, Moore S, Rausen AR, Vietti TJ, Grier HE. Treatment of Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor of Bone: Evaluation of Combination Ifosfamide and Etoposide—A Children's Cancer Group and Pediatric Oncology Group Study, 2873
- Misset JL, *see* Yovine A
- Mitchell DY, *see* Rinehart J
- Mitchell EP, *see* Benson AB III
- Mitchell MS. Chemotherapy for Melanoma: The Resultant of Conflicting Vectors (editorial), 2043
- Mitelman F, *see* Bardi G
- Mitropoulos D, *see* Bamias A
- Mitry E, *see* Bouché O
- Mitsudomio T, *see* Endoh H
- Miyoshi I, *see* French CA
- Mo F, *see* Chan ATC
- Moaddeli SN, *see* Tisman G
- Möbus V, *see* Zander AR
- Mocini D, *see* Longo R
- Modak S, *see* Kushner BH
- Modak S, Gardner S, Dunkel IJ, Balmaceda C, Rosenblum MK, Miller DC, Halpern S, Finlay JL. Thiotepa-Based High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Patients With Recurrent or Progressive CNS Germ Cell Tumors, 1934
- Mohr B, *see* Schlenk RF
- Mohr P, *see* Avril MF
- Mok TSK, *see* Chan ATC
see Yeo W
- Mokhtari K, *see* Hoang-Xuan K
- Molinari AL, *see* Zinzani PL
- Moliterni A, *see* Bonadonna G
- Molto L, *see* Alatrash G
- Mon R, *see* Crombet T
- Monfardini S, *see* Aschele C
see Brandes AA
- Monfardini S. Geriatric Oncology: A New Subspecialty? (correspondence), 4655
- Monk BJ, *see* Morris M
- Monnier A, *see* Bonnetterre J
see Fargeot P
- Monstad SE, Drivsholm L, Storstein A, Aarseth JH, Haugen M, Lang B, Vincent A, Vedeler CA. Hu and Voltage-Gated Calcium Channel (VGCC) Antibodies Related to the Prognosis of Small-Cell Lung Cancer, 795
- Montalbán C, García JF, Abaira V, González-Camacho L, Morente MM, Bello JL, Conde E, Cruz MA, García-Sanz R, García-Laraña J, Grande C, Llanos M, Martínez R, Flores E, Méndez M, Ponderós C, Rayón C, Sánchez-Godoy P, Zamora J, Piris MA. Influence of Biologic Markers on the Outcome of Hodgkin's Lymphoma: A Study by the Spanish Hodgkin's Lymphoma Study Group, 1664
- Montbarbon X, *see* Pommier P
- Montcuquet P, *see* Bonnetterre J
- Montella L, Vardanega A, Farruggio A, Bonciarelli G. Unusual Aspects of Melanoma: Jejunal Malignant Melanoma: Intestinal or Unknown Primary?, 743
- Montie J, *see* Kent E
- Montie JE, *see* Thomas CH
- Montillo M, *see* Rossi J-F
- Montserrat E, *see* Beà S
- Moog U, *see* van Roosmalen MS
- Moon D, *see* Fife KM
- Moore DF Jr, *see* Alberts SR
- Moore DH, *see* Morris M
- Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, Miller DS, Olt G, King S, Boggess JF, Rocereto TF. Phase III Study of Cisplatin With or Without Paclitaxel in Stage IVB, Recurrent, or Persistent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study, 3113
- Moore DH. In Reply (correspondence), 5022
- Moore DT, *see* Socinski MA
- Moore JO, *see* Byrd JC
see Kolitz JE
- Moore MJ, *see* Michael M
- Moore S, *see* Miser JS
- Morente MM, *see* Montalbán C
- Morgan E, *see* Campbell AD
- Morgan PB, Kessel IL, Xiao S-Y, Colman M. Uncommon Presentations of Hodgkin's Disease: Hodgkin's Disease of the Jejunum, 193
- Morgan R Jr, *see* Somlo G
- Morganti A, *see* Lima CMR
- Morice P, *see* Nimubona S
- Mori M, *see* Fromme EK
see Roberts SS
- Morris C, *see* Howell A

AUTHOR INDEX

- Morris C, Iacobelli S, Brand R, Bjorkstrand B, Drake M, Niederwieser D, Gahrton G. Benefit and Timing of Second Transplantations in Multiple Myeloma: Clinical Findings and Methodological Limitations in a European Group for Blood and Marrow Transplantation Registry Study, 1674
- Morris DE, *see* Fried DB
see Socinski MA
- Morris J, *see* Ajani JA
- Morris M, *see* Eifel PJ
see Scher HI
- Morris M, Blessing JA, Monk BJ, McGehee R, Moore DH. Phase II Study of Cisplatin and Vinorelbine in Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study, 3340
- Morrow M, *see* Golub RM
- Morschhauser F, *see* Mounier N
- Morselli M, *see* Potenza L
- Mortimer JE, *see* Tripathy D
- Morton DL, *see* Lee JH
see Takeuchi H
- Morton RF, *see* Goldberg RM
- Moschos SJ, Kirkwood JM, Konstantinopoulos PA. Present Status and Future Prospects for Adjuvant Therapy of Melanoma: Time to Build upon the Foundation of High-Dose Interferon Alfa-2b (editorial), 11
- Moschovi M, *see* French CA
- Moscinski L, *see* Johnson JL
- Moses MA, *see* Chan LW
- Mosley ST, *see* Rich TA
- Mossavar-Rahmani Y, *see* Chlebowski RT
- Motzer RJ, *see* Kondagunta GV
- Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M. Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma, 454
- Motzer RJ. In Reply (correspondence), 1158
- Moul JW, *see* Amling CL
see Scher HI
- Moulet I, *see* Hequet O
- Mounier N, Gisselbrecht C, Brière J, Haioun C, Feugier P, Offner F, Recher C, Stamatoullas A, Morschhauser F, Macro M, Thieblemont C, Sonet A, Fabiani B, Reyes F. Prognostic Factors in Patients With Aggressive Non-Hodgkin's Lymphoma Treated by Front-Line Autotransplantation After Complete Remission: A Cohort Study by the Groupe d'Etude des Lymphomes de l'Adulte, 2826
- Mountain A, *see* Palmer DH
- Mouridsen H, Chaudri-Ross HA. In Reply (correspondence), 3200
- Mouridsen HT, *see* Ejlertsen B
- Mouridsen HT. Exemestane Following Tamoxifen in Postmenopausal Women With Primary Breast Cancer (correspondence), 3833
- Mourits MJE, *see* Buijs C
- Moyano J, *see* Bruera E
- Mrózek K, *see* Byrd JC
see Marcucci G
- Muanza T, *see* Chan LW
- Muckaden MA, *see* Laskar S
- Mueller SP, *see* Antoch G
- Muennig P, *see* Mandelblatt JS
- Muggia FM, *see* Hochster H
- Mühr-Wilkenshoff F, *see* Kiewe P
- Mulders PFA, *see* Patard J-J
- Muler JH, McGinn CJ, Normolle D, Lawrence T, Brown D, Hejna G, Zalupski MM. Phase I Trial Using a Time-to-Event Continual Reassessment Strategy for Dose Escalation of Cisplatin Combined With Gemcitabine and Radiation Therapy in Pancreatic Cancer, 238
- Mulhern RK, *see* Fouladi M
see Merchant TE
- Mulhern RK, Khan RB, Kaplan S, Helton S, Christensen R, Bonner M, Brown R, Xiong X, Wu S, Gururangan S, Reddick WE. Short-Term Efficacy of Methylphenidate: A Randomized, Double-Blind, Placebo-Controlled Trial Among Survivors of Childhood Cancer, 4795
- Mulholland P, *see* Casson AG
- Müller Hermelink HK, *see* Ströbel P
- Müller-Hermelink HK, *see* Alpen B
- Müller-Holzner E, *see* Fiegl M
- Müller SC, *see* Atzpodien J
- Muller T, *see* Hanna N
- Müller T, *see* Laack E
- Munárriz B, *see* Colomer R
- Munkarah AR, *see* Fleming GF
- Munsell MF, *see* Brown J
see Hanna H
see Slomovitz BM
- Munzer C, *see* Leclair M-D
- Muro K, *see* Shirao K
- Murphy BA, *see* Argiris A
- Murphy K, *see* Wieand S
- Murphy LM, *see* Garrity MM
- Murphy M, *see* Tripathy D
- Murray K, *see* Kretschmar CS
- Murrey D, *see* Tedesco KL
- Murtha A, *see* Roa W
- Muscaritoli M, *see* Breccia M
- Muss H, *see* Winer EP
- Muss HB, *see* Citron ML
see Hansen HH
- Mutch DG, *see* Eifel PJ
- Mutch MG, *see* Wang Y
- Muzikansky A, *see* Chakravarti A
- Myers DA, Bird BR, Ryan SM, Tormey P, McKenna P, O'Reilly S, Breathnach OS. Unusual Aspects of Melanoma: Melanoma-Associated Retinopathy Presenting With Night Blindness, 746
- Myerson R, *see* Ajani JA
see Martenson JA Jr

N

- Nabell L, *see* Garden AS
- Nabholtz J-M, *see* Keller AM
- Naeim A, *see* Reuben DB
- Nagai J, *see* Michael M
- Nagalla SR, *see* Roberts SS
- Nagasaka T, Sasamoto H, Notohara K, Cullings HM, Takeda M, Kimura K, Kambara T, MacPhee DG, Young J, Leggett BA, Jass JR, Tanaka N, Natsubara N. Colorectal Cancer With Mutation in *BRAF*, *KRAS* and Wild-Type With Respect to Both Oncogenes Showing Different Patterns of DNA Methylation, 4584
- Nagashima F, *see* Shirao K
- Naglieri E, *see* De Placido S
- Nagtegaal ID, *see* van den Brink M
- Naing A, Messina JL, Vrionis FR, Daud AI. Uncommon Manifestations of Common Malignancies: Malignant Melanoma Arising From A Spinal Nerve Root, 3194
- Nair S, *see* Jatoi A
- Nair Suresh, *see* Alberts SR
- Nakajima H, Oki M, Ando K. Unusual Lymphoma Manifestations: CD8⁺ T-Cell Prolymphocytic Leukemia, 560
- Nakajima H, Oki M, Matsukura S, Nakamura M, Tokunaga M, Ando K. Germ Cell Tumors: Intraocular Metastases From Testicular Cancer, 1753

AUTHOR INDEX

- Nakamura M, *see* Kumasaka R
see Nakajima H
- Nakamura N, *see* Kumasaka R
- Nakano T, *see* Akechi T
- Namer M, *see* Andre F
see Diéras V
see Fargeot P
- Nanus DM, *see* Milowsky MI
- Napoleon B, *see* Saurin J-C
- Naqvi A, *see* Sung L
- Naresh KN, *see* Laskar S
- Narni F, *see* Corradini P
- Narod SA, *see* Liede A
see Metcalfe K
see Rebbeck TR
- Nascimento A, *see* Figueroa BE
- Nashimoto A, *see* Sano T
- Nasiri N, *see* Hess V
- Natale RB, *see* Giaccone G
see Herbst RS
see Herr HW
see Rinehart J
- Natarajan L, *see* Rock CL
- Nathan PC, *see* Sung L
- Nathwani BN, *see* Levine AM
- Navo MA, Phan J, Vaughan C, Palmer JL, Michaud L, Jones KL, Bodurka DC, Basen-Engquist K, Hortobagyi GN, Kavanagh JJ, Smith JA. An Assessment of the Utilization of Complementary and Alternative Medication in Women With Gynecologic or Breast Malignancies, 671
- Naydich BG, *see* Okunieff P
- Naylor MD, *see* Houldin AD
- Nazario A, *see* Anderson KO
- Nazeer T, *see* Sparano JA
- Needle MN, *see* Saltz LB
see Xiong HQ
- Neel M, *see* Relling MV
- Neese PY, *see* Slingsluff CL Jr
- Neglia JP, *see* Landier W
- Négrier S. Better Survival With Interleukin-2–Based Regimens? Possibly Only in Highly Selected Patients (editorial), 1174
- Négrier S, Perol D, Menetrier-Caux C, Escudier B, Pallardy M, Ravaud A, Douillard J-Y, Chevreau C, Lasset C, Blay J-Y. Interleukin-6, Interleukin-10, and Vascular Endothelial Growth Factor in Metastatic Renal Cell Carcinoma: Prognostic Value of Interleukin-6—From the Groupe Français d’Immunothérapie, 2371
- Nekarda H, *see* Gertler R
- Nelson AD, *see* Sodee DB
- Nelson J, *see* Yu YP
- Nelson M, *see* Stebbing J
- Nemec C, *see* Alatrash G
- Nemoz C, *see* Gerard J-P
- Nemunaitis JJ, *see* Johnson DH
see Senzer N
- Neubauer A, *see* Alpen B
- Neubauer M, Schwartz J, Caracandas J, Conkling P, Ilegbodu D, Tuttle T, Asmar L. Results of a Phase II Study of Weekly Paclitaxel Plus Carboplatin in Patients With Extensive Small-Cell Lung Cancer With Eastern Cooperative Oncology Group Performance Status of 2, or Age \geq 70 Years, 1872
- Neuberg DS, *see* Gurubhagavatula S
- Neuber K, *see* Avril MF
- Neugut AI, Chen AC, Petrylak DP. The “Skinny” on Obesity and Prostate Cancer Prognosis (editorial), 395
- Neuhausen SL, *see* Rebbeck TR
- Neumann H, *see* Van Cutsem E
- Nevalainen MT, *see* Bubendorf L
see Torhorst J
see Xie J
- Neville BA, *see* Earle CC
- Neville K, *see* Blaney SM
- Newell B, *see* Dewar DJ
- Newlands ES. In Reply (correspondence), 204
- Newman VA, *see* Rock CL
- Neyton L, *see* Rauch P
- Ng C, *see* Izzo F
- Ng JSK, *see* Chan W-M
- Ng K, *see* Dupont J
- Nguyen VH, Lawrence HJ. Use of Gabapentin in the Prevention of Taxane-Induced Arthralgias and Myalgias (correspondence), 1767
- Nicholas MK, *see* Puduvali VK
- Nicholson BP, *see* Tedesco KL
- Nicodemus CF, *see* Berek JS
- Nicolardi L, *see* Brandes AA
- Nicolucci A, Belfiglio M, Pellegrini F, Sacco M, Valentini M. In Reply (correspondence), 1165
- Niederwieser D, *see* Morris C
see Schlenk RF
- Niedzwiecki D, *see* Meyerhardt JA
- Nielsen I, *see* Sartori S
- Niemeyer C, *see* Bader P
- Niessen H, *see* Jongbloed MRM
- Niethammer D, *see* Bader P
see Simon T
- Niho S, *see* Minami H
- Niitani H, *see* Kubota K
- Nilsson B, *see* Liljegren A
- Nimubona S, Bernard M, Morice P, Caulet-Maugendre S, Carsin B, Meunier C, Lamy T. Complications of Malignancy: Case 3. Chronic Lymphocytic Leukemia Presenting With Panhypopituitarism, 374
- Nishimura EK, *see* Tisman G
- Nishiwaki Y, *see* Kubota K
see Minami H
- Nitschke R. Physician–Patient Communication in Phase I Cancer Trials (correspondence), 571
- Nivers R, *see* Ajani JA
- Nix D, *see* Papandreou CN
- Nix W, *see* Ströbel P
- Noberasco C, *see* De Pas T
- Noda K, *see* Kubota K
- Nogova L, *see* Bredenfeld H
- Nokihara H, *see* Minami H
- Norman AR, *see* Chau I
see Lal R
- Normanno N, Di Maio M, Perrone F, Campiglio M. Molecular Markers to Predict Response to Gefitinib: EGFR, ErbB-2, or More? (correspondence), 2035
- Normolle D, *see* Muler JH
- Nortobagyi GN, *see* Huang EH
- Norton AJ, *see* Davies AJ
- Norton HJ, *see* Greene FL
- Norton L, *see* Citron ML
see Winer EP
- Norton TR, Manne SL, Rubin S, Carlson J, Hernandez E, Edelson MI, Rosenblum N, Warshal D, Bergman C. Prevalence and Predictors of Psychological Distress Among Women With Ovarian Cancer, 919
- Nose V, *see* French CA
- Nosrati M, *see* Kashani-Sabet M
- Notohara K, *see* Nagasaka T
- Notter M, *see* Huguenin P
see Kiewe P

- Novotny PJ, *see* Goetz MP
see Jatoi A
see Shanafelt TD
- Novotny WF, *see* Johnson DH
- Nowak AK, Stockler MR, Byrne MJ. Assessing Quality of Life During Chemotherapy for Pleural Mesothelioma: Feasibility, Validity, and Results of Using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module, 3172
- Nufer M, *see* Lukaschek J
- Numico G, *see* Anfossi M
- O**
- Oates J, *see* Chau I
see Lal R
- Oberg K, *see* Fazio N
- Oberlin O, *see* Carli M
- Oberneder R, *see* Atzpodien J
- Obertop H, *see* de Boer AGEM
see Hartgrink HH
- Ochs JS, *see* Giaccone G
see Herbst RS
- O'Connell MJ, *see* Garrity MM
see Gunderson LL
see Horning SJ
see Meyerhardt JA
- O'Day S, *see* Gulec SA
- Odenike OM, *see* Zimmerman TM
- Odom LF, *see* Trobaugh-Lotario AD
- O'Dorisio TM, *see* Benson AB III
- O'Dwyer PJ, *see* Shirao K
- Oechsle K, *see* De Santis M
- Oeffinger K, *see* Zebrack BJ
- Oeffinger KC, *see* Landier W
See See Ross JA
- Oertel J, *see* Bredenfeld H
- Oettle H, *see* Van Cutsem E
- Offit K, *see* Pasche B
- Offit K. *MSH6* Mutations in Hereditary Nonpolyposis Colon Cancer: Another Slice of the Pie (editorial), 4449
- Offner F, *see* Mounier N
- Ogata H, *see* Minami H
- Oggionni M, *see* Licitra L
- Øgreid D, *see* Sørbye H
- Oh WK, Kantoff PW, Weinberg V, Jones G, Rini BI, Derynck MK, Bok R, Smith MR, Bublely GJ, Rosen RT, DiPaola RS, Small EJ. Prospective, Multicenter, Randomized Phase II Trial of the Herbal Supplement, PC-SPES, and Diethylstilbestrol in Patients With Androgen-Independent Prostate Cancer, 3705
- Ohashi Y, *see* Kubota K
- Ohe Y, *see* Minami H
- Ohmatsu H, *see* Minami H
- Ohtsu A, *see* Shirao K
- Okajima K, *see* Sano T
- Oki M, *see* Nakajima H
- Okumura K, *see* Kumasaka R
- Okunieff P, Augustine E, Hicks JE, Cornelison TL, Altemus RM, Naydich BG, Ding I, Huser AK, Abraham EH, Smith JJ, Coleman N, Gerber LH. Pentoxifylline in the Treatment of Radiation-Induced Fibrosis, 2207
- Okuyama T, *see* Akechi T
- Olagüe C, *see* Sangro B
- Olak J, *see* Pfister DG
- Olencki T, *see* Alatrash G
- Oliff I, *see* Herbst RS
- Oliff S, *see* Palmer DH
- Oliveira AM, Fletcher DM. Molecular Prognostication for Soft Tissue Sarcomas: Are We Ready Yet? (editorial), 4031
- Oliveira-Filho AG, *see* Michalkiewicz E
- Olivotto IA, *see* Metcalfe K
see Chia SK
- Olivotto IA, Truong PT, Chua B. Postmastectomy Radiation Therapy: Who Needs It? (editorial), 4237
- Olivotto IA, Truong PT, Speers CH, Bernstein V, Allan SJ, Kelly SJ, Lesperance ML. Time to Stop Progesterone Receptor Testing in Breast Cancer Management (correspondence), 1769
- Olmi P, *see* Licitra L
- Olopade OI, *see* Metcalfe K
see Rebbeck TR
- Olson TA, *see* Cushing B
see Rogers PC
- Olszewski M, *see* Katzenstein HM
- Olt G, *see* Moore DH
- O'Malley JP, *see* Roberts SS
- Onn A, *see* Lev DC
- Oo TH, *see* Gaur S
- Ooi GC, *see* Chim CS
- Ooi WS, Crown JP. Medical Problems in Patients With Malignancy: Ulcerating Cytomegalovirus Bronchitis in a Patient With Relapsed Non-Hodgkin's Lymphoma, 4022
- Oosterhof GON, *see* Collette L
- Oosterwijk JC, *see* van Roosmalen MS
- O'Reilly S, *see* Myers DA
- Orlando N, *see* Lima CMR
- Orlow I, *see* Berwick M
- Orr J Jr, *see* Berek JS
- Orth J, *see* Al-Batran S-E
- O'Ryan ML, *see* Santolaya ME
- Osada H, *see* Endoh H
- Osawa H, *see* Kumasaka R
- Osborne CK, *see* Howell A
- Osburn CH, *see* Petereit DG
- Osoba D, *see* Bezzak A
- Osoegawa A, Yoshino I, Tanaka S, Sugio K, Kameyama T, Yamaguchi M, Maehara Y. Regulation of p27 by S-Phase Kinase-Associated Protein 2 Is Associated With Aggressiveness in Non-Small-Cell Lung Cancer, 4165
- Osoerio M, *see* Crombet T
- Ostruszka LJ, *see* Leu KM
- Oswald MJ, *see* Chen AM
- O'Toole EE, *see* Rose JH
- Otten W, *see* Jansen SJT
- Outlaw ED, *see* Chen AM
- Owens SE, *see* Davies AJ
- Oza A, *see* Michael M
- Ozcelik H, *see* Bull SB
- Ozsahin M, *see* Huguenin P
- P**
- Packer RJ, *see* Zebrack BJ
- Paczynski D, *see* Sung L
- Padmanabhan S, *see* Raez LE
- Page NC, *see* Read WL
- Pagliari L, *see* Papandreou CN
- Pagliari LC. In Reply (correspondence), 1163
- Pai SK, *see* Laskar S
- Paietta E, *see* Greenberg PL
see Tallman MS

AUTHOR INDEX

- Paitel JF, *see* Bouché O
- Palazzolo K, *see* Leu KM
- Palesty JA, Wang W, Javle MM, Yang GY. Side Effects of Therapy: Gastric Cancer After Radiotherapy of Pediatric Hodgkin's Disease, 2507
- Palla K, *see* Chatterjee R
- Palla SL, *see* Ursin G
- Pallardy M, *see* Negrier S
- Palmer CGS, *see* Hadley DW
- Palmer DH, Mautner V, Mirza D, Oliff S, Gerritsen W, van der Sijp JRM, Hubscher S, Reynolds G, Bonney S, Rajaratnam R, Hull D, Horne M, Ellis J, Mountain A, Hill S, Harris PA, Searle PF, Young LS, James ND, Kerr DJ. Virus-Directed Enzyme Prodrug Therapy: Intratumoral Administration of a Replication-Deficient Adenovirus Encoding Nitroreductase to Patients With Resectable Liver Cancer, 1546
- Palmer JL, *see* Bruera E
see Elsayem A
see Navo MA
- Palmer PA, *see* Rao S
- Palmer SC, *see* Coyne JC
- Palmieri C, Barron N, Vigushin DM. The Vincotube System: A Design Solution to Prevent the Accidental Administration of Intrathecal Vinca Alkaloids (correspondence), 965
- Palmieri G, *see* Casula M
- Palos GR, *see* Anderson KO
- Panasci L, *see* Labrie F
- Pane F, *see* Picardi M
- Panetta JC, *see* Daw NC
- Pantaleo MA, *see* Biasco G
- Pantanowitz L, *see* Doweiko J
- Pantanowitz L, Dezube BJ. Reasons for a Deficit of Breast Cancer Among HIV-Infected Patients (correspondence), 1347
- Pantuck AJ, *see* Patard J-J
- Panucci MG, *see* Brandes AA
- Pao W, *see* Miller VA
- Paoletti P, *see* Hanna N
- Papadimitriou C, *see* Bamias A
- Papakostas P, *see* Bamias A
- Papakotoulas P, *see* Georgoulas V
- Papaldo P, *see* Ferretti G
- Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu S-M, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ. Phase I Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Solid Tumors With Observations in Androgen-Independent Prostate Cancer, 2108
- Pape U-F, *see* Faiss S
- Papillon M, *see* Gerard J-P
- Parazzini F, *see* Bolis G
- Parekh J, *see* Slingsluff CL Jr
- Paridon SM, *see* Ginsberg JP
see Silber JH
- Park J, *see* Bomgaars L
see Kim H
see Kim JS
- Park J-H, *see* Kim H
- Park S, *see* Gurubhagavatula S
- Park Y, *see* Atkins MB
- Park YC, *see* Rao S
- Parker CE, *see* Dahut WL
- Parnes H, *see* Dahut WL
- Parr AL, *see* Tan AR
- Parra HS, Zucali PA, Colombo P, Balzarini L, Santoro A. Uncommon Manifestations of Common Malignancies: Soft-Tissue Metastases From Malignant Pleural Mesothelioma, 3191
- Parry A, *see* de Botton S
- Partensky C, *see* Gerard J-P
- Partin AN, *see* Scher HI
- Partridge AH, Gelber S, Peppercorn J, Sampson E, Knudsen K, Laufer M, Rosenberg R, Przepyszny M, Rein A, Winer EP. Web-Based Survey of Fertility Issues in Young Women With Breast Cancer, 4174
- Parwaresch R, *see* Alpen B
- Pasche B, Kaklamani V, Hou N, Rademaker A. In Reply (correspondence), 2754
- Pasche B, Kaklamani V, Hou N, Young T, Rademaker A, Peterlongo P, Ellis N, Offit K, Caldes T, Reiss M, Zheng T. *TGFBR1*6A* and Cancer: A Meta-Analysis of 12 Case-Control Studies (correspondence), 756
- Pasold R, *see* Schlenk RF
- Passe S, *see* Dupont J
- Passik S, *see* Fisch MJ
- Pastorino U, Roz L, Sozzi G, Leon ME. In Reply (correspondence), 3202
- Patard J-J, Kim HL, Lam JS, Dorey FJ, Pantuck AJ, Zisman A, Ficarra V, Han K-R, Cindolo L, De La Taille A, Tostain J, Artibani W, Dinney CP, Wood CG, Swanson DA, Abbou CC, Lobel B, Mulders PFA, Chopin DK, Figlin RA, Beldegrun AS. Use of the University of California Los Angeles Integrated Staging System to Predict Survival in Renal Cell Carcinoma: An International Multicenter Study, 3316
- Patel A, *see* Haque B
- Patel HK, *see* Kakkar AK
- Patel J, *see* Miller VA
- Patel P, *see* Tisman G
- Patel SR, *see* Pisters PWT
- Patriarca F, *see* Corradini P
- Pattee P, *see* Roberts SS
- Patterson JW, *see* Slingsluff CL Jr
- Patz EF Jr, Swensen SJ, Herndon JE II. Estimate of Lung Cancer Mortality From Low-Dose Spiral Computed Tomography Screening Trials: Implications for Current Mass Screening Recommendations, 2202
- Pauli E, *see* Hequet O
- Paul S, *see* Hanna N
- Paul SM, *see* Miaskowski C
- Payá E, *see* Santolaya ME
- Payne R, *see* Anderson KO
- Pazdur R, *see* Hoff PM
see Talarico L
- Pearce L, *see* Reyno L
- Pecci A, *see* Marchetti M
- Pectasides D, *see* Bamias A
- Pedrazzoli P, Tullio C, Cerea G, Siena S. Iron Supplement in Cancer Patients Receiving Erythropoietin (correspondence), 4428
- Peery T, *see* Rich JN
- Pehamberger H, *see* Avril MF
- Peiper M, *see* Stoecklein NH
- Pellegata NS, *see* Aldred MA
- Pellegrini F, *see* Nicolucci A
- Pelosi G, *see* De Pas T
- Pénault-Llorca F, *see* Diéras V
- Pencharz P, *see* Mandel K
- Pendlebury S, *see* Butow P
see Hagerty RG
- Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, Talpaz M, Sawyers CL, Rosamilia M, Ford J, Lloyd P, Capdeville R. Pharmacokinetics and Pharmacodynamics of Imatinib in a Phase I Trial With Chronic Myeloid Leukemia Patients, 935
- Pennanen M, *see* Schwartz MD
- Penne KL, *see* Rich JN
- Penson DF, *see* Johnson TK
- Peppercorn J, *see* Partridge AH
- Pereira JR, *see* Hanna N
- Perez C, *see* Mathew P
see Papandreou CN

- Perez EA, Hillman DW, Mailliard JA, Ingle JN, Ryan JM, Fitch TR, Rowland KM, Kardinal CG, Krook JE, Dakhil SR. Randomized Phase II Study of Two Irinotecan Schedules for Patients With Metastatic Breast Cancer Refractory to an Anthracycline, a Taxane, or Both, 2849
- Perez EA, Rodeheffer R. Clinical Cardiac Tolerability of Trastuzumab, 322
- Perez EA, Suman VJ, Davidson NE, Kaufman PA, Martino S, Dakhil SR, Ingle JN, Rodeheffer RJ, Gersh BJ, Jaffe AS. Effect of Doxorubicin Plus Cyclophosphamide on Left Ventricular Ejection Fraction in Patients With Breast Cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial, 3700
- Pérez R, *see* Crombet T
- Perez-Atayde AR, *see* French CA
- Perez-Ruixo JJ, *see* Rao S
- Pérez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabarbara P, Bonomi P. Determinants of Tumor Response and Survival With Erlotinib in Patients With Non-Small-Cell Lung Cancer, 3238
- Perkell C, *see* Dupont J
- Perkins GH, *see* Chen AM
see Huang EH
- Perlman EJ, *see* Cushing B
see Miser JS
- Perol D, *see* Negrier S
- Perrone F, *see* De Placido S
see Normanno N
- Perrone F, Di Maio M, Gallo C, Gridelli C. Outcome of Patients With a Performance Status of 2 in the Multicenter Italian Lung Cancer in the Elderly Study (MILES) (correspondence), 5018
- Perrotti A, *see* Zinzani PL
- Perrotti D, Marcucci G, Caligiuri MA. Loss of C/EBP α and Favorable Prognosis of Acute Myeloid Leukemias: A Biological Paradox (editorial), 582
- Perrotti M, *see* Kumar P
- Perry MC, *see* Winer EP
- Peschel C, *see* Völter V
- Peshkin BN, *see* Schwartz MD
- Pestalozzi B, *see* Huguenin P
- Petereit DG, Rogers D, Govern F, Coleman N, Osburn CH, Howard SP, Kaur J, Burhansstipanov L, Fowler CJF, Chappell R, Mehta MP. Increasing Access to Clinical Cancer Trials and Emerging Technologies for Minority Populations: The Native American Project, 4452
- Peterlongo P, *see* Pasche B
- Peters W, *see* Hryniuk W
- Peters WA, *see* Sabbatini P
- Petersen IA, *see* Goetz MP
- Petersen-Schaefer K, *see* Fife KM
- Peterson G, *see* Markman M
- Petrelli NJ. The Debate Is Over; It's Time to Move On (editorial), 2041
- Petretto E, *see* Casula M
- Petroni GR, *see* Slingluff CL Jr
- Petruk K, *see* Roa W
- Petrusch A, *see* Papandreou CN
- Petrylak D, *see* Scher HI
- Petrylak DP, *see* Neugut AI
- Pettenati MJ, *see* Byrd JC
see Marcucci G
- Pettinato G, *see* Picardi M
- Pettinger M, *see* Chlebowski RT
- Pezzulli S, *see* Dupont J
- Pfeffer MR, *see* Stemmer SM
- Pfeffer MR, Levitt ML, Aderka D. Gefitinib in Recurrent Glioblastoma (correspondence), 2755
- Pfister D, *see* Wreesmann VB
- Pfister DG, *see* Azzoli CG
see Sherman EJ
- Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR. American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003, 330
- Phan J, *see* Navo MA
- Phan S-C, *see* Meyers CA
- Philip PA, *see* Simon MS
- Philip T, *see* Burgers JS
- Philippe N, *see* de Botton S
- Phillips K-A, Milne RL, Friedlander ML, Jenkins MA, McCredie MRE, Giles GG, Hopper JL. Prognosis of Premenopausal Breast Cancer and Childbirth Prior to Diagnosis, 699
- Pianovski MAD, *see* Michalkiewicz E
- Picardi M, Gennarelli N, Ciancia R, De Renzo A, Gargiulo G, Ciancia G, Sparano L, Zeppa P, Martinelli V, Pettinato G, Lobello R, Pane F, Rotoli B. Randomized Comparison of Power Doppler Ultrasound-Directed Excisional Biopsy With Standard Excisional Biopsy for the Characterization of Lymphadenopathies in Patients With Suspected Lymphoma, 3733
- Piccaluga PP, *see* Ascani S
- Piccart M, *see* Bezjak A
see Bottomley A
- Piccart MJ, *see* Efficace F
- Piccirillo JF, *see* Read WL
- Picus J, *see* Small EJ
- Piedbois P, Buyse M. Meta-Analyses Based on Abstracted Data: A Step in the Right Direction, but Only a First Step (editorial), 3839
- Pien CS, *see* Papandreou CN
- Pienkowski T, *see* Reyno L
- Pienta KJ, *see* Scher HI
- Pierce JP, *see* Rock CL
- Pierotti MA, *see* Licitra L
- Pierre AF, *see* de Perrot M
- Pignata S, *see* De Placido S
- Pike MC, *see* Ursin G
- Pileri A, *see* Corradini P
- Pileri S, *see* Zinzani PL
- Pileri SA, *see* Ascani S
- Pillai A, *see* Stockler M
- Pilotti S, *see* Licitra L
- Pinedo HM, *see* van der Hoeven JJM
- Pinkerton R, *see* Carli M
- Pinnaduwege D, *see* Bull SB
- Pintilie M, *see* Krzyzanowska MK
- Pinyol M, *see* Beà S
- Piotrowski A, *see* Simpson L
- Pipeleers-Marichal M, *see* Samyn I
- Piris MA, *see* Montalbán C
- Pisters PW, *see* Ajani JA
- Pisters PWT, *see* Cormier JN
- Pisters PWT, Patel SR, Prieto VG, Thall PF, Lewis VO, Feig BW, Hunt KK, Yasko AW, Lin PP, Jacobson MG, Burgess MA, Pollock RE, Zagars GK, Benjamin RS, Ballo MT. Phase I Trial of Preoperative Doxorubicin-Based Concurrent Chemoradiation and Surgical Resection for Localized Extremity and Body Wall Soft Tissue Sarcomas, 3375
- Pitot HC, *see* Goldberg RM
- Pizzo B, *see* Miller VA
- Plant A, *see* Tisman G
- Plaschke J, Engel C, Krüger S, Holinski-Feder E, Pagenstecher C, Mangold E, Moeslein G, Schulmann K, Gebert J, von Knebel Doeberitz M, Rüschoff J, Loeffler M, Schackert HK. Lower Incidence of Colorectal Cancer and Later Age of Disease Onset in 27 Families with Pathogenic *MSH6* Germline Mutations Compared With Families With *MLH1* or *MSH2* Mutations: The German Hereditary Nonpolyposis Colorectal Cancer Consortium, 4486

AUTHOR INDEX

- Pless M, *see* Hanna N
- Plimack ER, *see* Hochster H
- Plukker JTM, *see* Hartgrink HH
see van Westreenen HL
- Plunkett T, *see* Harper P
- Pluzanska A, *see* Giaccone G
see Reyno L
- Podack ER, *see* Raez LE
- Podoloff DA, *see* Hamaoka T
- Poggi MM, Stockel J. Medical Problems in Patients With Malignancy: Syringohydromyelia Masquerading As Malignant Cord Compression in a Patient With Small-Cell Lung Cancer, 4019
- Polikoff J, *see* Kemeny N
- Polito D, *see* Hoff PM
- Polivka M, *see* Hoang-Xuan K
- Polk OD, *see* Adams-Campbell LL
- Pollack A, DeSilvio M, Khor L-Y, Li R, Al-Saleem TI, Hammond ME, Venkatesan V, Lawton CA, Roach M III, Shipley WU, Hanks GE, Sandler HM. Ki-67 Staining Is a Strong Predictor of Distant Metastasis and Mortality for Men With Prostate Cancer Treated With Radiotherapy Plus Androgen Deprivation: Radiation Therapy Oncology Group Trial 92-02, 2133
- Pollack BH, *see* Thomas CH
- Pollak M, *see* Labrie F
- Pollicino CA, *see* Viney RC
- Pollock RE, *see* Cormier JN
see Pisters PWT
- Polosajian L, *see* Harandi A
- Poluri A, *see* Wreesmann VB
- Polverino G, *see* Bolis G
- Polyzos A, *see* Georgoulis V
- Pomeroy SL, *see* Fernandez-Teijeiro A
- Pomer S, *see* Atzpodien J
- Pommier P, Gomez F, Sunyach MP, D'Hombres A, Carrie C, Montbarbon X. Phase III Randomized Trial of *Calendula Officinalis* Compared With Trolamine for the Prevention of Acute Dermatitis During Irradiation for Breast Cancer, 1447
- Ponchon T, *see* Saurin J-C
- Ponderós C, *see* Montalbán C
- Pont J, *see* De Santis M
- Poole C, *see* Fried DB
- Popat S, Matakidou A, Houlston RS. Thymidylate Synthase Expression and Prognosis in Colorectal Cancer: A Systematic Review and Meta-Analysis, 529
- Porcheron J, *see* Glehen O
- Porta VG, *see* Avril MF
- Porterfield H, *see* Loblaw DA
- Portlock CS, *see* Chang DZ
- Possinger K, *see* Zander AR
- Post S, *see* Van Cutsem E
- Potenza L, Luppi M, Morselli M, Riva G, Saviola A, Ferrari A, De Santis M, Rossi R, Torelli G. Cardiac Involvement in Malignancies: Right Ventricular Lesion As Presenting Feature of Acute Promyelocytic Leukemia, 2742
- Potosky AL, *see* Ayanian JZ
- Potosky AL, Saxman S, Wallace RB, Lynch CF. Population Variations in the Initial Treatment of Non-Small-Cell Lung Cancer, 3261
- Pottek T, *see* Rick O
- Potter JD, *see* Robien K
- Potvin M, *see* Labrie F
- Pouillart P, *see* des Guetz G
see Diéras V
- Powell BL, *see* Kolitz JE
- Powell BWEM, *see* Dewar DJ
- Powell JB Jr, *see* Rich JN
- Powles T, Bower M. HIV and the Risk of Lung Cancer (correspondence), 1348
- Prabhash K, *see* Devi VL
- Prados M, *see* Puduvalli VK
- Presti JC Jr, *see* Freedland SJ
- Presti M, *see* Bolis G
- Price JE, *see* Lev DC
- Prieto J, *see* Sangro B
- Prieto VG, *see* Pisters PWT
- Pritchard DJ, *see* Miser JS
- Pritchard K, *see* Reyno L
see Wright JR
- Pritchard KI, *see* Bull SB
see Goodwin PJ
- Pritchard-Jones K, *see* Little SE
- Pro B, *see* Dang NH
see Escalón MP
- Provencher L, *see* Labrie F
- Provenzale DT, *see* Ayanian JZ
- Pruim J, *see* van Westreenen HL
- Przypyszny M, *see* Partridge AH
- Psyrrri A, Kwong M, DiStasio S, Lekakis L, Kassari M, Sasaki C, Wilson LD, Haffty BG, Son YH, Ross DA, Weinberger PM, Chung GG, Zelterman D, Burtneis BA, Cooper DL. Cisplatin, Fluorouracil, and Leucovorin Induction Chemotherapy Followed by Concurrent Cisplatin Chemoradiotherapy for Organ Preservation and Cure in Patients With Advanced Head and Neck Cancer: Long-Term Follow-Up, 3061
- Puchades R, *see* Fernández-Martos C
- Puchalski TA, *see* Garcia-Carbonero R
- Puchberger T, *see* Atzpodien J
- Puduvalli VK, Yung WKA, Hess KR, Kuhn JG, Groves MD, Levin VA, Zwiebel J, Chang SM, Cloughesy TF, Junck L, Wen P, Lieberman F, Conrad CA, Gilbert MR, Meyers CA, Liu V, Mehta MP, Nicholas MK, Prados M. Phase II Study of Fenretinide (NSC 374551) in Adults With Recurrent Malignant Gliomas: A North American Brain Tumor Consortium Study, 4282
- Pueyo J, *see* Sangro B
- Pui C-H, *see* Relling MV
- Puig S, *see* Cao MG
- Puig X, *see* Beà S
- Pujade-Lauraine E, *see* Diéras V
- Pulsoni A, *see* Zinzani PL
- Puppe B, *see* Ströbel P
- Purkalne G, *see* Hansen HH
- Pusztai L, *see* Ayers M
- Putter H, *see* Hartgrink HH
- Pytynia KB, Grant JR, Etzel CJ, Roberts DB, Wei Q, Sturgis EM. Matched-Pair Analysis of Survival of Never Smokers and Ever Smokers With Squamous Cell Carcinoma of the Head and Neck, 3981

Q

- Qian C, *see* Sangro B
- Qizilbash AH, *see* Bull SB
- Qu W, *see* Aquino VM
see Reid JM
- Qualman SJ, *see* Walterhouse DO
- Quattrone P, *see* Licitra L
- Quenet F, *see* Glehen O
- Quigley M, *see* Kakkar AK
- Quigley MT, *see* Garcia-Carbonero R
- Quinaux E, *see* Tournigand C
- Quinn C, *see* Su YB

Quinn JA, *see* Rich JN
 Quiroga J, *see* Sangro B

R

- Raad I, *see* Hanna H
 Rachud B, *see* Rick O
 Racine-Poon A, *see* Peng B
 Rademaker A, *see* Campbell AD
 see Dolan NC
 see Pasche B
 Rademaker AW, *see* Katzenstein HM
 Rader J, *see* Grigsby PW
 Radford JA, *see* Davies AJ
 Radzyner MH, *see* Sherman EJ
 Raetz LE, Cassileth PA, Schlesselman JJ, Sridhar K, Padmanabhan S, Fisher EZ, Baldie PA, Podack ER. Allogeneic Vaccination With a B7.1 HLA-A Gene Modified Adenocarcinoma Cell Line in Patients With Advanced Non-Small-Cell Lung Cancer, 2800
 Ragaz J, *see* Hryniuk W
 Rahbar M, *see* Given C
 Rahman N, *see* Little SE
 Rai S, *see* Hudson MM
 Rajaratnam R, *see* Palmer DH
 Raja V, Bryant B, Bessman DJ, Alperin JB. Soft Tissue Sarcomas: Granulocytic Sarcoma: Presentation With Nodal and Skin Involvement, 2026
 Rajkumar SV, *see* Kumar S
 Rakowski W, *see* Fink AK
 Ramanathan RK, *see* Goldberg RM
 Rambaldi A, *see* Corradini P
 Ramirez J, *see* Innocenti F
 Ramnath N, *see* Aljada IS
 Ramos M, *see* Alba E
 see Crombet T
 Ramsey S, *see* Linden HM
 Ramsey SD, Howlader N, Etzioni RD, Donato B. Chemotherapy Use, Outcomes, and Costs for Older Persons With Advanced Non-Small-Cell Lung Cancer: Evidence from Surveillance, Epidemiology and End Results-Medicare, 4971
 Rana J, *see* Auerbach M
 Ranaie G, *see* Steiner HH
 Randall T, *see* Armstrong K
 Ranieri N, *see* Kissane DW
 Rankin EM, *see* Agarwala SS
 Rao BN, *see* Wagner LM
 Rao PH, *see* Wreesmann VB
 Rao S, Cunningham D, de Gramont A, Scheithauer W, Smakal M, Humblet Y, Kourteva G, Iveson T, Andre T, Dostalova J, Illes A, Belly R, Perez-Ruixo JJ, Prk YC, Palmer PA. Phase III Double-Blind Placebo-Controlled Study of Farnesyl Transferase Inhibitor R115777 in Patients With Refractory Advanced Colorectal Cancer, 3950
 Raoul JL, *see* Bouché O
 Rasheed BKA, *see* Rich JN
 Rasmussen C, *see* Senzer N
 Rasmussen H, *see* Senzer N
 Raspagliesi F, *see* Bolis G
 Rassidakis GZ, *see* Schlette EJ
 Rastelli F, *see* Benedetti G
 Ratain MJ, *see* Innocenti F
 see Meyerhardt JA
 see Zimmerman TM
 Ratain MJ, Eckhardt SG. Phase II Studies of Modern Drugs Directed Against New Targets: If You Are Fazed, Too, Then Resist RECIST (editorial), 4442
 Rat P, *see* Glehen O
 Ratschiller D, *see* Gautschi O
 Rauch P, Miny J, Conroy T, Neyton L, Guillemin F. Quality of Life Among Disease-Free Survivors of Rectal Cancer, 354
 Rausen AR, *see* Miser JS
 Raut CP, Daley MD, Hunt KK, Akins J, Ross MI, Singletary SE, Marshall GD Jr, Meric-Bernstam F, Babiera G, Feig BW, Ames FC, Kuerer HM. Anaphylactoid Reactions to Isosulfan Blue Dye During Breast Cancer Lymphatic Mapping in Patients Given Preoperative Prophylaxis (correspondence), 567
 Ravaud A, *see* Negrier S
 Rawal R, *see* Hemminki K
 Raymond E, *see* Spatz A
 Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J, Leister C, Korth-Bradley J, Hanauske A, Armand J-P. Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR Inhibitor, in Patients With Cancer, 2336
 Rayón C, *see* de Botton S
 see Montalbán C
 Read EJ, *see* Bishop MR
 Read WL, Tierney RM, Page NC, Costas I, Govindan R, Spitznagel ELJ, Piccirillo JF. Differential Prognostic Impact of Comorbidity, 3099
 Reardon DA, *see* Rich JN
 Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van't Veer L, Garber JE, Evans GR, Narod SA, Isaacs C, Matloff E, Daly MB, Olopade OI, Weber BL. Bilateral Prophylactic Mastectomy Reduces Breast Cancer Risk in *BRCA1* and *BRCA2* Mutation Carriers: The PROSE Study Group, 1055
 Rebmann U, *see* Atzpodiën J
 Reboussin BA, *see* Ursin G
 Recher C, *see* Mounier N
 Recht A. Impact on Outcome of Delay in Starting Radiotherapy (correspondence), 1341
 Reddick WE, *see* Mulhern RK
 Reddy S, *see* Elsayem A
 Reece E, *see* Tisman G
 Reeves JA, *see* Herbst RS
 Regan MM, *see* Bober SL
 Regge D, *see* Goetz MP
 Reid GC, *see* Fleming GF
 Reid JM, Qu W, Safgren SL, Ames MM, Krailo MD, Seibel NL, Kuttesch J, Holcenberg J. Phase I Trial and Pharmacokinetics of Gemcitabine in Children With Advanced Solid Tumors, 2445
 Reiffers J, *see* Ringdén O
 Rein A, *see* Partridge AH
 Reinhard H, Aliani S, Ruebe C, Stöckle M, Leuschner I, Graf N. Wilms' Tumor in Adults: Results of the Society of Pediatric Oncology (SIOP) 93-01/Society for Pediatric Oncology and Hematology (GPOH) Study, 4500
 Reinhardt D, *see* Creutzig U
 Reisfeld R, *see* King, DM
 Reisfeld GM, Wilson GR. Use of Metaphor in the Discourse on Cancer, 4024
 Reiss M, *see* Pasche B
 Reitz M, *see* Atzpodiën J
 Relling MV, Yang W, Das S, Cook EH, Rosner GL, Neel M, Howard S, Ribeiro R, Sandlund JT, Pui C-H, Kaste SC. Pharmacogenetic Risk Factors for Osteonecrosis of the Hip Among Children With Leukemia, 3930
 Reman O, *see* Thomas X
 Remberger M, *see* Kiehl MG
 Ren B, *see* Yu YP
 Ren H, Tang X, Lee JJ, Feng L, Everett AD, Hong WK, Khuri FR, Mao L. Expression of Hepatoma-Derived Growth Factor Is a Strong Prognostic Predictor for Patients With Early-Stage Non-Small-Cell Lung Cancer, 3230

- Renginfo E, *see* Crombet T
- Reni M, *see* Brandes AA
- Reni M, Ferreri AJM. Is Withdrawal of Consolidation Radiotherapy an Evidence-Based Strategy in Primary Central Nervous System Lymphomas? (correspondence), 1165
- Rennie P, *see* Giaccone G
- Renschler MF, *see* Meyers CA
- Renshaw AA, *see* D'Amico AV
- Repine TB, DeArmond G, López JD. Unusual Sites of Metastatic Malignancy. Case 2 Burkitt's Lymphoma Involving the Gallbladder, 5014
- Repley EA, *see* Little SE
- Rescorla F, *see* Cushing B
see Rogers PC
- Resta D, *see* Peng B
- Reitsas S. Treatment at Random: The Ultimate Science or the Betrayal of Hippocrates?, 5005
- Retsky MW, *see* Demicheli R
- Reuben DB, Naeim A. Perspectives, Preferences, Care Practices, and Outcomes in Late-Stage Cancer Patients: Connecting the Dots (editorial), 4869
- Reuter V, *see* Motzer RJ
- Reyes F, *see* Mounier N
- Reyno L, Seymour L, Tu D, Dent S, Gelmon K, Walley B, Pluzanska A, Gorbunova V, Garin A, Jassem J, Pienkowski T, Dancy J, Pearce L, MacNeil M, Marlin S, Lebowitz D, Voi M, Pritchard K. Phase III Study of *N,N*-Diethyl-2-[4-(Phenylmethyl)Phenoxy] Ethanamine (BMS-217380-01) Combined With Doxorubicin Versus Doxorubicin Alone in Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19, 269
- Reynolds CP, *see* Roberts SS
- Reynolds G, *see* Palmer DH
- Reynolds M, *see* Campbell AD
- Reynolds SM, *see* Diener-West M
- Rhein B, *see* Denis F
- Ribeiro R, *see* Relling MV
- Ribeiro RC, *see* Michalkiewicz E
- Ribuffo D, *see* Gradilone A
- Rich JN, Friedman HS, Powell JB Jr, Dancy JE. In Reply (correspondence), 2756
- Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancy JE, McLendon RE, Kao JC, Stenzel TT, Rasheed BKA, Tourt-Uhlig SE, Herndon JE II, Vredenburgh JJ, Sampson JH, Friedman AH, Bigner DD, Friedman HS. Phase II Trial of Gefitinib in Recurrent Glioblastoma, 133
- Rich TA, *see* Gunderson LL
- Rich TA, Shepard RC, Mosley ST. Four Decades of Continuing Innovation With Fluorouracil: Current and Future Approaches to Fluorouracil Chemoradiation Therapy, 2214
- Richardson D, *see* Hanna H
- Richardson P, Anderson K. Immunomodulatory Analogs of Thalidomide: An Emerging New Therapy in Myeloma (editorial), 3212
- Richardson S, *see* Gassas A
- Richart JM, *see* Fernández-Martos C
- Richel DJ, *see* Graaf MR
- Richiardi G, *see* Bolis G
- Richman SP, *see* Anderson KO
- Richmond A, *see* Alatrash G
- Rick O, *see* Kollmannsberger C
- Rick O, Bokemeyer C, Weinknecht S, Schirren J, Pottek T, Hartmann JT, Braun T, Rachud B, Weißbach L, Hartmann M, Siegert W, Beyer J. Residual Tumor Resection After High-Dose Chemotherapy in Patients With Relapsed or Refractory Germ Cell Cancer, 3713
- Rico MA, *see* Bruera E
- Ridge JA, *see* Garden AS
- Riehle DL, *see* Garrity MM
- Riffenburgh RH, *see* Amling CL
- Rigas J, *see* Pérez-Soler R
- Rigden O. In Reply (correspondence), 4430
- Rinaldi S, *see* Stattin P
- Rinehart J, Adjei AA, LoRusso PM, Waterhouse D, Hecht JR, Natale RB, Hamid O, Varterasian M, Asbury P, Kaldjian EP, Gulyas S, Mitchell DY, Herrera R, Sebolt-Leopold JS, Meyer MB. Multicenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-Small-Cell Lung, Breast, Colon, and Pancreatic Cancer, 4456
- Ringdén O, *see* Eapen M
see Kiehl MG
- Ringdén O, Labopin M, Gorin N-C, Le Blanc K, Rocha V, Gluckman E, Reiffers J, Arcese W, Vossen JM, Jouet J-P, Cordonnier C, Frassoni F. Treatment With Granulocyte Colony-Stimulating Factor After Allogeneic Bone Marrow Transplantation for Acute Leukemia Increases the Risk of Graft-Versus-Host Disease and Death: A Study From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation, 416
- Rini BI, *see* Oh WK
see Small EJ
- Riofrio M, *see* Yovine A
- Risby P, *see* Lipton LR
- Ritchey ML, *see* Seibel NL
- Ritenbaugh C, *see* Rock CL
- Riva G, *see* Potenza L
- Rival J, *see* Khalid I
- Rivard M, *see* Hébert-Croteau N
- Rivera MP, *see* Socinski MA
- Rives S, *see* Beà S
- Rivkin S, *see* Berek JS
see Sabbatini P
- Rizvi N, *see* Miller VA
- Rizzo E, *see* Corradini P
- Roa W, Brasher PMA, Bauman G, Anthes M, Bruera E, Chan A, Fisher B, Fulton D, Gulavita S, Hao C, Husain S, Murtha A, Petruk K, Stewart D, Tai P, Urtasun R, Cairncross JG, Forsyth P. Abbreviated Course of Radiation Therapy in Older Patients With Glioblastoma Multiforme: A Prospective Randomized Clinical Trial, 1583
- Roach M III, *see* Pollack A
see Scher HL
- Roach M III. In Reply (correspondence), 2255
- Robert A, *see* de Botton S
- Robert F, *see* Cheng JD
- Robert J, *see* Labrie F
- Roberts DB, *see* Pytynia KB
- Roberts RS, *see* Wright JR
- Roberts SS, Mori M, Pattee P, Lapidus J, Mathews R, O'Malley JP, Hsieh YC, Turner MA, Wang Z, Tian Q, Rodland MJ, Reynolds, Seeger RC, Nagalla SR. GABA System Gene Expression Predicts Clinical Outcome in Patients With Neuroblastoma, 4127
- Robertson DM, *see* Diener-West M
- Robertson JFR, *see* Howell A
- Robertson KD, *see* Chan ATC
- Robien K, Schubert MM, Bruemmer B, Lloid ME, Potter JD, Ulrich CM. Predictors of Oral Mucositis in Patients Receiving Hematopoietic Cell Transplants for Chronic Myelogenous Leukemia, 1268
- Robinson L, *see* Bepler G
- Robison LL, *see* Landier W
see Ross JA
see Zebrack BJ
- Robledo M, *see* Valle L
- Roca C, *see* Crombet T
- Rocereto TF, *see* Moore DH
- Roché H, *see* Fargeot P
- Rocha V, *see* Ringdén O

AUTHOR INDEX

- Roché H, *see* Bonnetterre J
- Rock CL, Flatt SW, Thomson CA, Stefanick ML, Newman VA, Jones LA, Natarajan L, Ritenbaugh C, Hollenbach KA, Pierce JP, Chang RJ. Effects of a High-Fiber, Low-Fat Diet Intervention on Serum Concentrations of Reproductive Steroid Hormones in Women With a History of Breast Cancer, 2379
- Rockwell L, Hetzel P, Freeman JK, Fereshetian A. Cardiac Involvement in Malignancies: Primary Cardiac Lymphoma, 2744
- Rodeheffer R, *see* Perez EA
- Rodland MJ, *see* Roberts SS
- Rodriguez-Galindo C, *see* Michalkiewicz S
- Rodriguez-López R, *see* Valle L
- Rodriguez MA, *see* Dang NH
- Roffe L, Schmidt K, Ernst E. Efficacy of Coenzyme Q10 for Improved Tolerability of Cancer Treatments: A Systematic Review, 4418
- Rogatko A, *see* Cheng JD
- Rogers D, *see* Petereit DG
- Rogers PC, *see* Cushing B
- Rogers PC, Olson TA, Cullen JW, Billmire DF, Marina N, Rescorla F, Davis MM, London WB, Lauer SJ, Giller RH, Cushing B. Treatment of Children and Adolescents With Stage II Testicular and Stages I and II Ovarian Malignant Germ Cell Tumors: A Pediatric Intergroup Study—Pediatric Oncology Group 9048 and Children’s Cancer Group 8891, 3563
- Rohatiner AZS, *see* Davies AJ
see Last KW
- Roigas J, *see* Atzpodien J
- Rojo F, *see* Vanhoefer U
- Romaguera JE, *see* Dang NH
- Romero I, *see* Waber DP
- Romestaing P, *see* Gerard J-P
- Romieu G, *see* Diéras V
- Rorke LB, *see* Hilden JM
- Rosamilia M, *see* Peng B
- Rosato R, *see* Corradini P
- Rosdahl I, *see* Lens MB
- Rose JH, O’Toole EE, Dawson NV, Lawrence R, Gurley D, Thomas C, Hamel MB, Cohen HJ. Perspectives, Preferences, Care Practices, and Outcomes Among Older and Middle-Aged Patients With Late-Stage Cancer, 4907
- Rosell R, *see* Giaccone G
see Herbst RS
- Rosell R. Toward Customized Trastuzumab in HER-2/*neu*-Overexpressing Non–Small-Cell Lung Cancers (editorial), 1171
- Rosemurgy A, *see* Senzer N
- Rosenberg A, *see* Xiong HQ
- Rosenberg CL, *see* Schlechter BL
- Rosenberg R, *see* Gertler R
see Partridge AH
- Rosenberg SA, *see* Advani R
- Rosenblum M, *see* Kellie SJ
- Rosenblum MK, *see* Modak S
- Rosenblum N, *see* Norton TR
- Rosenman J, *see* Marks LB
see Socinski MA
- Rosenman JG, *see* Fried DB
- Rosen O, *see* Vanhoefer U
- Rosen RT, *see* Oh WK
- Rosenthal DI, *see* Michaelson MD
- Rosner B, *see* Kroenke CH
- Rosner GL, *see* Relling MV
- Ross DA, *see* Psyrris A
- Ross J, *see* Ayers M
- Ross JA, Oeffinger KC, Davies SM, Mertens AC, Langer EK, Kiffmeyer WR, Sklar CA, Stovall M, Yasui Y, Robison LL. Genetic Variation in the Leptin Receptor Gene and Obesity in Survivors of Childhood Acute Lymphoblastic Leukemia: A Report From the Childhood Cancer Survivor Study, 3558
- Ross MI, *see* Chen AM
see Raut CP
- Ross PJ, *see* Chau I
see Lal R
- Rossi J-F, Van Hoof A, De Boeck K, Johnson SA, Bron D, Foussard C, Lister TA, Berthou C, Kramer MHH, Littlewood TJ, Marcus RE, Deconinck E, Montillo M, Guibon O, Tollerfield SM. Efficacy and Safety of Oral Fludarabine Phosphate in Previously Untreated Patients With Chronic Lymphocytic Leukemia, 1260
- Rossi R, *see* Potenza L
- Rost A, *see* Al-Batran S-E
- Rotche R, *see* Lima CMR
- Rotman M, *see* Eifel PJ
- Rotoli B, *see* Picardi M
- Rotstein S, *see* Liljegren A
- Rougier P, *see* Bouché O
- Rouzier R, *see* Andre F
- Rowe JM, *see* Greenberg PL
see Tallman MS
- Rowinsky EK, *see* Pérez-Soler R
- Rowinsky EK, Schwartz GH, Gollob JA, Thompson JA, Vogelzang NJ, Figlin R, Bukowski R, Haas N, Lockbaum P, Li Y-P, Arends R, Foon KA, Schwab G, Dutcher J. Safety, Pharmacokinetics, and Activity of ABX-EGF, a Fully Human Anti-Epidermal Growth Factor Receptor Monoclonal Antibody in Patients With Metastatic Renal Cell Cancer, 3003
- Rowland JH, *see* Figueiredo MI
- Rowland K, *see* Jatoi A
- Rowland KM, *see* Perez EA
- Rowland KM Jr, *see* Alberts SR
- Roy A, *see* Banerjee M
- Roy J, *see* Labrie F
- Roy J-A, *see* Bejjani A
- Royce M, *see* Ayers M
- Roz L, *see* Pastorino U
- Rozzo C, *see* Casula M
- Rubie H, *see* Leclair M-D
- Rubin DM, *see* Sherman EJ
- Rubin EH, *see* Goodin S
- Rubin J, *see* Goetz MP
- Rubin S, *see* Norton TR
- Rubin SC, *see* Armstrong K
- Ruccione KS, *see* Landier W
- Ruchlin HS, *see* Sherman EJ
- Rudin CM, *see* Innocenti F
- Rudin CM, Kozloff M, Hoffman PC, Edelman MJ, Karnauskas R, Tomek R, Szeto L, Vokes EE. Phase I Study of G3139, a *bcl-2* Antisense Oligonucleotide, Combined With Carboplatin and Etoposide in Patients With Small-Cell Lung Cancer, 1110
- Rue M, *see* Waber DP
- Ruebe C, *see* Reinhard H
- Rufibach K, *see* Huguenin P
- Ruggeri EM, *see* Ferretti G
- Ruggieri P, *see* Bacci G
- Rui H, *see* Nevalainen MT
- Ruixio JP, *see* Van Cutsem E
- Ruiz J, *see* Sangro B
- Ruiz M, *see* Lev DC
- Rummel MJ, *see* Al-Batran S-E
- Runowicz CD, *see* Hochster H
- Ruppert AS, *see* Byrd JC
see Marcucci G
- Rusch V, *see* Downey RJ

AUTHOR INDEX

see Miller VA
 Russo P, *see* Kondagunta GV
see Motzer RJ
 Rustgi AK, *see* Wei SJ
 Rustin G, *see* Kakkar AK
 Rustin GJS. Can We Now Agree to Use the Same Definition to Measure Response According to CA-125? (editorial), 4035
 Rutka JT, *see* Spiegel BJ
 Rutkowski M, *see* Ginsberg JP
see Silber JH
 Rutqvist LE, *see* Sverrisdóttir A
 Rutten HJT, *see* van den Brink M
 Ryan CW, *see* Davis NB
 Ryan DP, *see* Garcia-Carbonero R
 Ryan JM, *see* Perez EA
 Ryan SM, *see* Myers DA
 Ryback ME, *see* Kurzrock R
 Rychik J, *see* Ginsberg JP
see Silber JH

S

Saäiag P, *see* Avril MF
 Sabbatini P, *see* Dupont J
 Sabbatini P, Aghajanian C, Dizon D, Anderson S, Dupont J, Brown JV, Peters WV, Jacobs A, Mehdi A, Rivkin S, Eisenfeld AJ, Spriggs D. Phase II Study of CT-2103 in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma, 4523
 Sacco M, *see* Nicolucci A
 Sádaba B, *see* Sangro B
 Safgren SL, *see* Reid JM
 Safran H, *see* Van Cutsem E
 Sagebiel RW, *see* Kashani-Sabet M
 Sahin AA, *see* Chen AM
see Huang EH
 Saijo N, *see* Minami H
 Saikia TK, *see* Laskar S
 Sainsbury R, *see* Cuzick J
 Saker MB, *see* Goetz MP
 Salama ME, *see* Khalid I
 Salaverria I, *see* Beà S
 Salazar LG, *see* Disis ML
 Saleh M, *see* Tripathy D
 Salgado C, *see* Santolaya ME
 Salhi Y, *see* Yovine A
 Saliba RM, *see* Escalón MP
 Salim M, *see* Garrity MM
 Sallan SE, *see* Waber DP
 Salles G, *see* Hequet O
 Salmon JR, *see* Louis-Sylvestre C
 Saltz L, *see* Temple LKF
 Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor, 1201
 Salvesen HB, *see* Stefansson IM
 Samaniego F, *see* Dang NH
 Samantas E, *see* Bamias A
 Samaras N, *see* Georgoulas V
 Sametti S, *see* Corradini P
 Samid D, *see* Gradishar WJ
see Hoff PM
 Sampson E, *see* Partridge AH
 Sampson JH, *see* Rich JN
 Samson B, *see* Labrie F

Samson DJ, *see* Schrag D
 Samson DJ, Seidenfeld J, Ziegler K, Aronson N. Chemotherapy Sensitivity and Resistance Assays: A Systematic Review, 3618
 Samuels B, *see* Dang NH
 Samyn I, Fontaine C, Van Tussenbroek F, Pipeleers-Marichal M, De Grève J. Paraneoplastic Syndromes in Cancer: Polycythemia As a Result of Ectopic Erythropoietin Production in Metastatic Pancreatic Carcinoid Tumor, 2240
 Sánachez-Rovira P, *see* Alba E
 Sánchez-Godoy P, *see* Montalbán C
 Sancho MA, *see* Garcia-Carbonero R
 Sanders RP, Drissi R, Billups CA, Daw NC, Valentine MB, Dome JS. Telomerase Expression Predicts Unfavorable Outcome in Osteosarcoma, 3790
 Sandherr M, *see* Maier BO
 Sandler ES, *see* Godder K
 Sandler H, *see* Kent E
 Sandler HM, *see* Pollack A
 Sandler RS, *see* Ayanian JZ
 Sandlund JT, *see* Relling MV
 Sandrini R, *see* Michalkiewicz E
 Sanford RA, *see* Merchant TE
 Sangro B, Mazzolini G, Ruiz J, Herraiz M, Quiroga J, Herrero I, Benito A, Larrache J, Pueyo J, Subtil JC, Olagüe C, Sola J, Sádaba B, Lacasa C, Melero I, Qian C, Prieto J. Phase I Trial of Intratumoral Injection of an Adenovirus Encoding Interleukin-12 for Advanced Digestive Tumors, 1389
 San Miguel J, *see* de Botton S
 Sano T, Sasako M, Yamamoto S, Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai K, Yamamura Y, Okajima K. Gastric Cancer Surgery: Morbidity and Mortality Results From a Prospective Randomized Controlled Trial Comparing D2 and Extended Para-Aortic Lymphadenectomy—Japan Clinical Oncology Group Study 9501, 2767
 Sansal I, Sellers WR. The Biology and Clinical Relevance of the *PTEN* Tumor Suppressor Pathway, 2954
 Sanson M, *see* Hoang-Xuan K
 Santabárbara P, *see* Pérez-Soler R
 Santana VM, *see* Daw NC
see Geller JJ
see Wagner LM
 Santini D, *see* Vincenzi B
 Santini M, *see* Longo R
 Santolaya ME, Alvarez AM, Avilés CL, Becker A, Cofré J, Cumsille MA, O’Ryan ML, Payá E, Salgado C, Silva P, Tordecilla J, Varas M, Villarreal M, Viviani T, Zubieta M. Early Hospital Discharge Followed by Outpatient Management Versus Continued Hospitalization of Children With Cancer, Fever, and Neutropenia at Low Risk for Invasive Bacterial Infection, 3784
 Santoro A, *see* Parra HS
 Sanz M, *see* de Botton S
 Saoudi N, *see* Antoch G
 Sara G, *see* Harandi A
 Sargent D, *see* Grothey A
see Tisman G
 Sargent DJ, *see* Crane CH
see Garrity MM
see Gill S
see Goldberg RM
see Gunderson LL
see Martenson JA Jr
 Sarkesh S, *see* Chakravarti A
 Sarosdy MF, *see* Herr HW
 Sartor CI, *see* Citron ML
 Sartori S, Tassinari D, Ceccotti P, Tombesi P, Nielsen I, Trevisani L, Abbasciano V. Prospective Randomized Trial of Intrapleural Bleomycin

- Versus Interferon Alfa-2b via Ultrasound-Guided Small-Bore Chest Tube in the Palliative Treatment of Malignant Pleural Effusions, 1228
- Sasaki C, *see* Psyrrri A
- Sasako M, *see* Hartgrink HH
see Sano T
- Sasamoto H, *see* Nagasaka T
- Sasieni P, *see* Lipton LR
- Satagopan J, *see* Shuch B
- Sato T, *see* Berd D
- Satriano SMR, *see* Casula M
- Satta MP, *see* Casula M
- Sauerland C, *see* Schlenk RF
- Saurin J-C, Gutknecht C, Napoleon B, Chavaillon A, Ecochard R, Scoazec J-Y, Ponchon T, Chayvialle J-A. Surveillance of Duodenal Adenomas in Familial Adenomatous Polyposis Reveals High Cumulative Risk of Advanced Disease, 493
- Sause W, *see* Pfister DG
- Sausville EA. Genes in the Service of Therapeutic Index: Progress for Virus-Directed Enzyme Prodrug Therapy (editorial), 1535
- Sauter G, *see* Nevalainen MT
see Went PT
- Saviola A, *see* Potenza L
- Sawada N, *see* Cassidy J
- Sawaya RE, *see* Barnholtz-Sloan JS
- Sawyers CL, *see* Peng B
- Saxman S, *see* Potosky AL
- Scagliotti G, *see* Giaccone G
see Herbst RS
- Scambia G, *see* De Placido S
- Scarfone G, *see* Bolis G
- Scarpa S, *see* Gradilone A
- Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G, Cascinu S. Epidermal Growth Factor Receptor (EGFR) Status in Primary Colorectal Tumors Does Not Correlate with EGFR Expression in Related Metastatic Sites: Implications for Treatment with EGFR-Targeted Monoclonal Antibodies, 4772
- Schaich M, *see* Schlenk RF
- Schaid DJ, *see* Hartmann LC
- Schalch H, *see* King, DM
- Schalke B, *see* Ströbel P
- Schechter CB, *see* Mandelblatt JS
- Schechter NR, *see* Chen AM
see Huang EH
- Scheid C, *see* Kiehl MG
- Scheinfeld N, *see* Gettinger S
- Scheithauer BW, *see* Hilden JM
- Scheithauer W, *see* Rao S
- Scher HI, *see* Loblaw DA
- Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR. Eligibility and Outcomes Reporting Guidelines for Clinical Trials for Patients in the State of a Rising Prostate-Specific Antigen: Recommendations From the Prostate-Specific Antigen Working Group, 537
- Scherrer A, *see* Avril MF
- Scheunemann P, *see* Stoecklein NH
- Schey SA, Fields P, Bartlett JB, Clarke IA, Ashan G, Knight RD, Streetly M, Dagleish AG. Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma, 3269
- Schiegnitz E, *see* Lenz G
- Schiff S, *see* Wright JR
- Schiffer CA. In Reply (correspondence), 570
- Schiffman K, *see* Disis ML
- Schiller J, *see* Cheng JD
- Schiller JH, *see* Giaccone G
see Herbst RS
see King, DM
- Schilsky RL, *see* Citron ML
- Schirren J, *see* Rick O
- Schirrmacher V, *see* Steiner HH
- Schirrmacher H, Hetzel M, Hetzel J, Habig T, Schumann C, Bommer M, Blum P, von Beauvais H, Babiak A. Challenging Manifestations of Malignancies: Fibrinous Tracheitis: An Uncommon Manifestation of Hodgkin's Lymphoma, 3642
- Schlechter BL, Yang Q, Larson PS, Golubeva A, Blanchard RA, de Las Morenas A, Rosenberg CL. Quantitative DNA Fingerprinting May Distinguish New Primary Breast Cancer From Disease Recurrence, 1830
- Schlenk RF, *see* Fröhling S
- Schlenk RF, Benner A, Krauter J, Büchner T, Sauerland C, Ehninger G, Schaich M, Mohr B, Niederwieser D, Krahl R, Pasold R, Döhner K, Ganser A, Döhner H, Heil G. Individual Patient Data-Based Meta-Analysis of Patients Aged 16 to 60 Years With Core Binding Factor Acute Myeloid Leukemia: A Survey of the German Acute Myeloid Leukemia Intergroup, 3741
- Schlesselman JJ, *see* Raez LE
- Schlette EJ, Medeiros LJ, Goy A, Lai R, Rassidakis GZ. Survivin Expression Predicts Poorer Prognosis in Anaplastic Large-Cell Lymphoma, 1682
- Schleucher N, *see* Vanhoefler U
- Schlimok G, *see* Maier BO
- Schlom J, *see* Kaufman HL
- Schmalfeldt B, *see* Scorilas A
- Schmid S, *see* Huguenin P
- Schmidt B, *see* Schuck A
- Schmidt EH, *see* Zander AR
- Schmidt K, *see* Roffe L
- Schmidt W, *see* Xiong HQ
- Schmitt BP, *see* Dolan NC
- Schmitt M, *see* Scorilas A
- Schmoldt J, *see* Katzenstein HM
- Schmoll H-J, *see* Grothey A
- Schmoor C, *see* Zander AR
- Schneider A, *see* Glas J
- Schneider BP, Kesler KA, Brooks JA, Yiannoutsos C, Einhorn LH. Outcome of Patients With Residual Germ Cell or Non-Germ Cell Malignancy After Resection of Primary Mediastinal Nonseminomatous Germ Cell Cancer, 1195
- Schneider DT, Calaminus G, Göbel U. In Reply (correspondence), 2033
- Schneider EC, Epstein AM, Malin JL, Kahn KL, Emanuel EJ. Developing a System to Assess the Quality of Cancer Care: ASCO's National Initiative on Cancer Care Quality, 2985
- Schnittger S, *see* Kern W
- Schnitt SJ, *see* Elkin EB
see Sorscher SM
- Schoch C, *see* Kern W
- Schoeffski P, *see* Kollmannsberger C
- Schöffski P, *see* Cassidy J
see Van Cutsem E
- Scholnik A, *see* Keith B
- Schott A, Hayes DF. Adjuvant Chemotherapy for Elderly Women with Hormone Receptor-Positive Breast Cancer: An Old(er) Problem (editorial), 4660
- Schott H, *see* Atzpodien J
- Schrag D, *see* Benson AB III
see Meyerhardt JA
see Temple LKF
- Schrag D, Garewal HS, Burstein HJ, Samson DJ, Von Huff DD, Somerfield MR. American Society of Clinical Oncology Technology Assessment: Chemotherapy Sensitivity and Resistance Assays, 3631
- Schraml P, *see* Went PT

AUTHOR INDEX

- Schrappé M, *see* Bader P
see Simon T
- Schraub S, *see* Fargeot P
- Schraut W, *see* Stoecklein NH
- Schriber J, *see* Somlo G
- Schrijvers D, *see* Hansen HH
- Schroeder M, *see* Alberts SR
- Schubert MM, *see* Robien K
- Schuchter L, *see* Gimotty PA
- Schuchter LM. Adjuvant Interferon Therapy for Melanoma: High-Dose, Low-Dose, No Dose, Which Dose? (editorial), 7
- Schuck A, Mattke AC, Schmidt B, Kunz DS, Harms D, Knietig R, Treuner J, Koscielniak E. Group II Rhabdomyosarcoma and Rhabdomyosarcoma-like Tumors: Is Radiotherapy Necessary?, 143
- Schuele-Freyer R, *see* Steiner HH
- Schulman KA, *see* Meropol NJ
- Schultes BC, *see* Berek JS
- Schultze W, *see* Zander AR
- Schumacher K, *see* Miaskowski C
- Schumacher M, *see* Zander AR
- Schumann C, *see* Schirrmeyer H
- Schwab G, *see* Rowinsky EK
- Schwaiger M, *see* Wieder HA
- Schwamborn G, *see* Sung L
- Schwartz GH, *see* Rowinsky EK
- Schwartz GK, *see* Sherman EJ
- Schwartz J, *see* Neubauer M
- Schwartz JS, *see* Armstrong K
- Schwartz L, *see* Kondagunta GV
- Schwartz LH, *see* Motzer RJ
- Schwartz MD, *see* Cullen J
- Schwartz MD, Lerman C, Brogan B, Peshkin BN, Halbert CH, DeMarco T, Lawrence W, Main D, Finch C, Magnant C, Pennanen M, Tsangaris T, Willey S, Isaacs C. Impact of *BRCA1/BRCA2* Counseling and Testing on Newly Diagnosed Breast Cancer Patients, 1823
- Schwarz RE, Strair RK. Complications of Malignancy: Case 2. Infectious Tissue Pneumatosis As a Result of Colon Cancer Perforation in a Survivor of Hodgkin's Disease, 373
- Schweifer N, *see* Haslinger C
- Schwerdtfeger R, *see* Kiehl MG
- Sciuk J, *see* Maier BO
- Scoazec J-Y, *see* Saurin J-C
- Scopece L, *see* Brandes AA
- Scorilas A, Borrego CA, Harbeck N, Dorn J, Schmalfeldt B, Schmitt M, Diamandis EP. Human Kallikrein 13 Protein in Ovarian Cancer Cytosols: A New Favorable Prognostic Marker, 678
- Scuderi N, *see* Gradilone A
- Searle PF, *see* Palmer DH
- Sebolt-Leopold JS, *see* Rinehart J
- Seeber S, *see* Vanhoefer U
- Seeger RC, *see* Roberts SS
- Seele LG, *see* Stewart CF
- Seewaldt VL, *see* Shaw HS
- Segawa Y, *see* Kubota K
- Seibel N, *see* Lange BJ
- Seibel NL, *see* Reid JM
- Seibel NL, Li S, Breslow NE, Beckwith JB, Green DM, Haase GM, Ritchey ML, Thomas PRM, Grundy PE, Finklestein JZ, Kim T, Shochat SJ, Kelalis PP, D'Angio GJ. Effect of Duration of Treatment on Treatment Outcome for Patients With Clear-Cell Sarcoma of the Kidney: A Report From the National Wilms' Tumor Study Group, 468
- Seidenfeld J, *see* Samson DJ
- Seiden MV, *see* Garcia-Carbonero R
- Seipelt G, *see* Al-Batran S-E
- Seitz JF, *see* Bouché O
- see* Gill S
- Sekine I, *see* Minami H
- Selby JV, *see* Cullen J
- Selby PJ, *see* Velikova G
- Sellers WR, *see* Sansal I
- Sellner F, *see* De Santis M
- Semik M, *see* Ströbel P
- Senn E, *see* Studer UE
- Senzer N, Mani S, Rosemurgy A, Nemunaitis J, Cunningham C, Guha C, Bayol N, Gillen M, Chu K, Rasmussen C, Rasmussen H, Kufe D, Weichselbaum R, Hanna N. TNFerade Biologic, an Adenovector With a Radiation-Inducible Promoter, Carrying the Human Tumor Necrosis Factor Alpha Gene: A Phase I Study in Patients With Solid Tumors, 592
- Senzer NN, *see* Soulieres D
- Sepkowitz KA, *see* Su YB
- Seshadri R, *see* Campbell AD
- Setola E, *see* Bacci G
- Sevastianos VA, Deutsch M, Dourakis SP. Unusual Sites of Metastatic Involvement: Grey-Turner's Sign As the First Indication of a Ruptured Hepatocellular Carcinoma, 1156
- Sexton WJ, *see* Amling CL
- Seymour L, *see* Reyno L
- Shaffer J, *see* Whitworth MK
- Shafman T, *see* Marks LB
- Shah JP, *see* Wreesmann VB
- Shah N, *see* Miller VA
- Shah NV, *see* Shariat SF
- Shaha AR, *see* Wreesmann VB
- Shahab N, Haider S. Is Docetaxel Now an Essential Component of Neoadjuvant Breast Chemotherapy? (correspondence), 1766
- Shaharyar, *see* Hanna N
- Shaikh L, *see* Kashani-Sabet M
- Sham JST, *see* Kwong DLW
- Shanafelt TD, Loprinzi C, Marks R, Novotny P, Sloan J. Are Chemotherapy Response Rates Related to Treatment-Induced Survival Prolongations in Patients With Advanced Cancer?, 1966
- Shane E, *see* Breen TL
- Shannahan W, *see* Tisman G
- Shannon KF, *see* Fife KM
- Shapira I, *see* Gettinger S
- Shapiro CL, *see* Andersen BL
- Shapiro PJ, *see* Coyne JC
- Shargall Y, *see* de Perrot M
- Shariat SF, Anwuri VA, Lamb DJ, Shah NV, Wheeler TM, Slawin KM. Association of Preoperative Plasma Levels of Vascular Endothelial Growth Factor and Soluble Vascular Cell Adhesion Molecule-1 With Lymph Node Status and Biochemical Progression After Radical Prostatectomy, 1655
- Shariat SF, Tokunaga H, Zhou JH, Kim JH, Ayala GE, Benedict WF, Lerner SP. p53, p21, pRB, and p16 Expression Predict Clinical Outcome in Cystectomy With Bladder Cancer, 1014
- Sharma A, *see* Bepler G
- Sharma S, *see* Bepler G
- Sharpless NE, *see* Turner JE
- Sharp SA, *see* Loblaw DA
see Winer EP
- Shaw EG. Nothing Ventured, Nothing Gained: Treatment of Glioblastoma Multiforme in the Elderly (editorial), 1540
- Shaw HS, Hobbs KB, Seewaldt VL, Kroll DJ. Delayed-Type Hypersensitivity Reaction With Iscador M Given in Combination With Cytotoxic Chemotherapy (correspondence), 4432
- Shaw JM, *see* Diener-West M
- Shea TC, *see* Kolitz JE
- Sheinfeld J, *see* Kondagunta GV
- Shen P, *see* Glehen O

- Shen P, Levine EA, Loggie BW. Peritoneal Carcinomatosis: What Can We Do About It? (correspondence), 202
- Shepard RC, *see* Rich TA
- Shepherd FA, *see* Hanna N
- Shepherd JH, *see* Hess V
- Shepherd L, *see* Efficace F
- Shepherd LE, *see* Gill S
- Sherman EJ, Rubin DM, Venkatraman E, Schwartz GK, Miller VA, Radzyner MH, Ruchlin HS, Spriggs D, Pfister DG. Using Patients As Their Own Controls for Cost Evaluation of Phase I Clinical Trials, 1308
- Sherman ML, *see* Atkins MB
- Sherrod A, *see* Levine AM
- Shewach D, *see* Leu KM
- Shi S-R, *see* Chatterjee SJ
- Shi W, *see* Wreesmann VB
- Shibata S, *see* Somlo G
- Shibuya M, *see* Kubota K
- Shih J-Y, *see* Tsai M-S
- Shim YM, *see* Kim H
see Kim JS
- Shima Y, *see* Akechi T
- Shin D, *see* Friedberg JS
- Shindell N, *see* Tisman G
- Shinn EH, *see* Taylor CLC
- Shipley WU, *see* Pollack A
- Shirao K, Hoff PM, Ohtsu A, Loehrer PJ, Hyodo I, Wadler S, Wadleigh RG, O'Dwyer PJ, Muro K, Yamada Y, Boku N, Nagashima F, Abbruzzese JL. Comparison of the Efficacy, Toxicity, and Pharmacokinetics of a Uracil/Tegafur (UFT) Plus Oral Leucovorin (LV) Regimen Between Japanese and American Patients With Advanced Colorectal Cancer: Joint United States and Japan Study of UFT/LV, 3466
- Shirato K, *see* Kumasaka R
- Shochat SJ, *see* Seibel NL
- Shore RM, *see* Katzenstein HM
- Shpall EJ, *see* Ueno NT
- Shuch B, Mikhail M, Satagopan J, Lee P, Yee H, Chang C, Cordon-Cardo C, Taneja SS, Osman I. Racial Disparity of Epidermal Growth Factor Receptor Expression in Prostate Cancer, 4725
- Shumaker G, *see* Kemeny N
- Shvartsman HS, *see* Brown J
- Shyr Y, *see* Tedesco KL
- Sibley G, *see* Marks LB
- Sidler D, *see* Kühne M
- Sidlofsky S, *see* Bull SB
- Siebels M, *see* Atzpodien J
- Siegel BA, *see* Bradley JD
see Grigsby PW
see Wahl RL
- Siegert W, *see* Rick O
- Siemers R, *see* Meyers CA
- Siena S, *see* Pedrazzoli P
- Siewert J-R, *see* Gertler R
see Wieder HA
- Sikic BI, *see* Greenberg PL
- Silber JH, *see* Ginsberg JP
- Silber JH, Cnaan A, Clark BJ, Paridon SM, Chin AJ, Rychik J, Hogarty AN, Cohen MI, Barber G, Rutkowski M, Kimball TR, Delaat C, Steinerz LJ, Zhao H. Enalapril to Prevent Cardiac Function Decline in Long-Term Survivors of Pediatric Cancer Exposed to Anthracyclines, 820
- Silliman RA, *see* Fink AK
- Silliman RA. Crossing the Quality Chasm in Breast Cancer Care (editorial), 3654
- Silva P, *see* Santolaya ME
- Silverman LB, *see* Waber DP
- Siminoff LA, *see* Simon CM
- Simon CM, Siminoff LA, Kodish ED, Burant C. Comparison of the Informed Consent Process for Randomized Clinical Trials in Pediatric and Adult Oncology, 2708
- Simon G, *see* Bepler G
- Simon JM, *see* Hoang-Xuan K
- Simon MS, Du W, Flaherty L, Philip PA, Lorusso P, Miree C, Smith D, Brown DR. Factors Associated With Breast Cancer Clinical Trials Participation and Enrollment at a Large Academic Medical Center, 2046
- Simon R, *see* Went PT
- Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Niethammer D, Berthold F. Consolidation Treatment With Chimeric Anti-GD2-Antibody ch14.18 in Children Older Than 1 Year With Metastatic Neuroblastoma, 3549
- Simpson L, Taylor S, Piotrowski A. Uncommon Presentations of Hodgkin's Disease: Hodgkin's Disease: Rectal Presentation, 196
- Simunovic M, Gafni A, Levine M. Economics of Preoperative Radiotherapy With Total Mesorectal Excision: What Can We Learn From the Dutch Experience? (editorial), 217
- Singal R, *see* Das PM
- Singh B, *see* Wreesmann VB
- Singletary SE, *see* Chen AM
see Cristofanilli M
see Raut CP
see Thomas E
- Sire C, *see* Denis F
- Siu L, *see* Michael M
- Siu LL, *see* Soulieres D
- Sjöström J, *see* Ejlertsen B
- Skarlos D, *see* Agarwala SS
- Skates SJ, Horick N, Yu Y, Xu F-J, Berchuck A, Havrilesky LJ, de Buijn HWA, van der Zee AGJ, Woolas RP, Jacobs IJ, Zhang Z, Bast RC Jr. Preoperative Sensitivity and Specificity for Early-Stage Ovarian Cancer When Combining Cancer Antigen CA-125II, CA 15-3, CA72-4, and Macrophage Colony-Stimulating Factor Using Mixtures of Multivariate Normal Distributions, 4059
- Skinner DG, *see* Chatterjee SJ
- Sklar CA, *see* Landier W
see Ross JA
- Slamon DJ, *see* Tripathy D
- Slawin KM, *see* Shariat SF
- Sledge GW Jr, *see* Tedesco KL
- Slimane K, *see* Andre F
- Slingluff CL Jr. In Reply (correspondence), 3835
- Slingluff CL Jr, Petroni GR, Yamshchikov GV, Hibbits S, Grosh WW, Chianese-Bullock KA, Bissonette EA, Barnd DL, Deacon DH, Patterson JW, Parekh J, Neese PY, Woodson EMH, Wiernasz CJ, Merrill P. Immunologic and Clinical Outcomes of Vaccination With a Multi epitope Melanoma Peptide Vaccine Plus Low-Dose Interleukin-2 Administered Either Concurrently or on a Delayed Schedule, 4474
- Sloan AE, *see* Barnholtz-Sloan JS
- Sloan J, *see* Shanafelt TD
- Sloan JA, *see* Dy GK
see Goetz MP
see Jatoi A
- Slocum HK, *see* Aljada IS
- Slomovitz BM, Broaddus RR, Burke TW, Sneige N, Soliman PT, Wu W, Sun CC, Munsell MF, Gershenson DM, Lu KH. Her-2/*neu* Overexpression and Amplification in Uterine Papillary Serous Carcinoma, 3126
- Slone S, *see* Ursin G
- Sloof GW, *see* van Westreenen HL
- Slot A, *see* Creutzberg CL
- Slotman BJ, *see* Langendijk JA
- Slovin SF, *see* Scher HI
- Smakal M, *see* Rao S
- Small EJ, *see* Oh WK

AUTHOR INDEX

- see* Scher HI
- Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, Gable P, Torti FM, Kaplan E, Vogelzang NJ. Antiandrogen Withdrawal Alone or in Combination With Ketoconazole in Androgen-Independent Prostate Cancer Patients: A Phase III Trial (CALGB 9583), 1025
- Small EJ. In Reply (correspondence), 2035
- Small EJ. Monoclonal Antibody Therapy for Prostate Cancer: Finally a Reality? (editorial), 2515
- Smalley SR, *see* Gunderson LL
- Smith AB, *see* Velikova G
- Smith B, *see* Citron ML
- Smith BD, Glusac EJ, McNiff JM, Smith GL, Heald PW, Cooper DL, Wilson LD. Primary Cutaneous B-Cell Lymphoma Treated With Radiotherapy: A Comparison of the European Organization for Research and Treatment of Cancer and the WHO Classification Systems, 634
- Smith BD, Kapur D, Esfahanian S, Dhami MS, Fischer JJ. Challenging Problems in Malignancy: Isolated Needle-Track Recurrence Following Fine Needle Aspiration for Non-Small-Cell Lung Cancer, 3828
- Smith D, *see* Friedberg JS
see Simon MS
- Smith DC, *see* Kent E
- Smith EI, *see* Kretschmar CS
- Smith FO, *see* Lange BJ
- Smith G, *see* Kissane DW
- Smith GL, *see* Smith BD
- Smith JA, *see* Meyers CA
see Navo MA
- Smith JJ, *see* Okunieff P
- Smith MA, *see* Anderson BD
- Smith MA, Anderson BD. A Window on Reality? (editorial), 1360
- Smith ML, *see* Hwang JP
- Smith MR, *see* Michaelson MD
see Oh WK
- Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS. Bicalutamide Monotherapy Versus Leuprolide Monotherapy for Prostate Cancer: Effects on Bone Mineral Density and Body Composition, 2546
- Smith TJ, *see* Loblaw DA
see Pfister DG
- Smith TL, *see* Thomas E
- Smoot D, *see* Adams-Campbell LL
- Sneige N, *see* Ayers M
see Slomovitz BM
- Snyder RD, *see* Kissane DW
- Soballe PW, *see* Jatoi I
- Sobrero A, *see* Cassidy J
- Sobrero AF. Scheduling of Fluorouracil: A Forget-Me-Not in the Jungle of Doublets (editorial), 4
- Socinski MA, *see* Fried DB
see Marks LB
- Socinski MA, Morris DE, Halle JS, Moore DT, Hensing TA, Limentani SA, Fraser R, Tynan M, Mears A, Rivera MP, Detterbeck FC, Rosenman J. Induction and Concurrent Chemotherapy With High-Dose Thoracic Conformal Radiation Therapy in Unresectable Stage IIIA and IIIB Non-Small-Cell Lung Cancer: A Dose-Escalation Phase I Trial, 4341
- Sodee DB, Faulhaber PF, Nelson AD, Bakale G. The Prognostic Significance of Indium-111-Capromab Penetide (correspondence), 379
- Soderdahl DW, *see* Amling CL
- Sohn S, *see* Su YB
- Soignet SL, *see* Dupont J
- Sola J, *see* Sangro B
- Soliman PT, *see* Slomovitz BM
- Somerfield MR, *see* Azzoli CG
see Benson AB III
see Lippman SM
- see* Loblaw DA
- see* Pfister DG
- see* Schrag D
- Somlo G, Frankel P, Chow W, Leong L, Margolin K, Morgan R Jr, Shibata S, Chu P, Forman S, Lim D, Twardowski P, Weitzel J, Alvarnas J, Kogut N, Schriber J, Fermin E, Yen Y, Damon L, Doroshow JH. Prognostic Indicators and Survival in Patients With Stage IIIB Inflammatory Breast Carcinoma After Dose-Intense Chemotherapy, 1839
- Sommers E, *see* Bepler G
- Son YH, *see* Psyrrri A
- Sondak V, *see* Leu KM
- Sondak VK, *see* Sosman JA
- Sondel P, *see* King, DM
- Sonet A, *see* Mounier N
- Song EY, *see* Banerjee M
- Songun I, *see* Hartgrink HH
- Song YS, *see* Berwick M
- Sørbye H, Glimelius B, Berglund Å, Fokstuen T, Tveit KM, Brændengen M, Øgreid D, Dahl O. Multicenter Phase II Study of Nordic Fluorouracil and Folinic Acid Bolus Schedule Combined With Oxaliplatin As First-Line Treatment of Metastatic Colorectal Cancer, 31
- Soria J-C, *see* Lu C
- Sorich J, *see* Hochster H
- Sorscher SM. HER-2 Overexpression in Breast Tumors Lacking Gene Amplification (correspondence), 4232
- Sosman JA, Weeraratna AT, Sondak VK. When Will Melanoma Vaccines Be Proven Effective? (editorial), 387
- Sotti G, *see* Brandes AA
- Sotto JJ, *see* de Botton S
- Soule HR, *see* Scher HI
- Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck, 77
- Soverini S, *see* Zinzani PL
- Sozzi G, *see* Pastorino U
- Spaggiari L, *see* De Pas T
- Span PN, Waanders E, Manders P, Heuvel JJTM, Foekens JA, Watson MA, Beex LVAM, Sweep FCGJ. Mammaglobin Is Associated With Low-Grade, Steroid Receptor-Positive Breast Tumors From Postmenopausal Patients, and Has Independent Prognostic Value for Relapse-Free Survival Time, 691
- Spano JP, *see* Andre F
- Sparano JA, Bernardo P, Stephenson P, Gradishar WJ, Ingle JN, Zucker S, Davidson NE. Randomized Phase III Trial of Marimastat Versus Placebo in Patients With Metastatic Breast Cancer Who Have Responding or Stable Disease After First-Line Chemotherapy: Eastern Cooperative Oncology Group Trial E2196, 4683
- Sparano JA, Lee S, Chen MG, Nazeer T, Einzig A, Ambinder RF, Henry DH, Manalo J, Li T, Von Roenn JH. Phase II Trial of Infusional Cyclophosphamide, Doxorubicin, and Etoposide in Patients With HIV-Associated Non-Hodgkin's Lymphoma: An Eastern Cooperative Oncology Group Trial (E1494), 1491
- Sparano L, *see* Picardi M
- Sparreboom A, *see* Tan AR
- Sparreboom A, Cox MC, Acharya MR, Figg WD. Herbal Remedies in the United States: Potential Adverse Interactions With Anticancer Agents, 2489
- Spatz A, Bressac-de Paillerets B, Raymond E. Soft Tissue Sarcomas: Gastrointestinal Stromal Tumor and Carney's Triad, 2029
- Speers CH, *see* Chia SK
see Olivetto IA
- Spence C, *see* Lutz S
- Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu X, Boyd J, Libermann

AUTHOR INDEX

- TA, Cannistra SA. Gene Expression Signature With Independent Prognostic Significance in Epithelial Ovarian Cancer, 4700
- Speyer J, *see* Hochster H
- Spiegler BJ, Bouffet E, Greenberg ML, Rutka JT, Mabbott DJ. Change in Neurocognitive Functioning After Treatment With Cranial Radiation in Childhood, 706
- Spielmann M, *see* Andre F
- Spitz F, *see* Gimotty PA
- Spitznagel ELJ, *see* Read WL
- Spott C, *see* Kollmannsberger C
- Sprague E, *see* Zimmerman TM
- Sprangers MA, *see* Efficace F
- Sprangers MAG, *see* de Boer AGEM
- Spriggs D, *see* Dupont J
see Sabbatini P
see Sherman EJ
- Spriggs DR, *see* Dupont J
see Hensley ML
- Sproull M, *see* Chan LW
- Spruyt O, *see* Bruera E
- Sridhar K, *see* Raetz LE
- Stadler WM, *see* Atkins MB
see Davis NB
see Small EJ
- Stahel R, *see* Dubs A
see Hansen HH
- Stahel RA, *see* Gautschi O
see Weder W
- Stalmeier PFM, *see* de Boer AGEM
see van Roosmalen MS
- Stamatoullas A, *see* Mounier N
see Thomas X
- Stamberg J, *see* Byrd JC
- Stanford JL, *see* Johnson TK
- Sary J, *see* Creutzig U
- Stattin P, Rinaldi S, Biessy C, Stenman U-H, Hallmans G, Kaaks R. High Levels of Circulating Insulin-Like Growth Factor-I Increase Prostate Cancer Risk: A Prospective Study in a Population-Based Nonscreened Cohort, 3104
- Stauffer E, *see* Guillou L
- Stebbing J, Gazzard B, Mandalia S, Teague A, Waterston A, Marvin V, Nelson M, Bower M. Antiretroviral Treatment Regimens and Immune Parameters in the Prevention of Systemic AIDS-Related Non-Hodgkin's Lymphoma, 2177
- Stec J, *see* Ayers M
- Steen PD, *see* Alberts SR
- Steensma DP. Reassurance, 3196
- Steer CJ, Lee C. Addressing Spiritual Care: Calling for Help, 4856
- Stefanick ML, *see* Chlebowski RT
see Rock CL
- Stefanou A, Dooley M. In Reply (correspondence), 965
- Stefansson IM, Salvesen HB, Akslen LA. Prognostic Impact of Alterations in P-Cadherin Expression and Related Cell Adhesion Markers in Endometrial Cancer, 1242
- Stegmaier C, *see* Arndt V
- Stein H, *see* Kiewe P
- Stein HJ, *see* Wieder HA
- Stein JP, *see* Chatterjee SJ
- Steinberg SM, *see* Bishop MR
see Dahut WL
see Low JA
see Tan AR
- Steiner HH, Bonsanto MM, Beckhove P, Brysch M, Geletneky K, Ahmadi R, Schuele-Freyer R, Kremer P, Ranaie G, Matejic D, Bauer H, Kiessling M, Kunze S, Schirmacher V, Herold-Mende C. Antitumor Vaccination of Patients With Glioblastoma Multiforme: A Pilot Study to Assess Feasibility, Safety, and Clinical Benefit, 4272
- Steinherz LJ, *see* Ginsberg JP
see Silber JH
- Stelljes M, *see* Kiehl MG
- Stemmer SM, Pfeffer MR. In Reply (correspondence), 2258
- Stengele K, *see* Kollmannsberger C
- Stenman U-H, *see* Stattin P
- Stenzel TT, *see* Rich JN
- Stephenson P, *see* Langer CJ
see Sparano JA
- Sterling LJ, *see* Marcucci G
- Sterman DH, *see* Albelda SM
- Sternberg DW, Gilliland DG. The Role of Signal Transducer and Activator of Transcription Factors in Leukemogenesis, 361
- Stern F, *see* Stoecklein NH
- Stevens GN, *see* Fife KM
- Stevens M, *see* Carli M
- Stevenson JP, *see* Friedberg JS
- Stewart AK, *see* Greene FL
- Stewart CF, *see* Daw NC
- Stewart CF, Iacono LC, Chintagumpala M, Kellie SJ, Ashley D, Zamboni WC, Kirstein MN, Fouladi M, Seele LG, Wallace D, Houghton PJ, Gajjar A. Results of a Phase II Upfront Window of Pharmacokinetically Guided Topotecan in High-Risk Medulloblastoma and Supratentorial Primitive Neuroectodermal Tumor, 3357
- Stewart D, *see* Roa W
- Stewart SJ, *see* Tripathy D
- Stiggelbout AM, *see* Jansen SJT
see van den Brink M
- Stilgenbauer S, *see* Haslinger C
- Stinson T, *see* Golub RM
- Stock W, *see* Zimmerman TM
- Stockel J, *see* Poggi MM
- Stocken D, *see* Casson AG
- Stöckle M, *see* Reinhard H
- Stockler M, Vardy J, Pillai A, Warr D. Acetaminophen (Paracetamol) Improves Pain and Well-Being in People With Advanced Cancer Already Receiving a Strong Opioid Regimen: A Randomized, Double-Blind, Placebo-Controlled Cross-Over Trial, 3389
- Stockler MR, *see* Nowak AK
- Stoecklein NH, Luebke AM, Erbersdobler A, Knoefel WT, Schraut W, Verde PE, Stern F, Scheunemann P, Peiper M, Eisenberger CF, Izbicki JR, Klein CA, Hosch SB. Copy Number of Chromosome 17 but Not *HER2* Amplification Predicts Clinical Outcome of Patients With Pancreatic Ductal Adenocarcinomas, 4737
- Stoiber F, *see* De Santis M
- Stolte M, *see* Alpen B
see Glas J
- Stolze I, *see* Fröhling S
- Stone V, *see* Lev DC
- Stoppa-Lyonnet D, *see* Adem C
- Storstein A, *see* Monstad SE
- Storti S, *see* Zinzani PL
- Stovall M, *see* Ross JA
- Stover D, *see* Pfister DG
- Strair RK, *see* Schwarz RE
- Strassels S, *see* McNicol E
- Strasser F, *see* Bruera E
- Stratowa C, *see* Haslinger C
- Stratton MR, *see* Casula M
- Straus DJ, *see* Vickers AJ
- Strawn JR, *see* Pfister DG
- Streety M, *see* Schey SA
- Stricker D, *see* Gertler R

- Ströbel P, Bauer A, Puppe B, Kraushaar T, Krein A, Toyka K, Gold R, Semik M, Kiefer R, Nix W, Schalke B, Müller-Hermelink HK, Marx A. Tumor Recurrence and Survival in Patients Treated for Thymomas and Thymic Squamous Cell Carcinomas: A Retrospective Analysis, 1501
- Strom EA, *see* Chen AM
see Huang EH
- Strom SS, *see* Zagars GK
- Stuart G, *see* Bezjak A
- Studer UE, *see* Madersbacher S
- Studer UE, Hauri D, Hanselmann S, Chollet D, Leisinger H-J, Gasser T, Senn E, Trinkler FB, Tscholl RM, Thalmann GN, Dietrich D. Immediate Versus Deferred Hormonal Treatment for Patients With Prostate Cancer Who Are Not Suitable for Curative Local Treatment: Results of the Randomized Trial SAKK 08/88, 4109
- Sturgill J, *see* Hirschowitz EA
- Sturgis EM, *see* Pytynia KB
- Sturla LM, *see* Fernandez-Teijeiro A
- Styczynski J, Wysocki M. Is the In Vitro Drug Resistance Profile the Strongest Prognostic Factor in Childhood Acute Lymphoblastic Leukemia? (correspondence), 963
- Su L, *see* Gurubhagavatula S
- Su YB, Sohn S, Crown SE, Livingston PO, Wolchok JD, Quinn C, Williams L, Foster T, Sepkowitz KA, Chapman PB. Selective CD4⁺ Lymphopenia in Melanoma Patients Treated With Temozolomide: A Toxicity With Therapeutic Implications, 610
- Suardi S, *see* Licitra L
- Subtil JC, *see* Sangro B
- Sufliarsky J, *see* Avril MF
- Sugarbaker PH, *see* Glehen O
see Levitz JS
- Sugawara Y, *see* Akechi T
- Sugio K, *see* Osoegawa A
- Sugiura T, *see* Kubota K
- Sullivan PA, *see* Erwin BA
- Suman VJ, *see* Perez EA
- Sumer C, *see* Maier BO
- Sun CC, *see* Slomovitz BM
- Sun L, *see* Amling CL
- Sun P, *see* Metcalfe K
- Sundstrøm S, Bremnes R, Aasebø U, Aamdal S, Hatlevoll R, Brunsvig P, Johannessen DC, Klepp O, Fayers PM, Kaasa S. Hypofractionated Palliative Radiotherapy (17 Gy per two fractions) in Advanced Non-Small-Cell Lung Carcinoma Is Comparable to Standard Fractionation for Symptom Control and Survival: A National Phase III Trial, 801
- Sung L, *see* Gassas A
- Sung L, Feldman BM, Schwamborn G, Paczesny D, Cochrane A, Greenberg ML, Maloney AM, Hendershot EI, Naqvi A, Barrera M, Llewellyn-Thomas HA. Inpatient Versus Outpatient Management of Low-Risk Pediatric Febrile Neutropenia: Measuring Parents' and Healthcare Professionals' Preferences, 3922
- Sung L, Nathan PC, Lange B, Beyene J, Buchanan GR. Prophylactic Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor Decrease Febrile Neutropenia After Chemotherapy in Children With Cancer: A Meta-Analysis of Randomized Controlled Trials, 3350
- Sunyach MP, *see* Pommier P
- Supko JG, *see* Garcia-Carbonero R
- Surfus J, *see* King, DM
- Sutherland DAJ, *see* Bull SB
- Suzuki Y, *see* Chakravarti A
- Sverrisdóttir A, Fornander T, Jacobsson H, von Schoultz E, Rutqvist LE. Bone Mineral Density Among Premenopausal Women With Early Breast Cancer in a Randomized Trial of Adjuvant Endocrine Therapy, 3694
- Swain SM, *see* Low JA
see Tan AR
- Swanson DA, *see* Patard J-J
- Sweeney C, *see* Bruera E
see Kaufman HL
- Sweeney T, *see* Landier W
- Sweep FCGJ, *see* Span PN
- Swensen SJ, *see* Patz EF Jr
- Swint K, *see* Elsayem A
- Sykes M, *see* Mapara MY
- Sykora K-W, *see* Bader P
- Symmans WF, *see* Ayers M
- Synnerstad I, *see* Lens MB
- Syrigos K, *see* Georgoulas V
- Szawlowski A, *see* Van Cutsem E
- Szeto L, *see* Rudin CM
- Sznol M, *see* Wadler S
- Szondy K, *see* Hanna N

T

- Taamma A, *see* Yovine A
- Taat CW, *see* Hartgrink HH
- Taback B, *see* Takeuchi H
- Tabata M, *see* Hotta K
- Taber DA, *see* Davis NB
- Taberner J, *see* Cassidy J
- Tadic L, *see* Jeremic B
- Taghian A, Jeong J-H, Mamounas E, Anderson S, Bryant J, Deutsch M, Wolmark N. Patterns of Locoregional Failure in Patients With Operable Breast Cancer Treated by Mastectomy and Adjuvant Chemotherapy With or Without Tamoxifen and Without Radiotherapy: Results From Five National Surgical Adjuvant Breast and Bowel Project Randomized Clinical Trials, 4247
- Tai P, *see* Roa W
- Taillibert S, *see* Hoang-Xuan K
- Tait D, *see* Chau I
- Tajima K, *see* Endoh H
- Takahashi T, *see* Endoh H
- Takanashi S, *see* Kumasaka R
- Takeda M, *see* Nagasaka T
- Takeuchi H, Morton DL, Kuo C, Turner RR, Elashoff D, Elashoff R, Taback B, Fujimoto A, Hoon DSB. Prognostic Significance of Molecular Upstaging of Paraffin-Embedded Sentinel Lymph Nodes in Melanoma Patients, 2671
- Talantov D, *see* Wang Y
- Talarico L, Chen G, Pazdur R. Enrollment of Elderly Patients in Clinical Trials for Cancer Drug Registration: A 7-Year Experience by the US Food and Drug Administration, 4626
- Talcott JA, *see* Loblaw DA
- Tallman MS, *see* Greenberg PL
- Tallman MS, Kim HT, Paietta E, Bennett JM, Dewald G, Cassileth PA, Wiernik PH, Rowe JM. Acute Monocytic Leukemia (French-American-British classification M5) Does Not Have a Worse Prognosis Than Other Subtypes of Acute Myeloid Leukemia: A Report From the Eastern Cooperative Oncology Group, 1276
- Talpaz M, *see* Peng B
- Tamayo P, *see* Fernandez-Teijeiro A
- Tamura M, *see* Kumasaka R
- Tan AR, Yang X, Hewitt SM, Berman A, Lepper ER, Sparreboom A, Parr AL, Figg WD, Chow C, Steinberg SM, Bacharach SL, Whatley M, Carrasquillo JA, Brahim JS, Ettenberg SA, Lipkowitz S, Swain SM. Evaluation of Biologic End Points and Pharmacokinetics in Patients With Metastatic Breast Cancer After Treatment With Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, 3080

- Tan D, *see* Aljada IS
- Tanaka N, *see* Nagasaka T
- Tanaka S, *see* Osoegawa A
- Tanda F, *see* Casula M
- Tang LH, *see* Brenner B
- Tang X, *see* Lu C
see Ren H
- Tanimoto M, *see* Hotta K
- Tannenbaum C, *see* Alatrash G
- Tannock IF, *see* Krzyzanowska MK
- Tannock IF, Ahles TA, Ganz PA, van Dam FS. Cognitive Impairment Associated With Chemotherapy for Cancer: Report of a Workshop, 2233
- Tanwar MK, *see* Dupont J
- Tao Q, *see* Chan ATC
- Taplin ME, *see* Loblaw DA
- Tarbell NJ, *see* Adams MJ
see Hudson MM
see Jagsi R
see Miser JS
see Waber DP
- Tarella C, *see* Corradini P
- Tassinari D, *see* Sartori S
- Tateo S, *see* Bolis G
- Tattersall MHN, *see* Butow P
see Hagerty RG
see Leigh NB
- Taverna C, *see* Dubs A
see Weder W
- Taylor CLC, Basen-Engquist K, Shinn EH, Bodurka DC. Predictors of Sexual Functioning in Ovarian Cancer Patients, 881
- Taylor JMG, *see* Thomas CH
- Taylor PT, *see* Berek JS
- Taylor S, *see* Guillou L
see Simpson L
- Taylor SA, *see* Edelman MJ
- Teague A, *see* Stebbing J
- Tebbutt N, *see* Chau I
- Tedesco KL, Thor AD, Johnson DH, Shyr Y, Blum KA, Goldstein LJ, Gradishar WJ, Nicholson BP, Merkel DE, Murrey D, Edgerton S, Sledge GW Jr. Docetaxel Combined With Trastuzumab Is an Active Regimen in HER-2-3+ Overexpressing and Fluorescent In Situ Hybridization-Positive Metastatic Breast Cancer: A Multi-Institutional Phase II Trial, 1071
- Teel K, *see* Ladas EJ
- Tempero MA. Clinical Oncology 2004: The President's Report, 4437
- Temple LKF, Hsieh L, Wong WD, Saltz L, Schrag D. Use of Surgery Among Elderly Patients With Stage IV Colorectal Cancer, 3475
- Ten Have TR, *see* Erwin BA
- Tendler C, *see* Keller AM
- Tentes AAK, *see* Glehen O
- Teo PML, *see* Chan ATC
- Teot LA, *see* Wharam MD
- Tepper JE, *see* Gunderson LL
see Meyerhardt JA
- Tepper JE. Patient Selection, Realism, and Randomized Clinical Trials (editorial), 3215
- Terrier P, *see* Guillou L
- Terris MK, *see* Freedland SJ
- Teule GJJ, *see* van der Hoeven JJM
- Teunissen JJM, Kwekkeboom DJ, Krenning EP. Quality of Life in Patients With Gastroenteropancreatic Tumors Treated With [¹⁷⁷Lu-DOTA⁰, Tyr³]octreotate, 2724
- Tewes M, *see* Vanhoefer U
- Thaler HT, *see* Dupont J
see Moore DH
see Wreesmann VB
- Thall PF, *see* Cormier JN
see Mathew P
see Pisters PWT
- Thalmann GN, *see* Madersbacher S
see Studer UE
- Thames H, *see* Thomas CH
- Thames HD, *see* Chen AM
- Thatcher N, *see* Agarwala SS
see Hancock BW
- The Italian Group for Antiemetic Research. Randomized, Double-Blind, Dose-Finding Study of Dexamethasone in Preventing Acute Emesis Induced by Anthracyclines, Carboplatin, or Cyclophosphamide, 725
- The Meta-Analysis Group in Cancer. Modulation of Fluorouracil by Leucovorin in Patients With Advanced Colorectal Cancer: An Updated Meta-Analysis, 3766
- Theodore C, *see* Gholam D
see Toumi N
- Therasse P, *see* Efficace F
- Theriault RL, *see* Thomas E
- Therneau TM, *see* Dispenzieri A
- Thertulien R, *see* Miceli M
- Thibault A, *see* Kurzrock R
- Thieblemont C, *see* Hequet O
see Mounier N
- Thiel E, *see* Kiewe P
see Zander AR
- Thigpen JT, Brady MF, Homesley HD, Malfetano J, DuBeshter B, Burger RA, Liao S. Phase III Trial of Doxorubicin With or Without Cisplatin in Advanced Endometrial Carcinoma: A Gynecologic Group Study, 3902
- Thoma J, *see* Diener-West M
- Thomas C, *see* Rose JH
- Thomas CH, Bradshaw PT, Pollack BH, Montie JE, Taylor JMG, Thames H, McLaughlin PW, DeBiose DA, Hussey D, Wahl RL. In Reply (correspondence), 380
- Thomas CR Jr, *see* Martenson JA Jr
- Thomas DA, *see* Kurzrock R
- Thomas E, Holmes FA, Smith TL, Buzdar AU, Frye DK, Fraschini G, Singletary SE, Theriault RL, McNeese MD, Ames F, Walters R, Hortobagyi GN. The Use of Alternate, Non-Cross-Resistant Adjuvant Chemotherapy on the Basis of Pathologic Response to a Neoadjuvant Doxorubicin-Based Regimen in Women With Operable Breast Cancer: Long-Term Results From a Prospective Randomized Trial, 2294
- Thomas HJW, *see* Lipton LR
- Thomas M, *see* Kakkar AK
- Thomas PRM, *see* Seibel NL
- Thomas R, *see* Yu YP
- Thomas X, Boiron J-M, Huguet F, Dombret H, Bradstock K, Vey N, Kovacovics T, Delannoy A, Fegueux N, Fenaux P, Stamatoullas A, Vernant J-P, Tournilhac O, Buzyn A, Reman O, Charrin C, Boucheix C, Gabert J, Lhéritier V, Fiere D. Outcome of Treatment in Adults With Acute Lymphoblastic Leukemia: Analysis of the LALA-94 Trial, 4075
- Thomé SD, *see* Gill S
- Thompson CB, *see* Thompson JE
- Thompson D, *see* Burris H III
- Thompson JA, *see* Rowinsky EK
- Thompson JE, Thompson CB. Putting the Rap on Akt, 4217
- Thompson JF, *see* Fife KM
- Thompson MA, Harker-Murray A, Lockett AJ, Chareonthaitawee P. Unusual Lymphoma Manifestations: Myocardial Lymphoma Presenting As Atrial Flutter, 558
- Thomson CA, *see* Rock CL
- Thöni A, *see* Huguenin P
- Thor A, *see* Langer CJ

AUTHOR INDEX

- Thor AD, *see* Tedesco KL
 Thorner P, *see* Kretschmar CS
 Thum P, *see* Huguenin P
 Thurman PW, *see* Cox MC
 Tian Q, *see* Roberts SS
 Tierney RM, *see* Read WL
 Tilanus H, *see* Hartgrink HH
 Tilanus HW, *see* de Boer AGEM
 Tillner J, *see* Vanhoefer U
 Timmerman J, *see* Weng W-K
 Tinga DJ, *see* Buijs C
 Tirelli W, *see* Caraceni A
 Tisch A, *see* Marks LB
 Tisman G, MacDonald D, Shindell N, Reece E, Patel P, Honda N, Nishimura EK, Garris J, Shannahan W, Chisti N, McCarthy J, Moaddeli SN, Sargent D, Plant A. Oxaliplatin Toxicity Masquerading As Recurrent Colon Cancer (correspondence), 3202
 Tiwari D, *see* Hoerr AL
 Tobias J, *see* Cuzick J
 Tobis K, *see* Fröhling S
 Todd M, *see* Kumar P
 Tokunaga H, *see* Shariati SF
 Tokunaga M, *see* Nakajima H
 Tollerfield SM, *see* Rossi J-F
 Tombesi P, *see* Sartori S
 Tomek R, *see* Rudin CM
 Tomida S, *see* Endoh H
 Tomlinson IPM, *see* Lipton LR
 Toner GC. Early Identification of Therapeutic Failure in Nonseminomatous Germ Cell Tumors by Assessing Serum Tumor Marker Decline during Chemotherapy: Still Not Ready for Routine Clinical Use (editorial), 3842
 Tong AT, *see* Dang NH
 Tong W, *see* Brenner B
 Tonini G, *see* Vincenzi B
 Töpfer M, *see* Huguenin P
 Topham C, *see* Lal R
 Topping AP, *see* Dewar DJ
 Tordecilla J, *see* Santolaya ME
 Torelli G, *see* Potenza L
 Toretsky JA, *see* French CA
 Torhorst J, *see* Nevalainen MT
 Torino F, *see* Longo R
 Torisu-Itakura H, *see* Lee JH
 Tormey P, *see* Myers DA
 Tormo A, *see* Fernández-Martos C
 Török H-P, *see* Glas J
 Torregrosa M, *see* Fernández-Martos C
 Torres MA, *see* Lieskovsky YE
 Torres O, *see* Crombet T
 Torti FM, *see* Small EJ
 Tortochaux J, *see* Denis F
 Tosoni A, *see* Brandes AA
 Tostain J, *see* Patard J-J
 Toumbis M, *see* Georgoulas V
 Toumi N, Chaumette-Plankaert M-T, Cherqui D, de Revel T, Duvillard P, Theodore C. Germ Cell Tumors: Primary Yolk Sac Tumor of the Liver, 1756
 Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A. FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study, 229
 Tournilhac O, *see* Thomas X
 Tourt-Uhlig SE, *see* Rich JN
 Toyka K, *see* Ströbel P
 Trarbach T, *see* Vanhoefer U
 Trassard M, *see* Guillou L
 Treuner J, *see* Carli M
 see Schuck A
 Treves ST, *see* Adams MJ
 Trevisani L, *see* Sartori S
 Tricot G, *see* Miceli M
 Tridello G, *see* Carli M
 Trinkaus K, *see* Bradley JD
 Trinkler FB, *see* Studer UE
 Tripathy D, *see* Miaskowski C
 Tripathy D, Slamon DJ, Cobleigh M, Arnold A, Saleh M, Mortimer JE, Murphy M, Stewart SJ. Safety of Treatment of Metastatic Breast Cancer With Trastuzumab Beyond Disease Progression, 1063
 Trobaugh-Lotario AD, Liang X, Janik JS, Lovell MA, Odom LF. Difficult Diagnostic and Therapeutic Cases: Thymoma and Tumor Lysis Syndrome in an Adolescent, 955
 Troncoso P, *see* Mathew P
 Trotti A, Bentzen SM. The Need for Adverse Effects Reporting Standards in Oncology Clinical Trials (editorial), 19
 Trout JR, *see* Auerbach M
 Trudeau ME, *see* Goodwin PJ
 Trümper L, *see* Zander AR
 Truong PT, *see* Olivetto IA
 Tsai M-S, Ko PC-I, Shih J-Y, Chang Y-L, Chen S-C, Chiang W-C, Chen W-J. Cardiac Involvement in Malignancies: Favorable Outcome of a Patient With Cardiac Invasion From Non-Small-Cell Lung Carcinoma, 2740
 Tsangaris T, *see* Schwartz MD
 Tsao Y, *see* Hanna N
 Tsaroucha E, *see* Georgoulas V
 Tschetter LK, *see* Alberts SR
 Tscholl RM, *see* Studer UE
 Tse MWY, *see* Chan W-M
 Tsujinaka T, *see* Sano T
 Tu D, *see* Bezzak A
 see Butler L
 see Reyno L
 Tu S-M, *see* Papanreou CN
 Tubiana-Hulin M, *see* Diéras V
 Tucci A, *see* Zinzani PL
 Tucker SL, *see* Huang EH
 Tuli S, *see* Figueroa BE
 Tullio C, *see* Pedrazzoli P
 Tulpule A, *see* Levine AM
 Tung N, *see* Metcalfe K
 Tung NM, *see* Bober SL
 Tunuguntla R, *see* Hillner BE
 Tupper T, *see* Harandi A
 Tura S, *see* Zinzani PL
 Turker A, *see* Altundag O
 Turk N, *see* Zebrack BJ
 Turner JE, Alley JG, Sharpless NE. Medical Problems in Patients With Malignancy: Wernicke's Encephalopathy: An Unusual Acute Neurologic Complication of Lymphoma and Its Therapy, 4020
 Turner MA, *see* Roberts SS
 Turner RR, *see* Takeuchi H
 Turrisi A, *see* Marks LB
 Turrisi AT, *see* Pfister DG
 Tur RY, *see* Caraceni A
 Tuttle T, *see* Neubauer M
 Tveit KM, *see* Sørbye H
 Twardowski P, *see* Somlo G
 Tweeddale ME, *see* Bull SB

- Twelves C, *see* Bottomley A
see Cassidy J
- Tynan M, *see* Socinski MA
- Tyson L, *see* Miller VA
- Tzontcheva AT, *see* Bull SB
- Tzortzatou-Stahopoulou F, *see* French CA
- U**
- Uchitomi Y, *see* Akechi T
- Ueno NT, *see* Escalón MP
see Hamaoka T
- Ueno NT, Shpall EJ, Champlin RE, Jones RB. Graft-Versus-Breast Cancer Effect by Allogeneic Hematopoietic Stem-Cell Transplantation: A Possible New Frontier (editorial), 3846
- Ueoka H, *see* Hotta K
- Ullrich R, *see* Daum S
- Ulm K, *see* Gertler R
- Ulrich CM, *see* Robien K
- Undevia SD, *see* Innocenti O
- Uner A, *see* Altundag O
- Unterhalt M, *see* Lenz G
- Uribe N, *see* Fernández-Martos C
- Urioste M, *see* Valle L
- Urkin J, *see* David YB
- Ursin G, Palla SL, Reboussin BA, Slone S, Wasilaukas C, Pike MC, Green-dale GA. Post-Treatment Change in Serum Estrone Predicts Mammographic Percent Density Changes in Women Who Received Combination Estrogen and Progestin in the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial, 2842
- Urtasun R, *see* Roa W
- V**
- Valagussa P, *see* Bonadonna G
see Demicheli R
- Valduga F, *see* Brandes AA
- Vale S. Is Methylphenidate an Irreplaceable Therapy for the Fatigued Cancer Patient? (correspondence), 4028
- Valentine MB, *see* Sanders RP
- Valentini M, *see* Nicolucci A
- Valerio MR, *see* De Placido S
- Valero V, *see* Anderson KO
see Ayers M
see Huang EH
- Vallabhajosula S, *see* Milowsky MI
- Valle L, Rodriguez-López R, Robledo M, Benítez J, Urioste M. Concurrency of Germline Mutations in the APC and PTEN Genes in a Colonic Polyposis Family Member (correspondence), 2252
- Vallone P, *see* Izzo F
- van Andel G, *see* Collette L
- van Beek J, zur Hausen A, Kranenborg EK, van de Velde CJH, Middeldorp JM, van den Brule AJC, Meijer CJLM, Bloemena E. EBV-Positive Gastric Adenocarcinomas: A Distinct Clinicopathologic Entity With a Low Frequency of Lymph Node Involvement, 664
- Vance G, *see* Houck W
- Van Cutsem E, *see* Benson AB III
see Cassidy J
- Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, Schoffski P, Post S, Verslype C, Neumann H, Safran H, Humblet Y, Ruixu JP, Ma Y, Von Hoff D. Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer, 1430
- van Daal WAJ, *see* van Roosmalen MS
- van Dam FS, *see* Tannock IF
- van den Bergh ACM, *see* Creutzberg CL
- Van Den Bossche B, Van de Wiele C. Receptor Imaging in Oncology by Means of Nuclear Medicine: Current Status, 3608
- van den Brink M, Stiggelbout AM, van den Hout WB, Kievit J, Kranenborg EK, Marijnen CAM, Nagtegaal ID, Rutten HJT, Wiggers T, van de Velde CJH. Clinical Nature and Prognosis of Locally Recurrent Rectal Cancer After Total Mesorectal Excision With or Without Preoperative Radiotherapy, 3958
- van den Brink M, van den Hout WB, Stiggelbout AM, Kranenborg EK, Marijnen CAM, van de Velde CJH, Kievit J. Cost-Utility Analysis of Preoperative Radiotherapy in Patients With Rectal Cancer Undergoing Total Mesorectal Excision: A Study of the Dutch Colorectal Cancer Group, 244
- van den Brule AJC, *see* van Beek J
- van den Hout WB, *see* van den Brink M
- van der AGJ, *see* Skates SJ
- van Der Hage J, *see* de Bock GH
- van der Hoeven JJM, Krak NC, Hoekstra OS, Comans EFI, Boom RPA, van Geldere D, Meijer S, van der Wall E, Buter J, Pinedo HM, Teule GJJ, Lammertsma AA. ¹⁸F-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Staging of Locally Advanced Breast Cancer, 1253
- van der Sijp JRM, *see* Palmer DH
- van der Wall E, *see* van der Hoeven JJM
- van de Velde CJH, *see* de Bock GH
see Hartgrink HH
see van Beek J
see van den Brink M
- van de Velde H, *see* Van Cutsem E
- Van de Wiele C, *see* Van Den Bossche B
- Van Duyn LB, *see* Rich JN
- van Elk PJ, *see* Hartgrink HH
- van Geldere D, *see* van der Hoeven JJM
- Vangel M, *see* Langer CJ
- Vanhoefer U, Tewes M, Rojo F, Dirsch O, Schleucher N, Rosen O, Tillner J, Kovar A, Braun AH, Trarbach T, Seeber S, Harstrick A, Baselga J. Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor Receptor, 175
- Van Hoof A, *see* Rossi J-F
- van Krieken JHJM, *see* Hartgrink HH
- van Lanschot JJB, *see* de Boer AGEM
see Hartgrink HH
see van Westreenen HL
- van Lent M, *see* Creutzberg CL
- Van Praagh I, *see* Bonnetterre J
see Fargeot P
- van Putten WLJ, *see* Creutzberg CL
- van Roosmalen MS, Stalmeier PFM, Verhoef LCG, Hoekstra-Weebers JEHM, Oosterwijk JC, Hoogerbrugge N, Moog U, van Daal WAJ. Randomized Trial of a Shared Decision-Making Intervention Consisting of Trade-Offs and Individualized Treatment Information for BRCA1/2 Mutation Carriers, 3293
- van Ryn M, *see* Ayanian JZ
- van Sandick JW, *see* de Boer AGEM
- Van Steen K, *see* Efficace F
- Van Tussenbroek F, *see* Samyn I
- van't Veer L, *see* Rebbeck TR
- van Westreenen HL, Westerterp M, Bossuyt PMM, Pruijm J, Sloof GW, van Lanschot JJB, Groen H, Plukker JThM. Systematic Review of the Staging Performance of ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography in Esophageal Cancer, 3805
- Varas M, *see* Santolaya ME
- Vardanega A, *see* Montella L

AUTHOR INDEX

- Vardiman JW, *see* Kolitz JE
 Vardy J, *see* Stockler M
 Varela-Garcia M, *see* Hirsch FR
 Vargas SO, *see* French CA
 Varterasian M, *see* Rinehart J
 Vasaturo F, *see* Gradilone A
 Vaskovic Z, *see* Jeremic B
 Vastola F, *see* Brandes AA
 Vaughan C, *see* Navo MA
 Veatch J, *see* DuBois SG
 Vedeler CA, *see* Monstad SE
 Velez-Garcia E, *see* Kolitz JE
 Velikova G, Booth L, Smith AB, Brown PM, Lynch P, Brown JM, Selby PJ. Measuring Quality of Life in Routine Oncology Practice Improves Communication and Patient Well-Being: A Randomized Controlled Trial, 714
 Venkatesan V, *see* Pollack A
 Venkatraman E, *see* Miller VA
 see Sherman EJ
 Venta L, *see* Golub RM
 Vera K, *see* Raymond E
 Verde PE, *see* Stoecklein NH
 Verhoef LCG, *see* van Roosmalen MS
 Vernant J-P, *see* Thomas X
 Veronesi G, *see* De Pas T
 Verslype C, *see* Van Cutsem E
 Vervenne WL, *see* Van Cutsem E
 Verwaal VJ. In Reply (correspondence), 1529
 Vesole DH, *see* Devine SM
 Veve R, *see* Hirsch FR
 Vey N, *see* Thomas X
 Veyret C, *see* Bonnetterre J
 Viale G, *see* De Pas T
 Viarengo G, *see* Marchetti M
 Vicent JM, *see* Fernández-Martos C
 Viciano V, *see* Fernández-Martos C
 Vickers AJ, Straus DJ, Fearon B, Cassileth BR. Acupuncture for Postchemotherapy Fatigue: A Phase II Study, 1731
 Vietti TJ, *see* Miser JS
 Vigneau FD, *see* Barnholtz-Sloan JS
 Vigushin DM, *see* Palmieri C
 Vij R, *see* Hoerr AL
 Vilcoq JR, *see* Louis-Sylvestre C
 Villa A, *see* Bolis G
 Villani F, *see* Bonadonna G
 Villarreal M, *see* Santolaya ME
 Villart M, *see* Annane D
 Vilmer E, *see* de Botton S
 Vimal S, *see* Laskar S
 Viñas G, *see* Colomer R
 Vince DR, *see* Guillou L
 Vincent A, *see* Downey RJ
 see Monstad SE
 Vincenzi B, Santini D, Grilli C, La Cesa A, Dianzani C, Tonini G. Complications of Therapy in Cancer Patients. Case 3. Toxic Epidermal Necrolysis Induced by Oral Phenobarbital and Whole-Brain Radiotherapy in a Breast Cancer Patient, 4649
 Vineis P, *see* Berwick M
 Viney RC, Boyer MJ, King MT, Kenny PM, Pollicino CA, McLean JM, McCaughan BC, Fulham MJ. Randomized Controlled Trial of the Role of Positron Emission Tomography in the Management of Stage I and II Non-Small-Cell Lung Cancer, 2357
 Vinnicombe S, *see* Davies AJ
 Vinocur CD, *see* Cushing B
 Virgo KS, *see* Johnson FE
 see Loblaw DA
 Visentin M, *see* Caraceni A
 Visser M, *see* Jongbloed MRM
 Viviani S, *see* Bonadonna G
 Viviani T, *see* Santolaya ME
 Vogel CL, *see* Keller AM
 Vogelzang NJ, *see* Davis NB
 see Loblaw DA
 see Rowinsky EK
 see Small EJ
 Vogelzang NJ. In Reply (correspondence), 4235
 Voi M, *see* Reyno L
 Vokes EE, *see* Benson AB III
 see Cohen EEW
 see Davis NB
 see Garden AS
 see Innocenti F
 see Rudin CM
 see Soulieres D
 Volpe A, *see* Marchetti M
 Völter V, Peschel C. Is Lanreotide and/or Interferon Alfa an Adequate Therapy for Neuroendocrine Tumors? (correspondence), 573
 von Beauvais H, *see* Schirrmeyer H
 Vongphrachanh P, *see* Dupont J
 Von Hoff D, *see* Van Cutsem E
 Von Huff DD, *see* Schrag D
 von Meyenfeldt MF, *see* Hartgrink HH
 von Minckwitz G, *see* Keller AM
 von Pawel J, *see* Giaccone G
 see Hanna N
 von Roemeling R, *see* Hrushesky W
 Von Roenn JH, *see* Sparano JA
 von Scheidt W, *see* Maier BO
 von Schoultz E, *see* Sverrisdóttir A
 von Stackelberg A, *see* Bader P
 see Herold R
 Vossen JM, *see* Ringdén O
 Vredenburg JJ, *see* Rich JN
 Vrionis FR, *see* Naing A
- W**
- Waanders E, *see* Span PN
 Waber DP, Silverman LB, Catania L, Mautz W, Rue M, Gelber RD, Levy DE, Goldwasser MA, Adams H, Dufresne A, Metzger V, Romero I, Tarbell NJ, Dalton VK, Sallan SE. Outcomes of a Randomized Trial of Hyperfractionated Cranial Radiation Therapy for Treatment of High-Risk Acute Lymphoblastic Leukemia: Therapeutic Efficacy and Neurotoxicity, 2701
 Waddell TK, *see* de Perrot M
 Wade JL Jr, *see* Loblaw DA
 Wadleigh RG, *see* Shirao K
 Wadler S, *see* Benson AB III
 see Hochster H
 see Shirao K
 Wadler S, Makower D, Clairmont C, Lambert P, Fehn K, Sznol M. Phase I and Pharmacokinetic Study of the Ribonucleotide Reductase Inhibitor, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, Administered by 96-Hour Intravenous Continuous Infusion, 1553
 Wagner JE, *see* Eapen M
 Wagner LM, Billups CA, Furman WL, Rao BN, Santana VM. Combined Use of Erythropoietin and Granulocyte Colony-Stimulating Factor Does Not Decrease Blood Transfusion Requirements During Induction

AUTHOR INDEX

- Therapy for High-Risk Neuroblastoma: A Randomized Controlled Trial, 1886
- Wahl RL, *see* Thomas CH
- Wahl RL, Siegel BA, Coleman RE, Gatsonis CG. Prospective Multicenter Study of Axillary Nodal Staging by Positron Emission Tomography in Breast Cancer: A Report of the Staging Breast Cancer With PET Study Group, 277
- Wain JC, *see* Gurubhagavata S
- Walker M, *see* Berwick M
- Walker P, *see* Elsayem A
- Walker PL, *see* Dang NH
- Walker R, *see* Miceli M
- Wall DA. Allogeneic Peripheral Blood Versus Bone Marrow Transplantation: Children Are Small Adults and More (editorial), 4865
- Wallace D, *see* Gajjar A
see Stewart CF
- Wallace RB, *see* Ayanian JZ
see Potosky AL
- Wallach RC, *see* Hochster H
- Walley B, *see* Reyno L
- Wallwiener D, *see* Krauss K
- Walsh D, *see* Davis MP
- Walter AW, *see* Hilden JM
- Walterhouse DO, Lyden ER, Breitfeld PP, Qualman SJ, Wharam MD, Meyer WH. Efficacy of Topotecan and Cyclophosphamide Given in a Phase II Window Trial in Children With Newly Diagnosed Metastatic Rhabdomyosarcoma: A Children's Oncology Group Study, 1398
- Walters R, *see* Thomas E
- Wan KY, *see* Kwong DLW
- Wandert T, *see* Atzpodien J
- Wandt H, *see* Zander AR
- Wanek L, *see* Lee JH
- Wang H, *see* Lee JH
- Wang L, *see* Lu C
- Wang M, *see* Dang NH
- Wang MJ, *see* Lin TY
- Wang R-C, *see* Chang G-C
- Wang W, *see* Kaufman HL
see Loehrer PJ Sr
see Palesty JA
- Wang X, *see* Cormier JN
see Papandreou CN
- Wang Y, Jatkoa T, Zhang Y, Mutch MG, Talantov D, Jiang J, McLeod HL, Atkins D. Gene Expression Profiles and Molecular Markers To Predict Recurrence of Dukes' B Colon Cancer, 1564
- Wang Z, *see* Roberts SS
- Wárlám-Rodenhuis CC, *see* Creutzberg CL
- Warner E, *see* Metcalfe K
- Warner T, *see* King, DM
- Warr D, *see* Stockler M
- Warshal D, *see* Norton TR
- Wasilaukas C, *see* Ursin G
- Watanabe K, *see* Kubota K
- Watanabe T, *see* Howell A
- Waterhouse D, *see* Rinehart J
- Waters JS, *see* Chau I
- Waterston A, *see* Stebbing J
- Watson MA, *see* Span PN
- Watters JW, *see* McLeod HL
- Wayne AS, *see* Godder K
- Weaver R, *see* Czuczman MS
- Weber A, Imisch P, Bergmann E, Christiansen H. Coamplification of *DDX1* Correlates With an Improved Survival Probability in Children With *MYCN*-Amplified Human Neuroblastoma, 2681
- Weber B, *see* Armstrong K
see Metcalfe K
see Rebbeck TR
- Weber G, *see* Beguin Y
- Weber WA, *see* Wieder HA
- Webster A, *see* Howell A
- Webster K, *see* Markman M
- Weder W, *see* Gautschi O
- Weder W, Kestenholz P, Taverna C, Bodis S, Lardinois D, Jerman M, Stahel RA. Neoadjuvant Chemotherapy Followed by Extrapleural Pneumonectomy in Malignant Pleural Mesothelioma, 3451
- Weeks JC, *see* Ayanian JZ
see Earle CC
see Elkin EB
see Meyerhardt JA
- Weeraratna AT, *see* Sosman JA
- Wehrmann M, *see* Krauss K
- Wei Q, *see* Pytynia KB
- Wei SJ, Metz JM, Coyle C, Hampshire M, Jones HA, Markowitz S, Rustgi AK. Recruitment of Patients Into an Internet-Based Clinical Trials Database: The Experience of OncoLink and the National Colorectal Cancer Research Alliance, 4730
- Weichenthal M, *see* Avril MF
- Weichselbaum R, *see* Senzer N
- Weil RJ. Potential Confounding Features in *p53* Gene Therapy of Recurrent Glioma (correspondence), 1344
- Weiman M, *see* Lange BJ
- Weinberger PM, *see* Psyrrri A
- Weinberg V, *see* Oh WK
- Weiner HL, *see* Chi SN
- Weiner LM, *see* Cheng JD
see Kaufman HL
- Weiner SL, *see* Anderson BD
- Weinfurt KP, *see* Meropol NJ
- Weinknecht S, *see* Rick O
- Weinstein HJ, *see* Hudson MM
- Weinstein MC, *see* Elkin EB
- Weiβbach L, *see* Rick O
- Weisdorf D, *see* Devine SM
- Weiss GR, *see* Edelman MJ
- Weiss R, *see* Kumar P
- Weitman SD, *see* Aquino VM
- Weitzel J, *see* Somlo G
- Welch TJ, *see* Goetz MP
- Weller E, *see* Horning SJ
- Welles L, *see* Levine AM
- Welnicka-Jaskiewicz M, *see* Efficace F
- Welte T, *see* Laack E
- Welvaart K, *see* Hartgrink HH
- Wen P, *see* Puduvalli VK
- Weng W-K, Czerwinski D, Timmerman J, Hsu FJ, Levy R. Clinical Outcome of Lymphoma Patients After Idiotype Vaccination Is Correlated With Humoral Immune Response and Immunoglobulin G Fc Receptor Genotype, 4717
- Went P, *see* Ascani S
- Went PT, Dirnhofer S, Bundi M, Mirlacher M, Schraml P, Mangialaio S, Dimitrijevic S, Kononen J, Lugli A, Simon R, Sauter G. Prevalence of KIT Expression in Human Tumors, 4514
- Werner M, *see* Gertler R
- Wertheim M, *see* Kemeny N
- West C, *see* Miaskowski C
- West DW, *see* Ayanian JZ
- Westerterp M, *see* van Westreenen HL
- Wharam MD, *see* Walterhouse DO
- Wharam MD, Meza J, Anderson J, Breneman JC, Donaldson SS, Fitzgerald TJ, Michalski J, Teot LA, Wiener ES, Meyer WH. Failure Pattern and

AUTHOR INDEX

- Factors Predictive of Local Failure in Rhabdomyosarcoma: A Report of Group III Patients on the Third Intergroup Rhabdomyosarcoma Study, 1902
- Whatley M, *see* Tan AR
- Wheatley K, *see* Hancock BW
- Wheeler TM, *see* Shariat SF
- Whelan TJ, *see* Wright JR
- White M, *see* Burris H III
- Whiteside TL, *see* Berek JS
see Kaufman HL
- Whitfield A, *see* Whitworth MK
- Whitman G, *see* Ayers M
- Whitton J, *see* Zebrack BJ
- Whitworth MK, Whitfield A, Holm S, Shaffer J, Makin W, Jayson GC. Doctor, Does This Mean I'm Going to Starve to Death?, 199
- Widmer L, *see* Lukaschek J
- Wieand S, Murphy K. A Commentary on Treatment at Random: The Ultimate Science or the Betrayal of Hippocrates?, 5009
- Wiedenmann B, *see* Faiss S
- Wieder HA, Brücher BLD, Zimmermann F, Becker K, Lordick F, Beer A, Schwaiger M, Fink U, Siewert JR, Stein HJ, Weber WA. Time Course of Tumor Metabolic Activity During Chemoradiotherapy of Esophageal Squamous Cell Carcinoma and Response to Treatment, 900
- Wiener ES, *see* Dillon PW
see Wharam MD
- Wiernasz CJ, *see* Slingluff CL Jr
- Wiernik PH, *see* Tallman MS
- Wiesenfeld M, *see* Garrity MM
- Wiggers T, *see* van den Brink M
- Wiklund T, *see* Brandberg Y
- Wikstrand CJ, *see* Rich JN
- Wilding G, *see* Kaufman HL
see Scher HI
- Wiley TJ, *see* Caprino D
- Wilking N, *see* Brandberg Y
- Wilkins EG, *see* Janz NK
- Willemsse PHB, *see* Buijs C
- Willett C, *see* Meyerhardt JA
- Willett CG, *see* Gunderson LL
see Martenson JA Jr
see Meyerhardt JA
- Willey J, *see* Bruera E
- Willey S, *see* Schwartz MD
- Williams G. Cancer Drug Development: For Populations or for Individuals? (editorial), 3441
- Williams L, *see* Su YB
- Williams N, *see* Cuzick J
- Williams T, *see* Merchant TE
- Williamson RCN, *see* Kakkar AK
- Williamson SK, *see* Goldberg RM
- Wilson GR, *see* Reisfield GM
- Wilson LD, *see* Psyrri A
see Smith BD
- Windschitl HE, *see* Garrity MM
- Winer EP, *see* Citron ML
see Elkin EB
see Lin NU
see Partridge AH
- Winer EP, Berry DA, Woolf S, Duggan D, Kornblith A, Harris LN, Michaelson RA, Kirshner JA, Fleming GF, Perry MC, Graham ML, Sharp SA, Keresztes R, Henderson IC, Hudis C, Muss H, Norton L. Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer: Cancer and Leukemia Goup B Trial 9342, 2061
- Winick NJ, *see* Aquino VM
- see* Bomgaars L
- Winter K, *see* Eifel PJ
- Wiper DW. What Is "Appropriate" Care for Ovarian Cancer? (correspondence), 378
- Wiseman SM, *see* Aljada IS
- Wisoff JH, *see* Chi SN
- Witzig TE, *see* Garrity MM
see Kumar S
- Wolchok JD, *see* Su YB
- Wolf M, *see* Dolan NC
- Wolf MK, *see* Giaccone G
see Herbst RS
- Wolff R, *see* Kouvaraki MA
- Wolff RA, *see* Xiong HQ
- Wolmark N, *see* Gunderson LL
see Taghian A
- Womer R, *see* Arndt C
- Wong GY, *see* Goetz MP
- Wong RM, *see* Lieskovsky YE
- Wong WD, *see* Temple LKF
- Woo S, *see* Fouladi M
- Wood CG, *see* Patard J-J
- Wood P, *see* Hrushesky W
- Woodson EMH, *see* Slingluff CL Jr
- Woolas RP, *see* Skates SJ
- Woolf S, *see* Winer EP
- Wreesmann VB, Shi W, Thaler HT, Poluri A, Kraus DH, Pfister D, Shaha AR, Shah JP, Rao PH, Singh B. Identification of Novel Prognosticators of Outcome in Squamous Cell Carcinoma of the Head and Neck, 3965
- Wren PA, *see* Janz NK
- Wright J, *see* Hochster H
- Wright JJ, *see* Dahut WL
- Wright JR, Whelan TJ, Schiff S, Dubois S, Crooks D, Haines PT, DeRosa D, Roberts RS, Gafni A, Pritchard K, Levine MN. Why Cancer Patients Enter Randomized Clinical Trials: Exploring the Factors That Influence Their Decision, 4312
- Wu M-S, *see* Kuo S-H
- Wu PM, *see* Kwong DLW
- Wu S, *see* Mulhern RK
- Wu W, *see* Slomovitz BM
- Wysocki M, *see* Styczynski J

X

- Xiao S-Y, *see* Morgan PB
- Xie J, *see* Nevalainen MT
- Xing Y, *see* Cormier JN
- Xiong HQ, Rosenberg A, LoBuglio A, Schmidt W, Wolff RA, Deutsch J, Needle M, Abbruzzese JL. Cetuximab, a Monoclonal Antibody Targeting the Epidermal Growth Factor Receptor, in Combination With Gemcitabine for Advanced Pancreatic Cancer: A Multicenter Phase II Trial, 2610
- Xiong X, *see* Merchant TE
see Mulhern RK
- Xiros N, *see* Bamias A
- Xu F-J, *see* Skates SJ
- Xu R, *see* Armanios M
- Xu X, *see* Gimotty PA
- Xu X-C, *see* Lu C

Y

- Yabroff KR, *see* Mandelblatt JS
- Yamabe H, *see* Kumasaka R

AUTHOR INDEX

- Yamada Y, *see* Shirao K
 Yamaguchi M, *see* Osoegawa A
 Yamamoto S, *see* Sano T
 Yamamura Y, *see* Sano T
 Yamshchikov GV, *see* Slingluff CL Jr
 Yang GY, *see* Palesty JA
 Yang H, *see* Papandreou CN
 Yang Q, *see* Schlechter BL
 Yang T-Y, *see* Chang G-C
 Yang W, *see* Relling MV
 Yang X, *see* Tan AR
 Yannelli J, *see* Hirschowitz EA
 Yao JC, *see* Kouvaraki MA
 Yardley D, *see* Burris H III
 Yasko AW, *see* Pisters PWT
 Yasko JM, *see* Demmy TL
 Yasui Y, *see* Ross JA
 Yatabe Y, *see* Endoh H
 Yataghene K, *see* Kushner BH
 Yau CC, *see* Kwong DLW
 Yavas O, *see* Altundag O
 Yaziji H, Gown AM. Testing for Epidermal Growth Factor Receptor in Lung Cancer: Have We Learned Anything From HER-2 Testing? (correspondence), 3646
 Yeager AM, *see* Godder K
 Yeap BY, *see* Ballen KK
 Yee H, *see* Shuch B
 Yeh K-H, *see* Kuo S-H
 Yeh P-Y, *see* Kuo S-H
 Yelle L, *see* Labrie F
 Yen Y, *see* Somlo G
 Yen Y, Chu PG, Feng W. Paraneoplastic Syndromes in Cancer: Parathyroid Hormone-Related Hypercalcemia in Cholangiocarcinoma, 2244
 Yeo W, *see* Chan ATC
 Yeo W, Chan PKS, Ho WM, Zee B, Lam KC, Lei KIK, Chan ATC, Mok TSK, Lee JJ, Leung TWT, Zhong S, Johnson PJ. Lamivudine for the Prevention of Hepatitis B Virus Reactivation in Hepatitis B s-Antigen Seropositive Cancer Patients Undergoing Cytotoxic Chemotherapy, 927
 Yiannoutsos C, *see* Schneider BP
 Yin M-C, *see* Chang G-C
 Yokota S, *see* Kubota K
 Yokoyama A, *see* Kubota K
 Yoneda S, *see* Kubota K
 Yonemura Y, *see* Glehen O
 Yoshino I, *see* Osoegawa A
 You CH, *see* Yun YH
 Younes A, *see* Dang NH
 Young J, *see* Nagasaka T
 Young JA, *see* Hudson MM
 Young L, *see* Chatterjee SJ
 Young LS, *see* Palmer DH
 Young T, *see* Pasche B
 Youssefzadeh D, *see* Chatterjee SJ
 Yovine A, Riofrio M, Blay JY, Brain E, Alexandre J, Kahatt C, Taamma A, Jimeno J, Martin C, Salhi Y, Cvitkovic E, Misset JL. Phase II Study of Ecteinascidin-743 in Advanced Pretreated Soft Tissue Sarcoma Patients, 890
 Yu CKH, *see* Chan ATC
 Yu LC, *see* Godder K
 Yu X, *see* Marks LB
 Yu Y, *see* Skates SJ
 Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, McDonald C, Thomas R, Dhir R, Finkelstein S, Michalopoulos G, Becich M, Luo J-H. Gene Expression Alterations in Prostate Cancer Predicting Tumor Aggression and Preceding Development of Malignancy, 2790
 Yun YH, Lee CG, Kim S-y, Lee S-w, Heo DS, Kim JS, Lee KS, Hong YS, Lee JS, You CH. The Attitudes of Cancer Patients and Their Families Toward the Disclosure of Terminal Illness, 307
 Yung WKA, *see* Lang FF
 see Pudevalli VK
- Z**
- Zacest AC, *see* Fife KM
 Zagars GK, *see* Pisters PWT
 Zagars GK, Ballo MT, Lee AK, Strom SS. Mortality After Cure of Testicular Seminoma, 640
 Zaidi SZA, Aljurf M. Is Rasburicase Needed for Prevention of Tumor Lysis Syndrome During Treatment of Less Aggressive Hematolymphoid Malignancies? (correspondence), 3430
 Zaja F, *see* Zinzani PL
 Zakowski M, *see* Miller VA
 Zallio F, *see* Corradini P
 Zalupski M, *see* Leu KM
 see Muler JH
 Zambetti M, *see* Bonadonna G
 Zamboni WC, *see* Stewart CF
 Zamora J, *see* Montalbán C
 Zander AR, *see* Kiehl MG
 Zander AR, Kröger N, Schmoor C, Krüger W, Möbus V, Frickhofen N, Metzner B, Schultze W, Berdel WE, Koenigsmann M, Thiel E, Wandt H, Possinger K, Trümper L, Kreienberg R, Carstensen M, Schmidt EH, Jänicke F, Schumacher M, Jonat W. High-Dose Chemotherapy With Autologous Hematopoietic Stem-Cell Support Compared With Standard-Dose Chemotherapy in Breast Cancer Patients With 10 or More Positive Lymph Nodes: First Results of a Randomized Trial, 2273
 Zanotti K, *see* Markman M
 Zebrack BJ, Gurney JG, Oeffinger K, Whitton J, Packer RJ, Mertens A, Turk N, Castleberry R, Dreyer ZA, Robison LL, Zeltzer LK. Psychological Outcomes in Long-Term Survivors of Childhood Brain Cancer: A Report From the Childhood Cancer Survivor Study, 999
 Zecca E, *see* Caraceni A
 Zee B, *see* Bezjak A
 see Butler L
 see Chan ATC
 see Yeo W
 Zeitz M, *see* Daum S
 Zeldenrust SR, *see* Dispenzieri A
 Zelterman D, *see* Psyrri A
 Zeltzer LK, *see* Zebrack BJ
 Zeng C, *see* Hirsch FR
 Zeppa P, *see* Picardi M
 Zervas A, *see* Bamias A
 Zhai G, *see* Chakravarti A
 Zhang JX, *see* Chang DZ
 Zhang M-J, *see* Godder K
 Zhang Y, *see* Wang Y
 Zhang Z, *see* Skates SJ
 Zhao H, *see* Ginsberg JP
 see Silber JH
 Zheng T, *see* Pasche B
 Zhi J, *see* Dupont J
 Zhong S, *see* Yeo W
 Zhou JH, *see* Shariat SF
 Zhou S, *see* Marks LB
 Zhou W, *see* Gurubhagavatula S

AUTHOR INDEX

- Zhukovsky D, *see* Elsayem A
- Zhu T, *see* Friedberg JS
- Ziegler A, *see* Gautschi O
- Ziegler H, *see* Arndt V
- Ziegler K, *see* Samson DJ
- Zietman AL, *see* Smith MR
- Zimmermann F, *see* Wieder HA
- Zimmermann M, *see* Creutzig U
- Zimmerman TM, Harlin H, Odenike OM, Berk S, Sprague E, Karrison T, Stock W, Larson RA, Ratain MJ, Gajewski TF. Dose-Ranging Pharmacodynamic Study of Tipifarnib (R11577) in Patients With Relapsed and Refractory Hematologic Malignancies, 4816
- Zinzani PL, *see* Ascani S
- Zinzani PL, Pulsoni A, Perrotti A, Soverini S, Zaja F, De Renzo A, Storti S, Lauta VM, Guardigni L, Gentilini P, Tucci A, Molinari AL, Gobbi M, Falini B, Fattori PP, Ciccone F, Alinari L, Martelli M, Pileri S, Tura S, Baccarani M. Fludarabine Plus Mitoxantrone With and Without Rituximab Versus CHOP With and Without Rituximab As Front-Line Treatment for Patients With Follicular Lymphoma, 2654
- Ziras N, *see* Georgoulas V
- Zisman A, *see* Patard J-J
- Zoberi I, *see* Grigsby PW
- Zorzou MP, *see* Bamias A
- Zoubek A, *see* Kager L
- Zubieta M, *see* Santolaya ME
- Zucali PA, *see* Parra HS
- Zuckerman K, *see* Johnson JL
- Zucker S, *see* Sparano JA
- Zunino F, *see* Licitra L
- Zuraw L, *see* Figueredo A
- zur Hausen A, *see* van Beek J
- Zwiebel J, *see* Puduvali VK